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I. ABBREVIATIONS 
 
aMφ´s: Alveolar macrophages  
BAL: Bronchoalveolar lavage 
C1q: First subcomponent of the C1 complex of complement activation 
CXCL10: C-X-C motif chemokine 10 
ETV7: Transcription factor ETV7 
i.p.: Intra-peritoneal 
IFN-γR1: Interferon gamma receptor 1 or CD119 
IL-: Interleukin 
IL-4c: IL-4 complex 
IL-4Rα: Interleukin 4 receptor alpha 
M(IL-4) or M2: Macrophage activated via the IL-4Rα 
M(LPS/ IFN-γ) or M1: Macrophage activated by LPS and/or IFN-γ 
MBP: Mannose binding protein 
MFI: Mean fluorescence intensity 
Myo18A: Unconventional cell surface myosin18A 
Mφ: Macrophage 
Mφ(GM-CSF): human GM-CSF-derived macrophages 
Mφ(M-CSF): human M-CSF-derived macrophages 
pMφs: Peritoneal macrophages  
RARRES3: Retinoic acid receptor responder 3 
RELMα: Resistin like protein alpha 
sIFN-γR1: soluble fraction of interferon gamma receptor 1  
SP-: Surfactant protein  
TGF-β: Transforming growth factor beta 
TNF-α: Tumor necrosis factor alpha 
WT: Wild type 
Ym1: Chitinase-like protein 3 
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II. RESUMEN 
Introducción 
Para facilitar el intercambio gaseoso, el pulmón tiene la mayor área del cuerpo 
en contacto con el medio externo. Se estima que hay alrededor de 300 millones de 
alvéolos en pulmones humanos adultos, lo que supone un área de contacto con el 
exterior 60 veces mayor que la superficie de la piel. Esta extensa superficie de 
contacto con el medio externo facilita la oxigenación, pero aumenta el riesgo de 
infección e inflamación por patógenos y endotoxinas presentes en el aire que 
respiramos. De hecho, el epitelio respiratorio es, con frecuencia, la puerta de entrada 
de microorganismos y alérgenos causantes de numerosas enfermedades. 
El sistema inmune innato en los alvéolos se caracteriza por una respuesta 
inmune humoral (lactoferrina, lisozima, colectinas pulmonares (SP-A y SP-D), β-
defensinas y otros péptidos antimicrobianos) y celular, constituida principalmente por 
los macrófagos alveolares que coordinan la defensa del huésped [1]. Los macrófagos 
alveolares promueven la tolerancia a antígenos inocuos presentes en el aire inhalado, 
reduciendo la respuesta inflamatoria que podría comprometer la integridad de pulmón 
[1, 2]. Sin embargo, durante una infección, los macrófagos reconocen señales de 
alarma a través de receptores capaces de inducir programas de activación 
especializados. La activación clásica de los macrófagos (M1) es inducida por IFN-γ y 
patrones moleculares asociados a patógenos que son ligandos de TLR [1, 2]. Sin 
embargo, los macrófagos también adquieren un programa de activación alternativa 
(M2) en respuesta a IL-4 e IL-13, importante para la respuesta inmune ante infecciones 
parasitarias y para la reparación del tejido [3-6].  
Los macrófagos tienen una extraordinaria plasticidad para adaptarse a cambios 
en su entorno. Los macrófagos activados por la vía clásica (M1) tienen potentes 
propiedades microbicidas y promueven una fuerte respuesta proinflamatoria, mientras 
que los macrófagos activados alternativamente (M2) tienen alta actividad fagocítica, 
promueven la remodelación del tejido y reducen la secreción de citoquinas 
proinflamatorias [4]. La flexibilidad de los macrófagos alveolares de cambiar de un 
estado de activación a otro podría ser importante para mantener los alvéolos estériles 
y poco inflamados. La alteración o desregulación de este balance M1↔M2 podría 
estar asociada a enfermedades respiratorias ya que la persistencia de una respuesta 
pro-inflamatoria (M1) es perjudicial para el tejido [4, 7] y, al contrario, la permanencia 
de un fenotipo de activación alternativa (M2) favorece la infección por bacterias y virus, 
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el progreso de tumores y el desarrollo de determinadas enfermedades respiratorias 
crónicas como la fibrosis pulmonar [4, 8]. 
Los macrófagos alveolares se encuentran en un entorno único. Están cubiertos 
por un fluido acuoso enriquecido en un material lipoproteico denominado surfactante 
pulmonar, que es esencial para mantener los alveolos abiertos durante los ciclos de 
inspiración-espiración [9]. La carencia o alteración del surfactante pulmonar ya sea 
debido a inmadurez pulmonar por nacimiento prematuro, daño pulmonar agudo, o 
mutación en genes críticos para la producción y función del surfactante, causa fallo 
respiratorio [10]. El surfactante pulmonar no sólo protege al pulmón del colapso 
alveolar, sino que también participa en la defensa inmune innata [9], especialmente 
debido a las proteínas SP-A y SP-D del surfactante [11]. El potencial efecto de los 
componentes del surfactante, y en concreto de la SP-A,  sobre la polarización de 
macrófagos alveolares hacia un fenotipo pro-inflamatorio M1 o un fenotipo anti-
inflamatorio M2 no ha sido investigado en profundidad. 
La proteína SP-A es una proteína oligomérica, estructuralmente similar a la 
proteína del complemento C1q. Pertenece a la familia de las colectinas por poseer 
dominios fibrilares de tipo colágeno que agrupan tres dominios globulares con 
actividad de lectina tipo-C dependiente de calcio.  
  
Modelo tridimensional de la forma trimétrica (A) y oligomérica (B) de la SP-A. En (A) se 
muestran los cuatro dominios estructurales de la cadena polipeptídica de la SP-A humana: I) 
Segmento NH2-terminal; II) dominio de colágeno con una irregularidad en la secuencia que 
divide dicho dominio en dos pates: NH2-terminal (IIN) y COOH-terminal (IIC); III) región del cuello 
entre el dominio colágeno y el globular, que forma una estructura de coiled coil; y IV) dominio 
globular COOH-terminal con dominio de reconocimiento de carbohidratos. Figura modificada de 
[9].  
Miembros de esta familia son la SP-D, la proteína de unión a manosa (MBP) o 
la adiponectina. La SP-A se une a lípidos del surfactante y a una gran variedad de 
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ligandos inmunes y no inmunes presentes en el fluido alveolar y en la superficie de 
células alveolares. Las principales funciones de la SP-A son: 1) regular la inflamación 
alveolar mediante su unión a distintos receptores en la superficie de células del epitelio 
alveolar, macrófagos y linfocitos [11] y favorecer la fagocitosis de células apoptóticas 
por macrófagos alveolares contribuyendo a la resolución de la inflamación [12];  y 2) 
controlar la infección. Para llevar a cabo esta segunda función, la SP-A aumenta la 
fagocitosis de patógenos por macrófagos alveolares y/o la expresión de receptores 
implicados en reconocimiento de patógenos, como el receptor de manosa [11, 13]. 
Además, la SP-A tiene una actividad microbicida directa en combinación con péptidos 
antimicrobianos presentes en el fluido alveolar [14] lo que explica que los lavados 
broncoalveolares libres de células de ratones SP-A+/+ tengan un efecto bactericida 
mucho mayor que los lavados provenientes de ratones SP-A-/- [15].   
 
Objetivo  
El objetivo principal de esta tesis fue evaluar el efecto de la SP-A sobre la 
polarización de macrófagos alveolares hacia un fenotipo pro-inflamatorio M1 o un 
fenotipo anti-inflamatorio M2 durante la activación clásica y alternativa de macrófagos, 
respectivamente. 
Esta tesis consta de tres capítulos de resultados con los siguientes objetivos 
específicos: 
1. Evaluar el efecto de la SP-A en el fenotipo clásico de los macrófagos alveolares 
inducido por IFN-γ en presencia o ausencia de LPS. 
 
2. Determinar el papel de la SP-A en la activación alternativa y proliferación de 
macrófagos alveolares mediada por IL- 4Rα e investigar si la SP-A podría ser 
un factor específico de tejido que regula la capacidad de los macrófagos de 
responder en mayor o menor media a IL-4. 
 
3. Estudiar el mecanismo por el cual la SP-A incrementa la proliferación y 
activación de macrófagos alveolares inducida por IL-4. 
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Resultados 
Capítulo 1 
Para determinar el efecto de la SP-A sobre macrófagos activados por la vía 
clásica, se aislaron macrófagos alveolares a partir de pulmones humanos y de rata, y 
se estimularon con IFN-γ y LPS simultáneamente o por separado, en presencia y 
ausencia de SP-A. 
Se observó que la SP-A inhibió la producción de TNF-α, iNOS y CXCL10 por 
macrófagos alveolares de rata estimulados con IFN-γ y LPS. Cuando las células se 
estimularon con LPS e IFN-γ por separado, la SP-A inhibió tanto la fosforilación de 
ERK inducida por LPS como la fosforilación de STAT1 inducida por IFN-γ. La SP-A 
también disminuyó la secreción de TNF-α y CXCL10 por macrófagos alveolares 
humanos cultivados ex vivo y macrófagos derivados de monocitos humanos con M-
CSF [Mφ(M-CSF)] estimulados con LPS y/o IFN-γ. Además, la SP-A inhibió la  
transcripción de genes regulados por IFN-γ (CXCL10, RARRES3 y ETV7), así como la 
fosforilación de STAT1 en Mφ(M-CSF). Finalmente, demostramos que la SP-A se unió 
al IFN-γ humano (KD =11 ± 0.5 nM) de manera dependiente de Ca2+ lo que impidió la 
interacción entre IFN-γ con su receptor IFN-γR1 en la superficie celular de macrófagos 
alveolares humanos. 
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Conclusiones del capítulo 1: Los resultados de este capítulo nos permiten concluir 
que la SP-A limita la activación clásica de macrófagos alveolares humanos y de rata 
inducida por IFN-γ y/o LPS. La acción de la SP-A en macrófagos activados por IFN-γ y 
LPS se basa en su capacidad para atenuar ambos agentes inflamatorios. Mientras que 
el mecanismo por el cual la SP-A limita la activación de macrófagos inducida por LPS 
se ha descrito anteriormente [16, 17], los resultados de este capítulo demuestran, por 
vez primera, que la SP-A se une al IFN-γ con alta afinidad, inhibiendo el 
reconocimiento de IFN-γ por su receptor en la superficie celular de macrófagos 
alveolares humanos. Por este mecanismo la SP-A podría aumentar el umbral de 
activación de macrófagos alveolares, evitando una respuesta inflamatoria ante agentes 
inocuos presentes en el aire inalado o facilitando la resolución de una respuesta 
inflamatoria. 
 
Capítulo 2 
Para determinar el efecto de la SP-A en la activación alternativa de macrófagos 
inducida por IL-4, se aislaron macrófagos alveolares a partir de pulmones humanos, de 
ratón y rata, y se estimularon con IL-4 en presencia y ausencia de SP-A. 
Alternativamente, se comparó la respuesta de macrófagos alveolares en ratones wild 
type y ratones deficientes en SP-A tratados con IL-4c exógena. Por último, la 
relevancia fisiológica del efecto de la SP-A en la activación alternativa de macrófagos 
alveolares se evaluó en un modelo de infección por el parasito Nippostrongylus 
brasiliensis. 
Se observó que la SP-A aumentó la activación y proliferación de macrófagos 
alveolares inducida por IL-4 in vitro e in vivo. Del mismo modo, la SP-A aumentó la 
activación y proliferación de los macrófagos alveolares en respuesta a la infección por 
el parasito N. brasiliensis, lo que contribuyó fundamentalmente a la eliminación del 
parásito y a la resolución del daño pulmonar causado por la migración del nematodo a 
través del pulmón. Además, en este capítulo identificamos a la miosina no 
convencional Myo18A (o SP-R210) como el receptor de la SP-A implicado en el 
aumento de la activación y proliferación de los macrófagos alveolares dependiente de 
IL-4 ya que el silenciamiento o bloqueo de dicho receptor (in vitro e in vivo) anula los 
efectos de la SP-A.  
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Para determinar si la SP-A es un factor específico de tejido, que incrementa la 
capacidad de los macrófagos de responder a IL-4, se realizaron experimentos con 
macrófagos aislados de la cavidad peritoneal y con una proteína estructuralmente 
análoga a SP-A, la C1q.  SP-A incrementó la activación y proliferación dependiente de 
IL-4 de macrófagos alveolares, pero no peritoneales, mientras que la C1q actuó de 
forma similar a la SP-A en macrófagos peritoneales, pero no alveolares. Experimentos 
in vivo con ratones C1qa-/- demostraron que C1q refuerza la activación y la 
proliferación de macrófagos mediada por IL-4 en la cavidad peritoneal también a través 
del receptor Myo18A. Este efecto de la C1q promovió el desarrollo de fibrosis 
peritoneal en un modelo de diálisis peritoneal en ratón, cuyo líquido de diálisis contiene 
lactato. 
Nuestros resultados indican que SP-A y C1q son amplificadores locales de la 
respuesta inmune tipo 2 y sugieren que otros colágenos de defensa (MBP o 
adiponectina) podrían tener la misma acción en otros tejidos. El hecho de que el 
mismo receptor Myo18A esté mediando funciones tejido-específicas para SP-A y C1q, 
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sugiere la existencia de co-receptores que actúen en concierto con Myo18A y que 
determinan la especificidad de tejido.  
Conclusiones del capítulo 2: la SP-A en el pulmón y la C1q en la cavidad peritoneal 
son factores específicos de tejido que actúan a través del receptor Myo18A para 
amplificar la activación y la proliferación de macrófagos residentes mediada por IL-
4Rα. La utilización de un modelo de infección pulmonar por nematodos indica que la 
acción amplificadora de la SP-A tiene consecuencias en la reparación del tejido 
dañado y en el control de la infección por el parásito. Por otra parte, la utilización de un 
modelo de diálisis peritoneal indica que la acción amplificadora de la C1q sobre la 
proliferación y activación alternativa de macrófagos peritoneales tiene consecuencias 
en la progresión de la fibrosis peritoneal inducida por diálisis peritoneal. 
 
Capítulo 3 
Para determinar los mecanismos moleculares por los que la SP-A amplifica la 
activación y la proliferación de macrófagos alveolares mediada por IL- 4, las células se 
trataron con IL-4 y SP-A en presencia de inhibidores farmacológicos de las rutas de 
señalización disparadas por IL-4 o involucradas en la potencial señalización de SP-A.   
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Conclusiones del capítulo 3: Los resultados permiten concluir que SP-A, a 
través de la unión al receptor Myo18A, activa PI3K y desencadena la fosforilación de 
Akt y PKCζ. Por un lado, SP-A amplifica la vía de señalización de PI3K-Akt inducida 
por IL-4, que está implicada en la proliferación de los macrófagos. Por otro lado, el eje 
SP-A/Myo18A/PI3K/PKCζ está implicado en incrementar la fosforilación de STAT6 
necesaria para la activación alternativa de macrófagos.  
La acción de SP-A es dependiente de su unión al receptor Myo18A por el 
dominio de colágeno, por lo que la expresión de Myo18A en la superficie celular podría 
ser una diana terapéutica para el tratamiento intratraqueal de patologías causadas por 
un descontrol en la activación de macrófagos alveolares hacia la vía alternativa.  
 
Conclusión 
Los resultados de esta tesis permiten concluir que la proteína del fluido alveolar 
SP-A modula la activación de macrófagos alveolares, limitando su activación clásica, 
inducida por IFN-γ, y promoviendo su activación alternativa y proliferación en 
presencia de IL-4. 
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III. SUMMARY 
 
Introduction 
To facilitate gas exchange, the lung has the largest area of the body in contact 
with the external environment. It is estimated that there are about 300 million alveoli in 
the adult human lungs, representing an area of contact with the environment 60 times 
larger than the surface of the skin. This massive area of contact with the environment 
facilitates oxygenation but increases the risk of infection and inflammation by 
pathogens and endotoxins present in the air we breathe. In fact, the lung epithelium is 
often the gateway for microorganisms and allergens that cause many respiratory 
diseases. 
The innate immune system in the alveoli is made up of a humoral arm 
(lactoferrin, lysozyme, pulmonary collectins (SP-A and SP-D), β-defensins, and other 
antimicrobial peptides) and a cellular arm dominated mainly by alveolar macrophages, 
which coordinate host defence [1]. Alveolar macrophages promote tolerance to 
innocuous antigens present in the inhaled air, reducing the inflammatory response, 
which could compromise the integrity of the lung [1, 2]. However, during an infection, 
macrophages recognise alarm signals through receptors capable of inducing 
specialised activation programs. Classical macrophage activation (M1) is induced by 
IFN-γ and pathogen-associated molecular patterns that are TLR ligands [1, 2]. 
However, macrophages also acquire an alternative activation program (M2) in 
response to IL-4 and IL-13, which is important for the immune response to parasite 
infections and tissue repair [3-6].  
Macrophages have an extraordinary plasticity to adapt to changes in their 
environment. Classically activated macrophages (M1) have potent microbicidal 
properties and promote a strong pro-inflammatory response, whereas alternatively 
activated macrophages (M2) have high phagocytic capacity, tissue remodelling activity, 
and reduced pro-inflammatory cytokine secretion [4]. The plasticity of alveolar 
macrophages in changing from one activation state to another could be important to 
keep the alveoli sterile and not inflamed. Alteration or dysregulation of this balance 
M1↔M2 might be associated with respiratory diseases since the persistence of a pro-
inflammatory response (M1) is harmful to the tissue [4, 7] and, conversely, the 
permanence of an alternatively activated phenotype (M2) favours bacterial and viral 
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infections, promotes tumour progress and the development of certain chronic 
respiratory diseases such as pulmonary fibrosis [4, 8]. 
Alveolar macrophages are located in a unique environment. They are covered 
by an aqueous fluid enriched in a lipid-protein material called pulmonary surfactant, 
which is essential to keep the alveoli open during cycles of inhalation-exhalation [9]. 
The lack or alteration of pulmonary surfactant, whether caused by premature birth, 
acute lung injury, or mutations in genes critical to surfactant production or function, 
causes respiratory failure [10]. Pulmonary surfactant not only protects the lung from 
alveolar collapse, but also participates in the innate immune defence [9], especially due 
to the activity of surfactant proteins SP-A and SP-D [11]. The potential effect of 
surfactant components, in particular of SP-A, on alveolar macrophage polarisation into 
either pro-inflammatory (M1) or anti-inflammatory (M2) phenotype has not been 
investigated in depth. 
SP-A is a large oligomeric protein, structurally similar to the first component of 
the complement system (C1q). SP-A belongs to the collectin family, which show 
collagen-type fibrillar domains and globular domains with calcium-dependent C-type 
lectin activity. 
 
Three-dimensional model of the trimeric (A) and oligomeric (B) form of SP-A. In (A) the four 
structural domains of the polypeptide chain of human SP-A are shown: I) N-terminal segment; II) 
collagen-like domain characterized by a sequence irregularity (kink), which divides the collagen-
like domain into two parts: N-terminal (IIN) and C-terminal (IIC) portions; III) neck region between 
the collagen and the globular domain, forming a coiled coil structure; and IV) C-terminal globular 
domain containing a carbohydrate recognition domain. Modified from [9]. 
Members of this family include SP-D, mannose binding protein (MBP), and 
adiponectin. SP-A binds to surfactant lipids and to a great variety of immune and non-
immune ligands, present in the alveolar fluid and alveolar cells. The main functions of 
SP-A are: 1) to regulate alveolar inflammation by binding to different receptors on the 
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surface of alveolar cells [11] and by promoting phagocytosis of apoptotic cells by 
alveolar macrophages contributing to the resolution of inflammation [12]; and 2) to 
control alveolar infections. To fulfil the latter function, SP-A enhances phagocytosis of 
pathogens by alveolar macrophages and/or up-regulates the expression of the 
mannose receptor involved in pathogen recognition [11, 13]. In addition, SP-A has a 
cooperative microbicidal action with antimicrobial peptides present in the alveolar fluid 
[14], which explains why cell-free bronchoalveolar lavages from SP-A+/+ mice have a 
much greater bactericidal effect than that from SPA-/- mice [15].  
 
Objective 
The main objective of this thesis was to evaluate the effect of SP-A on alveolar 
macrophage polarisation towards a pro-inflammatory M1 or anti-inflammatory M2 
phenotype during classical and alternative macrophage activation, respectively. 
This thesis consists of three experimental chapters with the following specific 
objectives: 
1. Evaluate the effect of SP-A on classical activation of alveolar macrophages 
induced by IFN-γ in the presence or absence of LPS. 
2. Determine the role of SP-A during IL-4Rα-mediated alternative activation and 
proliferation of alveolar macrophages and investigate whether SP-A might be a 
tissue-specific factor that determines the ability of macrophages to respond to 
IL-4. 
3. Study the mechanism by which SP-A enhances proliferation and activation of 
alveolar macrophages induced by IL-4. 
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Results 
Chapter 1 
To determine the effect of SP-A on macrophages activated by classical 
activation stimuli, alveolar macrophages were isolated from human and rat lungs, and 
cells were stimulated with IFN-γ and LPS simultaneously or separately, in the presence 
and absence of SP-A. 
We observed that SP-A inhibited the production of TNF-α, iNOS, and CXCL10 
by rat alveolar macrophages stimulated with IFN-γ and LPS. When cells were 
stimulated with LPS and IFN-γ separately, SP-A inhibited both LPS-induced ERK 
phosphorylation and STAT1 phosphorylation induced by IFN-γ. SP-A also decreased 
TNF-α and CXCL10 secretion by ex vivo cultured human alveolar macrophages and M-
CSF-derived macrophages stimulated with LPS and/or IFN-γ. Hence, SP-A inhibited 
up-regulation of IFN-γ-inducible genes (CXCL10, RARRES3, and ETV7) as well as 
STAT1 phosphorylation in Mφ (M-CSF). Finally, we demonstrated that SP-A bound to 
human IFN-γ (KD = 11 ± 0.5 nM) in a Ca2+-dependent manner and prevented IFN-γ 
interaction with IFN-γR1 receptor on the cell surface of human alveolar macrophages. 
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Conclusions of chapter 1: The results of this chapter allowed us to conclude that SP-
A limits classical activation of rat and human alveolar macrophages induced by IFN-γ 
and LPS together or separately. The action of SP-A on [IFN-γ + LPS]-activated 
macrophages was based on its capability to attenuate both inflammatory agents. 
Whereas the mechanism by which SP-A limits LPS-induced activation of macrophages 
was previously described [16, 17], this chapter demonstrates for the first time that SP-A 
binds to IFN-γ with high affinity, inhibiting IFN-γ recognition by its receptor on the cell 
surface of alveolar macrophages. These data unravel a previously unknown 
mechanism by which SP-A/IFN-γ interaction plays a significant role in tipping the 
balance of inflammation to protect the alveolar epithelium and maintains a tolerant lung 
environment in the steady state.  
 
Chapter 2 
To determine the effect of SP-A on the alternative activation of alveolar 
macrophages induced by IL-4, alveolar macrophages were isolated from human, 
mouse, and rat lungs, and these cells were stimulated with IL-4 in the presence and 
absence of SP-A. Alternatively, we compared the response of alveolar macrophages 
from wild type vs. SP-A-deficient mice to exogenous IL-4 treatment in vivo.  Finally, the 
physiological relevance of the effect of SP-A on the alternative activation of alveolar 
macrophages was assessed in a model of parasitic infection with N. brasiliensis. 
We found that SP-A enhanced IL-4-dependent activation and proliferation of 
alveolar macrophages in vitro and in vivo. Similarly, SP-A enhanced the activation and 
proliferation of alveolar macrophages in response to parasitic infection with 
Nippostrongylus brasiliensis. Critically, this contributed to the control of parasite 
infection and the resolution of lung injury caused by the lung-migrating nematode. We 
identified the unconventional myosin Myo18A (aka SP-R210) as the SP-A receptor 
involved in the enhancement of IL-4-dependent activation and proliferation of alveolar 
macrophages since silencing or blocking this receptor (in vitro and in vivo) abrogated 
SP-A’s effects.  
To determine whether SP-A might be a tissue-specific factor that could regulate 
the ability of macrophages to respond to IL-4, we performed experiments with 
macrophages isolated from the peritoneal cavity and with C1q, a protein structurally 
homologous to SP-A in its supra-trimeric assembly and collagen tail. We found that SP-
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A significantly boosted IL-4-dependent activation and proliferation of alveolar but not 
peritoneal macrophages, whereas C1q had an effect similar to SP-A on peritoneal, but 
not alveolar macrophages. In vivo experiments with C1qa-/- mice demonstrated that 
C1q enhances IL-4-mediated activation and proliferation of macrophages in the 
peritoneal cavity, acting also through Myo18A receptor. Enhancement of peritoneal Mφ 
alternative activation by C1q plays a relevant role in peritoneal fibrosis induced by a 
lactate dialysate used in the clinic. In this model, lactic acid seems to be a promoter of 
macrophage proliferation and Mφ2 activation, and C1q amplified peritoneal 
macrophage response to lactate, enhancing the development of peritoneal fibrosis.  
Our results indicate that SP-A and C1q are local amplifiers of the type 2 immune 
response and suggest that other defence collagens (MBP or adiponectin) might have 
the same action in other tissues. The fact that the same Myo18A receptor mediates 
tissue-specific functions of SP-A and C1q suggests the existence of co-receptors that 
act in concert with Myo18A to determine tissue specificity. Such molecules will be 
attractive candidates for tissue-targeted therapy. 
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Conclusions of chapter 2: SP-A in the lung and C1q in the peritoneal cavity are 
tissue-specific factors that act through Myo18A receptor to amplify the activation and 
proliferation of resident macrophages mediated by IL-4Rα. Our experiments using a 
model of pulmonary nematode infection indicate that the amplifying action of SP-A has 
consequences for the control of parasite infection and the resolution of lung injury 
caused by the lung-migrating nematode. Moreover, the use of a model of peritoneal 
dialysis indicates that the amplifying action of C1q on proliferation and alternative 
activation of peritoneal macrophages has consequences on the progression of 
peritoneal fibrosis induced by peritoneal dialysis. 
 
Chapter 3 
To determine the molecular mechanisms by which SP-A amplifies the IL-4-
mediated activation and proliferation of alveolar macrophages, these cells were treated 
with IL-4 and SP-A in the presence of pharmacological inhibitors of signalling triggered 
by IL-4 or SP-A. 
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Conclusions of chapter 3: Our results demonstrate that SP-A, through binding to 
Myo18A receptor, activates PI3K and induces subsequent phosphorylation of Akt and 
PKCζ downstream effectors. On the one hand, SP-A sustained the PI3K-Akt signalling 
pathway triggered by IL-4, which is involved in macrophage proliferation. On the other 
hand, SP-A/Myo18A/PI3K/PKCζ axis was involved in enhancing STAT6 
phosphorylation, necessary for the alternative activation of macrophages. 
The action of SP-A is dependent on its binding to Myo18A receptor through SP-
A collagen domain. Therefore, the expression of Myo18A receptor on the surface of 
alveolar cells could be a target of potential therapeutic value for intra-tracheal treatment 
of diseases caused by an imbalanced alternative activation of alveolar macrophages. 
 
Conclusion 
The results of this thesis allow us to conclude that the alveolar fluid protein SP-
A modulates the activation of alveolar macrophages, limiting macrophages’ classical 
activation induced by IFN-γ, and promoting macrophages’ alternative activation and 
proliferation in the presence of IL-4. 
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IV. INTRODUCTION 
 
1.- The respiratory system  
Respiration allows oxygen uptake, vital to generate the chemical energy, and a 
concomitant removal of carbon dioxide and other gaseous metabolic wastes.  
Anatomically, the respiratory system is divided into the upper and lower 
respiratory tracts. The upper tract structures consist of the nose, pharynx, and larynx, 
whilst the lower tract structures include the trachea, bronchi, bronchioles, alveolar 
ducts, and alveoli. Functionally, the same structures are also classified into the 
conducting zone and respiratory zone. The conducting zone consists of the nose, 
pharynx, larynx, trachea, bronchi, and bronchioles that form a continuous passageway 
for air to move in and out of the lungs. Alternatively, the respiratory zone is found deep 
inside the lungs and is made up of the respiratory bronchioles, alveolar ducts, and 
alveoli [18] (Fig. 1).  
The alveoli are the main structure involved in gas exchange and their walls are 
composed of three layers [18] (Fig. 1):  
• The capillary endothelium is composed of endothelial cells, which line the inner 
surface of the pulmonary capillaries and form an interface between bloodstream 
and alveoli facilitating gas exchange and metabolic functions.  
• The interstitial layer lies between the capillary endothelium and the alveolar 
epithelium and is comprised of collagen and elastin fibbers embedded in a 
hydrated porous proteoglycan gel. These components provide support and 
elasticity to the alveolar units. The extracellular matrix also contains fibroblasts, 
mast cells, pericytes and interstitial macrophages. 
• The alveolar epithelium is a physical and functional barrier, which is also 
involved in the clearance of environmental agents. Two types of epithelial cells 
form the alveolar epithelium [19, 20]: 
• Type I pneumocytes are flattened cells that constitute 40% of alveolar 
lining cells but cover ~90% of the alveolar surface facilitating gas 
exchange. 
• Type II pneumocytes are cuboidal cells (with apical microvilli) that 
perform essential functions to maintain alveolar homeostasis. Firstly, 
they are responsible for the synthesis, secretion and recycling of 
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pulmonary surfactant. Additionally, they participate in epithelial repair 
and play an important role in the immune defence of the lungs.  
The epithelial walls of the alveoli are covered by the alveolar fluid, which 
contains immune cells (mainly resident alveolar macrophages at the steady-state), as 
well as soluble proteins and peptides, and pulmonary surfactant [21].  
 
 
Figure 1. A) Schematic representation of the human respiratory system. B) Grouped 
alveoli forming two alveolar sacs. C) Schematic representation of the alveolar-capillary, 
the gas-exchange unit, showing their three layers and their components: alveolar 
epithelium, interstitial layer and capillary endothelium. 
 
2.- Mucosal immunity in the respiratory tract  
Mucosal surfaces comprising the respiratory tract, the gastrointestinal tract, and 
the urogenital tract, represent the most important portal of entry for pathogens, 
especially bacteria and viruses. Pathogens may either replicate and promote disease 
at the initial mucosal site or invade neighbouring tissues and the blood stream, inducing 
disease at distant systemic localities [22]. 
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In particular, the lung has the largest area of the body in contact with the 
external environment. It is estimated that there are about 300 million alveoli in the adult 
human lungs, representing an area of contact with the outside 60 times larger than the 
surface of the skin. This massive area of contact with the external environment 
facilitates oxygenation but increases the risk of infection and inflammation by 
pathogens and endotoxins present in the air we breathe. Therefore, airway mucosal 
surfaces must employ robust non-specific as well as specific mechanisms to be 
protected from respiratory tract infections [21, 23].  
Mechanical defences prevent particulate antigens and microorganisms from 
entering the lungs. These mechanisms begin at the nose, which functions as a filter by 
capturing or trapping large particles in the nasal hair or fimbriae [24]. The smaller 
particles that pass this filter are then inhaled and deposited in the lower airways, where 
mucins of the mucociliary blanket lining the airways surface act by trapping and 
removing them through ciliary movements [25]. The particles or microorganisms that 
pass this barrier are carried directly to the alveolar space, where they encounter the 
components of the alveolar innate immune system [26, 27]. 
3 - Components of the innate immune system in the alveolus. 
The innate immune system in the alveolar space can be divided into the 
humoral component, which comprises ubiquitous and secreted antimicrobial peptides 
and proteins (lactoferrin, lysozyme, pulmonary collectins (SP-A and SP-D), β-defensins 
and other antimicrobial peptides) able to neutralize and eliminate microbial components 
and pathogens, and the cellular component, composed of resident and recruited 
specific cells that participate actively in host defence [21]. 
3.1 - The cellular component: Lung Macrophages 
In addition to the vast repertoire of molecules that comprise the humoral innate 
defence, the innate system has a cellular arm that is formed by alveolar epithelial cells, 
macrophages, dendritic cells, innate lymphoid cells, neutrophils, eosinophils and other 
granulocytes. Their abundance and importance varies depending on many factors such 
as development and health conditions [19].  
At least three types of macrophages reside in the lungs: bronchial 
macrophages, interstitial macrophages and alveolar macrophages. Moreover, humans 
and other mammals (but no rodents) present intravascular macrophages located on the 
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inner side of capillaries [28]. Alveolar macrophages are found in the air space of the 
alveoli, where they comprise 90–95% of the cellular content in the steady state [2]. It 
has been reported that only a single alveolar macrophage is detected in approximately 
three alveoli [29]. However, it is thought that alveolar macrophages may travel between 
alveoli through the connecting pores of Kohn patrolling the entire lung surface [30]. 
Interstitial macrophages are located in the parenchymal space (interstitium) between 
adjacent alveoli, where they interact with dendritic cells and interstitial lymphocytes [2]. 
It has been proposed that interstitial macrophages promote immunity by presenting 
antigen to interstitial T cells. However, in a mouse asthma model it has been shown 
that they also promote tolerance and prevent TH2-type airway inflammation by IL-10-
mediated inhibition of DC activation [31]. By flow cytometric analysis, lung 
macrophages can be characterized by their expression of the surface macrophage 
markers as shown in table 1 [1, 2]: 
Table 1. Surface molecule expression on lung macrophages. Expression of 
characteristic surface molecules on alveolar (AMs) and interstitial (IMs) macrophages, 
from high (+++) to low (+) to absent (−). ‘?’ Indicates ‘still unclear’. (Taken from [1, 2]). 
 
 Molecule AMs IMs 
CD103 + + 
SIRPα + + 
CD64 + ? 
MerTK ++ + 
Siglec F +++ - 
CD24 + ? 
CD11c +++ + 
Ly6C + + 
F4/80 +++ ++ 
MHC class II + variable 
CD11b + + 
CD68 + ? 
CD200R ++ ? 
CD206 ++ + 
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3.1.1 - Alveolar macrophages  
Because the lungs function as the body’s gas-exchange organ, they are 
inevitably exposed to air that is contaminated with pathogens, allergens and pollutants. 
Host-defence mechanisms within the lungs must facilitate clearance of inhaled 
pathogens and particles while minimizing an inflammatory response that could damage 
the thin, delicate gas-exchanging epithelium [11]. For the naive host, the primary 
defences in the alveolar fluid are the resident alveolar macrophages and these cells 
function to maintain a tolerant state towards innocuous antigens present in the inhaled 
air [11]. 
Alveolar macrophages promote an immunologically tolerant state by balancing 
the responses of alveolar epithelial cells, dendritic cells and T cells to environmental 
challenges (Fig. 2). Previous studies established that alveolar macrophages suppress 
immune responses through the inhibition of dendritic cell-mediated activation of T cells 
and production of transforming growth factor-β (TGF-β) [32-34]. It is well established 
that TGF-β-induces forkhead box P3+ (Foxp3+) T regulatory cells. These cells generally 
suppress induction and proliferation of effector T cells [35, 36]. Alveolar macrophages 
produce TGF-β and retinoic acid that induce the generation of Foxp3+ T regulatory cells 
from naive CD4+ T cells, which induce tolerance to inhaled innocuous antigens [37]. In 
addition, TGF- β and prostaglandins produced by alveolar macrophages inhibit T cell 
activation [1]. Alveolar macrophages lose the ability to induce T regulatory cells and 
tolerance when harmless antigens are mixed with Toll-like receptor 4 ligands. The 
switch from a tolerogenic mode to an inflammatory mode is accompanied by induction 
of the secretion of IL-1, IL-6, TNF-α and other pro-inflammatory mediators [37].  
Previous studies have indicated that the interaction between alveolar 
macrophages and epithelial cells also contributes to maintain tolerance. Specifically it 
has been suggested that detachment of alveolar macrophages from epithelia upon 
infection may unleash alveolar macrophage inflammation by withdrawal of active TGF-
β [38-40]. It has also been published that inhibition of pathological airway inflammation 
occurs via the intercommunication of sessile alveolar macrophages located in different 
alveoli through the alveolar epithelium. A subset of alveolar macrophages form gap 
junctions with alveolar epithelial cells through the use of connexin Cx43 hemichannels 
that induce cyclic and synchronized waves of calcium release from both alveolar 
macrophages and alveolar epithelial cells. The communication between alveolar 
macrophages over distance via the epithelium, through synchronous Ca2+ spikes, is 
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immunosuppressive and mediates protection to the host from inflammatory acute lung 
injury following TLR ligation [29]. The prevention of inflammatory responses is also 
mediated by various inhibitory receptors on alveolar macrophages, with the ligands 
expressed on alveolar epithelial cells or present in the alveolar fluid. The interaction of 
the ligand CD200L on alveolar epithelial cells with its receptor CD200R on alveolar 
macrophages negatively regulates inflammatory responses induced by TLR signalling 
on alveolar macrophages [41]. Likewise, interaction of the signal-regulatory protein 
SIRPα (which mediates a so-called 'do not eat me' signal) on alveolar macrophages 
with the globular heads of the surfactant proteins SP-A and SP-D suppresses alveolar 
macrophages pro-inflammatory responses and phagocytosis, which can be overcome 
by TLR4 signalling that downregulates SIRPα [42]. Another class of immune-regulatory 
receptors that is expressed by macrophages is the triggering receptor expressed on 
myeloid cells (TREM) family. TREM-1-deficient mice efficiently control acute pulmonary 
bacterial and viral infection and undergo less morbidity than wild-type mice after 
infection with influenza virus, which indicates an anti-inflammatory role rather than a 
pro-inflammatory role for TREM-1. Conversely, silencing of TREM-2 causes an 
enhanced alveolar macrophage response to TLR4 agonists, which further emphasizes 
its role as a negative regulator of macrophage function. Alveolar macrophages 
upregulate TREM-1 expression in response to the recognition of TLR ligands, whereas 
TREM-2 is expressed by mouse alveolar macrophages following inflammation [1, 2].  
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Figure 2. Leukocyte interactions in the healthy lungs. Alveolar macrophages inhabit in the 
alveolar lumen in contact with type I alveolar epithelial cells (which account for as much as 98% 
of the total surface area of the lungs) or with type II alveolar epithelial cells. Macrophages found 
in the bronchus (larger airways) reside within the mucous layer. Mucus-producing goblet cells 
are present in both bronchus (large airways) and bronchioles (small airways), and secretory 
non-ciliated Club cells are more common in the bronchioles. Macrophages are also located in 
the interstitial space between the alveoli and the blood vessels where T cells, dendritic cells 
(DCs) and a scarce population of B cells also reside. Commensal (and pathogenic) bacteria can 
reach the airway mucosa the alveolar surface. A) Alveolar macrophages are regulated by the 
airway epithelium through their interactions with CD200, which is expressed by type II alveolar 
cells, with transforming growth factor-β (TGFβ), which is tethered to the epithelial cell surface by 
αvβ6 integrin, and with secreted interleukin-10 (IL-10). These interactions can also take place in 
the larger airways, where CD200 and αvβ6 integrin are also expressed by the bronchial 
epithelium. B) The secretion of TGFβ and retinoic acid by alveolar macrophages can induce 
forkhead box P3 (FOXP3) expression in both naive and activated CD4+ T cells that are present 
in the lumen of the airways. In addition, TGFβ and prostaglandins suppress T cell activation. C) 
Alveolar macrophage activation and the initiation of inflammation involves a complex balancing 
act between activating and repressing signals. On the one hand, Toll-like receptors (TLRs), 
along with their co-receptors such as MD2 and CD14, recognize pathogen-associated molecular 
patterns to trigger inflammatory cytokines, such as tumour necrosis factor (TNF), interleukin-1β 
(IL-1β) and interferon-γ, which, through binding to their receptors, perpetuate inflammation. On 
the other hand, mediators such as IL-10 and soluble or αvβ6 integrin-tethered transforming 
growth factor-β (TGFβ) block pathways that induce inflammation. Cell-cell interactions with 
bronchial or alveolar epithelial cells also trigger inhibitory signals to alveolar macrophages, for 
instance, through CD200 receptor (CD200R), triggering receptor expressed by myeloid cells 2 
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(Trem-2) or signal-regulatory protein-α (SIRPα). Loss of the ligands for the negative regulators, 
for example, following epithelial cell loss during inflammation, will tip the balance towards 
alveolar macrophage activation. Conversely, increased expression of the negative regulators 
and inhibition of TLR signalling pathways, for example, during the resolution of inflammation, 
tips the balance towards the immunosuppression of alveolar macrophages. Taken from [1]. 
 
The negative signals of the inhibitory receptors are overridden by infection with 
a pathogen that unleashes the alveolar macrophages by combined ligation of several 
pathogen-recognition receptors of the TLR family, C-type lectin family, NLRP family 
and/or scavenger receptor family [43]. Alveolar macrophages are ideally suited to act 
as first line of innate cellular defence in the lower airways due to their localization in the 
alveolar lumen, where they are attached to alveolar epithelial cells and sample the 
microbes that are transported towards them by alveolar liquid flow [29]. 
It is well known that alveolar macrophages play a key role in the defence 
against bacterial, fungal and viral infections and in the prevention of acute lung injury 
through the limitation of and restoration of normalcy after infection-mediated damage. 
By virtue of their potent phagocytic ability, alveolar macrophages are essential for the 
clearance of pulmonary infection with bacteria and fungi, including Streptococcus 
pneumonia, Mycobacteria tuberculosis, Pseudomonas aeruginosa and Pneumocystis 
carinii [44-47].  
3.1.2 - The development of alveolar macrophages 
Various studies addressing the ontogeny of tissue macrophages have laid the 
basis for a change in the long-held dogma of mononuclear phagocyte development, 
which assumed that bone marrow-derived circulating blood monocytes constantly enter 
tissues to replenish resident macrophages [2]. It is now well accepted that many tissue 
macrophage subsets, including lung alveolar macrophages, arise from embryonic 
progenitors that seed the organs and mature locally before and shortly after birth. They 
are maintained by proliferative self-renewal throughout life independently of bone 
marrow–derived monocytes in the steady state [48, 49]. 
Like many other organs, foetal lungs contain two distinct myeloid populations, 
foetal macrophages and foetal monocytes, which are considered to derive from 
embryonic haematopoiesis in the yolk sac and foetal liver, respectively [50, 51]. Foetal 
macrophages that are generated during primitive haematopoiesis in the yolk sac 
appear around embryonic day 8.5 (E8.5) and subsequently colonize tissues via the 
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blood circulation [52]. Foetal monocytes are generated in the foetal liver around E12 
and subsequently migrate to embryonic tissues, where they appear around E14 [53]. 
Both of those populations can be clearly identified in foetal lungs at E14.5–E18.5 [54, 
55].  
While the number of lung foetal macrophages remains relatively constant 
between E17 until around 1 week after birth, foetal lung monocyte populations expand 
dramatically, accompanied by a profound change in expression of characteristic 
surface markers during this period. They successively increase their expression of 
CD11c, Siglec-F, F4/80 and CD64 and concomitantly downregulate their expression of 
Ly6C and CD11b until they reach the mature stage. To reach the mature stage, lung 
environment seems to be essential [56-58] and transcriptional activity of peroxisome 
proliferator-activated receptor γ (PPARγ), following stimulation with granulocyte-
macrophage colony-stimulating factor (GM-CSF), as well as activity of the 
transcriptional repressor Bach2 have been found to be necessary for alveolar 
macrophages maturation. Foetal monocytes are able to develop to mature alveolar 
macrophages upon adoptive transfer into the lungs of newborn mice, but foetal 
macrophages are not [54, 55] (Fig. 3).  
After perinatal development, mature alveolar macrophages are maintained by 
homeostatic proliferation [54, 59] and self-renew without substantial contribution by 
immigrating monocyte precursor cells, as supported by the intact alveolar macrophage 
population in leukemic patients with decreased or absent blood monocytes [60]. The 
proliferative capacity of mature alveolar macrophages was already reported 40 years 
ago [61, 62]. Today, compelling evidence from several studies using genetic fate-
mapping approaches, parabiosis and partial-body irradiation has demonstrated that 
progenitor cells derived from hematopoietic stem cells in adults do not contribute much 
to alveolar macrophages under steady-state conditions [54, 59, 62, 63]. However, they 
have the ability to differentiate into functional alveolar macrophages under certain 
conditions, as shown by transfer of bone marrow hematopoietic stem cells into lethally 
irradiated recipients with ablated tissue macrophages [54, 59, 64]. Impaired self-
renewal ability of alveolar macrophages due to aging or certain environmental cues 
might also result in the replenishment of alveolar macrophages by circulating blood 
monocytes [2].  
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Figure 3. Development of alveolar macrophages. Foetal monocytes seed the lungs at 
around E15. The production of GM-CSF (CSF2) by alveolar epithelial cells induces expression 
of PPAR-γ in foetal monocytes, which ‘instructs’ the development and function of alveolar 
macrophages. There is gradual up- and downregulation of cell surface markers during AM 
ontogeny. E15, E18 and E19, embryonic day 15, 18 and 19. D3 and D4, day 3 and day 4 after 
birth. Taken from [2].  
  
In the absence of GM-CSF, differentiation of the alveolar macrophage 
progenitor is already abrogated in the foetal lungs at around E17, which indicates that 
GM-CSF is instrumental for licensing alveolar macrophage development. In the mouse 
foetus, the highest GM-CSF expression is found in the lungs, where stromal cells are 
the main source that provides it in a paracrine manner to foetal monocytes [54, 55]. 
GM-CSF instructs lung foetal monocyte differentiation shortly before and after birth 
through activation of the nuclear receptor PPAR-γ, which controls the transcriptional 
program intrinsically required for the differentiation and function of alveolar 
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macrophages, including cholesterol metabolism, β-oxidation of fatty acids, lipid 
transport, storage and degradation [55].  
Since alveolar macrophages participate in surfactant degradation and therefore 
the maintenance of lung surfactant homeostasis, disruption of GM-CSF signalling or 
the absence of alveolar macrophages results in the development of pulmonary alveolar 
proteinosis [65, 66]. Pulmonary alveolar proteinosis is a condition on which lungs suffer 
a progressive surfactant accumulation in alveoli that can lead to hypoxemic respiratory 
failure [67]. The development of pulmonary alveolar proteinosis in Csf2−/− mice and 
Csf2rb−/− mice provided first evidence of a critical role for this cytokine in lung 
homeostasis [67]. Another report confirmed that patients with acquired or congenital 
pulmonary alveolar proteinosis presented either auto-antibodies to GM-CSF or 
mutations in the genes encoding the α-chain or the β-chain of the GM-CSF receptor 
(GM-CSFR) [65]. Additionally, several reports have demonstrated, that Csf2−/− and 
Csf2rb−/− mice are completely devoid of alveolar macrophages [54, 59, 64]. These 
observations have established a link between GM-CSF and the development of 
functional alveolar macrophages capable to degrade pulmonary surfactant [65, 66].  
 
3.1.3 - Activation of macrophages  
Upon infection alveolar macrophages release cytokines that affect the activity or 
maturation of dendritic cells, which are believed to be the most potent antigen 
presenting cells. Dendritic cells are localized at the epithelial border where they capture 
antigens. Subsequently, they migrate to local draining lymph nodes and activate naïve 
T cells, which initiate the adaptive immune response [68-70].  
After being primed by antigen presentation T- lymphocytes migrate from the 
lymph nodes to peripheral blood for subsequent extravasation at mucosal effector sites. 
Antigen-specific T cells, together with Innate lymphoid cells, are key effectors of 
immune functions, through the secretion of TH1 and TH2 type of cytokines among 
others [68-70].  
The establishment of acquired immunity also triggers subsequent interactions 
between macrophages and activated T and B-lymphocytes providing macrophages a 
new level of regulation and acquisition of effector functions. It has been shown that 
TH1-derived interferon-gamma (IFN-γ) is essential during cell-mediated immunity to 
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intracellular infection whereas TH2-derived interleukin-4 (IL-4) is critical to fight 
extracellular parasitic infection [3, 4]. The fact that IFN-γ and IL-4 elicit distinct 
activation programs on cultured macrophages gave rise to the classification, as for the 
lymphocyte system (TH1 vs. TH2), of classical (M1 or M(LPS/IFN- γ)) and alternative 
(M2 or M(IL-4)) activation of macrophages [3, 4] (Fig. 4). However, in vivo under 
various physiological conditions, coexistence of macrophages in different activation 
states and unique or mixed phenotypes have been observed, a reflection of the 
diversity and plasticity of the monocyte-macrophage lineage, most likely caused by 
complex tissue-derived signals [71]. Therefore, M1 or M(LPS/IFN- γ) and M2 or M(IL-4) 
most likely represent extremes of in vitro generated macrophage phenotypes; whereas 
LPS/IFN-γ and IL-4 in combination with tissue-specific signals would elicit more  
“modular” phenotypes during in vivo activation of macrophages. 
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Figure 4. The signalling behind the effects of classic and alternative stimuli in 
macrophages. Alternative activation is mainly induced by IL-4 binding to its receptor, the 
heterodimer formed by IL4Rα and the common γ chain (γc). This triggers Jak1/3 driven 
phosphorylation of STAT-6, which dimerizes and translocates to the nucleus to activate gene 
transcription. IRS-1/2 are also phosphorylated and activate PI3K and the adaptor Grb2. Classic 
activation is elicited by stimulation with both IFNγ and lipopolysaccharide (LPS) or lipoteicoic 
acid (LTA). IFNγ binds to the heterodimeric receptor IFNGR1/2 to activate Jak1/2 and elicit 
phosphorylation and dimerization of STAT1 that translocates to the nucleus and activate 
transcription of pro-inflammatory genes. LTA and LPS bind to their receptors Toll like receptor 2 
and 4 (TLR-2 and -4), respectively, which trough the adaptor proteins MyD88 and TRIF lead to 
activation of the transcription factors AP-1, NF-κB and STAT5. Also, Interferon regulatory 
factors (IRFs) are activated upon IFNγ, LPS and LTA binding to their receptors. Taken from [4]. 
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3.1.3.1 - Classical activation of macrophages  
The so-called classical stimuli are grouped according to their ability to induce 
prototypic inflammatory responses and markers, but their source, role, receptors, and 
signalling pathways differ substantially [3, 4]. IFN-γ is the main cytokine associated 
with classical activation of macrophages and the main TH1 cell product. Other cells, 
such as natural killer (NK) cells and macrophages, themselves have been shown to 
produce this cytokine.  
The IFNGR-1 and IFNGR-2 chains form the IFN-γ receptor complex, whose 
cytoplasmic tails are associated with Janus kinases 1 and 2 (JAK1 and JAK2), 
respectively. IFN-γ binds to IFNγR1 with high affinity and activates crosslinking of two 
molecules of each IFNγR1 and IFNγR2 chain, which results in activation of tyrosine 
kinases Jak1 and Jak2 and phosphorylation of STAT1 (signal transducers and 
activators of transcription 1). Activated STAT-1 translocates to the nucleus, where it 
mediates the transcription of IFN-γ-induced genes such as C-X-C motif chemokine 10 
(CXCL10) or Interferon regulatory factors (IRFs), among others [72-74]. IFN-γ controls 
specific gene expression programs involving cytokine receptors, cell activation 
markers, and a number of cell adhesion molecules [75].  
IFN-γ and IFN-γ receptor-deficient mice are viable and fertile and their steady-
state macrophage populations appear normal [76, 77]. In these mice, however, 
macrophages show impaired production of antimicrobial products, and consequently, 
mice are susceptible to Mycobacterium bovis and Listeria monocytogenes infection. 
This defect is not only important for prototypical type-1 immune responses against 
bacteria and virus: IFN-γ deficient mice are susceptible to protozoa, such as 
Trypanosoma cruzi [78], Leishmania amazonensis, Leishmania major [79], and 
Cryptosporidium parvum [80], as well as showing a compromised defence against 
some nematodes (e.g. Litomosoides sigmodontis [81], Schistosoma mansoni [82], and 
Schistosoma japonicum [83]). In humans, mutations resulting in the lack of expression 
of the receptor lead to severe immunodeficiency (e.g. susceptibility to mycobacteria M. 
avium; M. kansasii and M. chelonei) [84]. 
Frequently IFN-γ is used in combination with Toll like receptor (TLR) ligands to 
induce classical activation of macrophages [85, 86]. Entire bacteria induce gene 
programs similar to those of isolated Toll-like receptors (TLRs) ligands, and major parts 
of the pathogen profiles can be ascribed to TLR ligands, such as LPS, muramyl 
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dipeptide, and lipoteichoic acid [86]. LPS is the best-studied classical-activation of 
macrophages signal and is recognized by TLR4, although recent evidence shows that 
LPS can also be recognized by TLR4-independent mechanisms leading to 
inflammasome activation [87, 88]. Conventionally, TLR4 activation induces myeloid 
differentiation primary response gene 88 (MyD88) and MaL/Tirap (MyD88 adapter 
like/Toll-interleukin 1 receptor domain containing adaptor protein)-dependent pathways 
that lead to strong pro-inflammatory cytokine profiles (e.g. IFN-β, IL-12, TNF-α, IL-6, 
and IL-1β), chemokines (e.g. CCL2, CXCL10, and CXCL11), and antigen presentation 
molecules, such as MHC members, co-stimulatory molecules, and antigen-processing 
peptidases. These pro-inflammatory profiles are controlled by nuclear factor of kappa 
light polypeptide gene enhancer (NF-κB), activator protein 1 (AP-1), IRFs, STAT1, and 
early growth response (EGR) family members, many of which participate in the IFN 
response. Although there is a degree of overlap between LPS and IFN-γ gene profiles, 
similarities are not enough to consider the stimuli to be homologous [72]. As for IFN-γ, 
the numbers of macrophages in TLR-deficient animals are normal, but their activation 
is defective and therefore survival to infection is severely impaired [89, 90]. In humans, 
genetic mutations in the TLR signalling pathway have been described, and as for mice, 
there is evidence for susceptibility to infection with mycobacteria, pneumococci, 
meningococci, malaria, and susceptibility to develop bacteremia [91].  
Synergy between IFNγ and LPS to induce pro-inflammatory activation of 
macrophages has been extensively addressed. There have been described several 
mechanisms through which this synergy takes place: increase in TLR expression 
induced by IFNγ, synergistic activation of promoters by STAT1 and NF-κB, enhanced 
activation of NF-κB, additive functions of NF-κB/MAPK and STAT-1 induced genes, 
and IFN-γ-mediated suppression of feedback inhibition loops in LPS-signalling [92, 93]. 
Physiologically, the synergistic induction of pro-inflammatory chemokines and cytokines 
by IFNγ and LPS leads to the recruitment and activation of neutrophils and the 
induction of effector molecules (e.g. nitric oxide), which mediate the immune response 
against bacteria and intracellular parasites. In addition, pro-inflammatory cytokines can 
have multiple functions in multiple locations such as neuronal reaction, infectious 
agents generating pathological pain and regulation of apoptosis in the infected cells [4]. 
A common in vitro model for the study of classic vs. alternative activation of 
human macrophages is GM-CSF- and macrophage colony stimulating factor (M-CSF)-
generated macrophages from peripheral blood monocytes. It has been determined that 
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some GM-CSF-mediated regulators are common with the IFN-γ and TLR signalling 
pathways [94] and GM-CSF is considered to drive macrophages to a classically 
activated phenotype [95]. In vitro experiments on GM-CSF-treated monocytes indicated 
that GM-CSF promoted the acquisition of pro-inflammatory markers (INHBA, MMP12, 
EGLN3, CCL17, ECSCR, and CCR2) [96-98]. Furthermore, GM-CSF enhances antigen 
presentation, complement- and antibody-mediated phagocytosis, microbicidal capacity, 
leukocyte chemotaxis, and adhesion. GM-CSF induces monocyte and macrophage 
cytokine production of IL-6, IL-8, G-CSF, M-CSF, TNF-α, and IL-1β, but less than, for 
example, LPS. Other stimuli that share pro-inflammatory properties have been termed 
classical activation inducers (e.g. TNF, IL-1β, and IL-6) [99].  
3.1.3.2 - Alternative activation of macrophages  
The alternative stimuli are commonly grouped by their ability to antagonize 
prototypic inflammatory responses and markers; however, as for M1 stimuli, their 
source, role, receptors, and signalling pathways differ [4]. One of the main factors that 
induce alternative activation is interleukin-4 (IL-4). IL-4 is produced by the TH2 cells, 
eosinophils, basophils, or macrophages themselves and is recognized by two different 
receptor pairs. IL-4Rα can pair with the common gamma chain (γc), enabling IL-4 
binding, and with the IL13Rα1 chain, enabling IL-4 or IL-13 binding. Cytoplasmic tails of 
the transmembrane receptors IL-4Rα, γ-c and IL-13Rα1 are bound to JAKs. Upon 
ligand-induced dimerization of the receptor complex JAKs become trans- and auto-
phosphorylated [100]. The activated JAKs phosphorylates tyrosine residues in the 
cytoplasmic tails of the receptor, which then serves as docking sites for a number of 
adaptor or signalling molecules including STAT6. JAK1 phosphorylates STAT6, which 
then dimerizes and translocates to the nucleus. Other transcription factors activated 
upon IL-4 stimulation of macrophages include c-Myc, IRF4, and Krüppel-like factor 4 
(KLF4). IL-4 induces macrophage fusion and decreases phagocytosis. The IL-4-
induced transcriptome in human and mouse includes transglutaminase 2 (TGM2), 
mannose receptor (MRC1), cholesterol hydroxylase CH25H, and the prostaglandin-
endoperoxide synthase PTGS1 (prostaglandin G/H synthase 1), and the signalling 
modulators CISH and SOCS1 [101]. However, in murine macrophages typical IL-4Rα-
mediated activation markers include: Resistin-like molecule alpha (RELMα), Ym1, 
Arginase-1 and Mannose Receptor (CD206) [73].  
Insulin receptor substrate 1 and 2 (IRS1 and IRS2), members of the insulin receptor 
substrate family are also recruited to the IL-4 receptor complexes. Phosphorylated IRS 
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activates PI3K and the adaptor Grb2. Recently, it has been shown that IL-4 induces 
macrophage proliferation [5, 102] through activation of the PI3K/Akt signalling pathway 
[103]. In IL-4-deficient animals, the numbers of macrophages and maturation are 
normal, and defects appear in the immune response against nematodes and some viral 
infections [3, 104]. In humans, polymorphisms in the IL-4R have been associated with 
the development of asthma and atopy [105, 106]. 
As discussed before GM-CSF and M-CSF are frequently used for in vitro model 
for the study of classic vs. alternative activation, respectively, of peripheral blood 
monocytes-derived human macrophages. M-CSF binding leads to receptor 
dimerization, auto phosphorylation, activation of ERK, phosphatidylinositol 3-kinase, 
phospholipase C, and eventually Sp1 transcription factor nuclear localization [85]. The 
transcriptional response to M-CSF includes SERPINB2, folate receptor β (FRβ), 
encoded by the FOLR2 gene [97, 98], transient gene clusters with overrepresentation 
of cell cycle genes (e.g. cyclins A2, B1, D1, and E1) and downregulation of human 
leukocyte antigen (HLA) members and stable gene clusters, including TLR7 and the 
complement C1QA/B/C subunits [85]. 
Other stimuli that drive “alternative” or anti-inflammatory/regulatory activation of 
macrophages are:  IgGs, glucocorticoids, IL-10 and TGF-β [4].  
 
3.1.3.3 - Classically and alternatively activated macrophages in disease 
Following tissue injury or infection by viral or bacterial pathogens, the first-
responder macrophages usually exhibit an inflammatory phenotype and secrete pro-
inflammatory mediators such as TNF-α, nitric oxide and IL-1, which participate in the 
activation of various antimicrobial mechanisms, including oxidative processes that 
contribute to the killing of invading organisms [107, 108]. Other mediators produced by 
classically activated macrophages include IL-12 and IL-23, which are decisive in 
influencing the polarization of TH1 and TH17 cells, which further drive inflammatory 
responses forward [109]. Classically activated macrophages produce reactive oxygen 
intermediates, such as superoxide, and, in the case of murine macrophages, nitrogen 
intermediates, including NO that are highly toxic for microorganisms but can also be 
highly damaging to neighbouring tissues and lead to aberrant inflammation [110]. 
Indeed, classical macrophages are believed to participate in various chronic 
inflammatory and autoimmune diseases. Therefore, pro-inflammatory and antimicrobial 
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classical macrophage responses must be controlled to prevent extensive collateral 
tissue damage to the host [111]. 
A protective role in tumorigenesis has been described for classically activated 
macrophages, which activate tumour-killing mechanisms and antagonize the 
suppressive activities of tumour associated macrophages and other cells which have 
been shown to suppress adaptive tumour-specific immune responses and promote 
tumour growth, invasion, metastasis, stroma remodelling and angiogenesis [112-117]. 
Classic macrophages also amplify TH1 responses, providing a positive feedback loop in 
the anti-tumour response [71]. 
By contrast, tumour associated macrophages isolated from solid and metastatic 
tumours have a suppressive alternative-like phenotype. Furthermore, accumulating 
evidence from many tumour models suggests that macrophages contribute to tumour 
progression, with increasing numbers of tumour associated macrophages among other 
cells [118-120]. These observations are also consistent with the tumour-promoting 
activities of IL-4 and IL-13, which also promote alternative macrophage differentiation 
[121-124].  
In addition to their innate phagocytic activity and role in antimicrobial immunity, 
macrophages are intimately involved in wound repair [125-128]. In contrast to pro-
inflammatory and anti-microbial classical macrophage responses, alternative 
macrophages exhibit potent anti-inflammatory activity and have important roles in 
wound healing, allergy, asthma and fibrosis [129-131]. The antagonism to classical 
macrophage responses elicited by alternatively activated macrophages, may be crucial 
for the activation of the wound healing response and for tissue homeostasis to be 
restored. It has also been shown that classically activated macrophages can 
themselves ‘convert’ into anti-inflammatory macrophages with an alternative wound-
healing phenotype [71, 132]. To activate the wound healing response, alternative 
macrophages produce growth factors that stimulate differentiation and proliferation of 
epithelial cells and fibroblasts, including TGFβ1 and PDGF [133]. Macrophage-derived 
TGFβ1 contributes to tissue regeneration and wound repair by promoting fibroblast 
differentiation into myofibroblasts, by enhancing expression of tissue inhibitors of 
metalloproteinases that block the degradation of extracellular matrix and by directly 
stimulating the synthesis of interstitial fibrillar collagens in myofibroblasts [134, 135]. 
Macrophage-derived PDGF also stimulates the proliferation of activated extracellular 
matrix-producing myofibroblasts [136]. 
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Alternatively activated macrophages can also regulate wound healing 
independently of their effects in myofibroblasts. Indeed, they produce matrix 
metalloproteinases and tissue inhibitors of metalloproteinases that control extracellular 
matrix turnover [137], engulf and digest dead cells, debris and various extracellular 
matrix components that would promote tissue-damaging classical macrophage 
responses [133, 138], and secrete specific chemokines that recruit fibroblasts, TH2 cells 
and regulatory T cells [139, 140]. Moreover, alternatively activated macrophages 
produce factors that induce myofibroblast apoptosis [141], serve as antigen-presenting 
cells that propagate antigen-specific TH2 and T regulatory cell responses, which 
promote wound healing while limiting the development of fibrosis [142, 143], and 
express immune-regulatory proteins (such as IL-10, RELMα, chitinase-like proteins and 
arginase 1) involved in promotion of wound healing and reduction of  the magnitude 
and duration of inflammatory responses  [144-149]. It has been suggested that a 
deregulation of the activity of alternatively activated macrophages can lead to the 
initiation and maintenance of fibrosis [109]. 
Numerous studies have identified roles for alternatively activated macrophages 
in allergic responses driven by IL-4 and IL-13. However, their function in allergy and 
asthma remains controversial, with some studies suggesting that M(IL-4) macrophages 
promote allergic inflammation and others indicating a suppressive role for these cells 
[109].  
Alternatively activated macrophages are also involved in the development of 
TH2-dependent immunity to some extracellular parasites and fungi [150]. Regarding 
their role during extracellular parasites infections, it has been reported that alternatively 
activated macrophages play a central role in nematode expulsion during intestinal 
infection, both in the memory response to a secondary infection with Heligmosomoides 
polygyrus [151], and in expulsion of primary Nippostrongylus brasiliensis infection 
[152]. In both these settings, parasite clearance is dependent upon a strong TH2 
response, which acts to rapidly recruit immune cells including macrophages to the 
infection site and to stimulate their expression of Arginase 1, RELMα, and Ym1/2 in a 
STAT-6-dependent manner [150]. 
Importantly, the classic dogma of macrophage differentiation from recruited 
monocytes during inflammation was challenged by a study that demonstrated that 
tissue macrophages undergo massive proliferation during nematode infection [5]. In 
this scenario, IL-4 produced by TH2 cells is sufficient to cause local macrophage 
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proliferation, resulting in increased numbers of alternatively activated macrophages, 
which are essential for parasite expulsion and wound healing during helminth infection 
[5]. Furthermore, recruited classically activated macrophages were induced to 
proliferate as long as sufficient IL-4 was present [5]. The signalling mechanism 
regulated by IL-4 to push macrophages into the cell cycle seems to be dependent on 
Akt phosphorylation [103]. It has been hypothesized that the expansion of tissue 
macrophages by proliferation would bypass the requirement for bone marrow-
generated monocytes and thus allows local sites to rapidly achieve macrophage-
mediated effector functions [109].  
Moreover, accumulating evidences suggest that the activity of macrophages 
has a key role in progression to obesity [153]. The activation program of macrophages 
in obese and nonobese individuals differs sharply [154]. Additionally, the number of 
macrophages embedded in adipose tissue rises as a person’s body fat increases [155]. 
These classically activated or “M1” macrophages produce, among others, the pro-
inflammatory cytokine TNF-α that act systemically and affect metabolism by decreasing 
the sensitivity of other cells to insulin [156]. Adipose tissue itself releases a collagenous 
protein hormone into the circulation called adiponectin that modulates a number of 
metabolic processes, including glucose regulation and fatty acid oxidation[153] . 
However, in obesity, adiponectin production declines and macrophages produce 
resistin, which induces insulin resistance and glucose intolerance leading to 
diabetes[153] . Slender individuals have fewer macrophages per gram of body fat and 
are in an alternatively activated or “M2” state [157]. This activation program is induced 
by IL-4 or IL-13, derived from fat-tissue residential eosinophils [158]. Downstream of 
the IL-4Rα, through which both IL-4 and IL-13 signal, is the nuclear hormone receptor 
PPARγ that, when activated by appropriate lipids, inhibits the expression of genes that 
promote inflammation and protects against insulin resistance [159, 160]. Accordingly, it 
has been shown that cell-intrinsic lysosomal lipolysis plays a critical role during 
alternative activation of macrophages, explaining why and how M2 polarization is 
dependent on fatty acid oxidation [161]. Whereas M2 macrophages are fuelled by 
oxidative phosphorylation and have increased levels of Arg-1, AMPK (5' AMP-activated 
protein kinase) and the liver type-phosphofructokinase 2 or 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 1 (PFKFB1) , M1 macrophages rely on glycolysis 
for ATP production and have increased levels of iNOS, HIF-1α (hypoxia-inducible 
factor 1-alpha) and ubiquitous PFK2  or PFKFB2 [162, 163]. 
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Finally, The plasticity of alveolar macrophages to change from one activation 
state to another could be important to keep the alveoli sterile and not inflamed. 
Alteration or dysregulation of this balance M1↔M2 might be associated with respiratory 
diseases since the persistence of a pro-inflammatory response (M1) is harmful to the 
tissue [4, 7] and, conversely, the permanence of an alternatively activated phenotype 
(M2) favours bacterial and viral infections, promotes tumour progress and the 
development of certain chronic respiratory diseases such as pulmonary fibrosis [4, 8]. 
Alveolar macrophages are located in a unique tissue compartment. They are 
covered by an aqueous fluid enriched in a lipo-protean material called pulmonary 
surfactant, which is essential to keep the alveoli open during cycles of inhalation-
exhalation [9]. Pulmonary surfactant not only protects the lung from alveolar collapse, 
but also participates in the innate immune defence [9], especially due to the activity of 
SP-A and SP-D [11]. The potential effect of surfactant components, in particular of SP-
A, on alveolar macrophage polarisation towards a pro-inflammatory phenotype M1 or 
an anti-inflammatory phenotype M2 has not been investigated in depth. 
 
3.2 - The humoral component of the innate immune defence 
The particles or microorganisms that reach the alveolar spaces get in contact 
with a range of soluble mediators produced by cells of the respiratory tract and 
therefore present in the mucus. These molecules can lead to lysis of pathogens directly 
through direct antimicrobial activity, or indirectly through opsonisation of bacteria and 
virus or the recruitment of inflammatory cells [21]. Among others, the most abundant 
and important defence proteins in the alveolar fluid are: immunoglobulin G, lysozyme, 
lactoferrin, cathelicidins, defensins, pattern recognition receptors (i.e. pentraxins, LBP, 
soluble CD14), galectins and some components of the pulmonary surfactant [21, 164, 
165] (Fig. 5). 
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Figure 5. Integration of innate and adaptive components in the alveoli. PAMPs derived 
from commensal microbes, allergens or pollutants are recognized and cleared by innate 
immune components (i.e. alveolar macrophages, epithelial cells and surfactant collectins) to 
avoid unnecessary inflammation. Respiratory pathogens and lung damage, activate the cellular 
components of the innate immune system, which induce the production of cytokines, 
chemokines and antimicrobial proteins that recruit and activate cells of the innate and adaptive 
immune systems and regulate barrier function.  Taken from [166].  
 
3.2.1- Pulmonary surfactant  
Pulmonary surfactant is present in the alveolar fluid as an extracellular 
membrane network that covers the air-liquid interface. Its main function is to reduce the 
surface tension at the air-liquid interface, thereby preventing alveolar collapse at the 
end of expiration [167]. Moreover, lung surfactant improves the mucociliary transport, 
and together with alveolar macrophages, constitutes the front line of defence against 
inhaled pathogens and toxins [168]. 
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Figure 6. Integration of pulmonary surfactant function, secretion and recycling, and 
composition. After synthesis by type II epithelial cells (A and C), pulmonary surfactant (detailed 
composition in B) is stored as tightly packed bilayer membranes called lamellar bodies that are 
then secreted by exocytosis to the alveolar fluid (A and D), where spontaneously unravel in a 
lattice-like structure termed tubular myelin and large surfactant aggregates (A and E-F). They 
have high surface activity and adsorb very rapidly to the air-liquid interface preventing alveolar 
collapse at the end of expiration. These structures form a surface film at the alveolar air/liquid 
interface consisting of a phospholipid monolayer with bilayer structures attached to it. With 
surface compression and expansion cycles, small surfactant aggregates (A and G) with poor 
surface activity are generated, which are taken up and degraded by alveolar macrophages and 
recycled by type II cells. The biophysical activities of surfactant are integrated with alveolar host-
defence functions that are mediated by the structural components of surfactant (SP-A, SP-B, 
SP-C and lipids) and soluble SP-D, which have intrinsic antimicrobial activity. Tubular myelin, 
formed by surfactant proteins SP-A and SP-B, and lipids create a highly structured reservoir of 
surfactant and host defence proteins that interact with alveolar macrophages and other cells of 
the immune system to bind to and remove microbial pathogens and ‘instruct’ inflammatory cells 
to mount appropriate host-defence responses (A).  Taken from [9, 166] 
3.2.2 - Surfactant protein A  
SP-A represents approximately ~3-5% of the total mass of surfactant. It is 
synthesized and secreted by type II pneumocytes and nonciliated bronchial epithelial 
cells (Club cells, previously called Clara cells). This protein has ability to bind lipids, 
and therefore is tightly associated with surfactant membranes. SP-A participates 
actively in surfactant adsorption, recycling, and subsequent homeostasis [11, 169] (Fig. 
6).  
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3.2.2.1 - SP-A structure  
SP-A along with SP-D, belongs to the mammalian collectin family, which are 
secreted to the alveolar or other mucosal fluids [11]. Collectins are characterized by the 
presence of an N-terminal collagen-like region and a C-terminal lectin domain, 
comprising a Ca2+-dependent carbohydrate recognition domain (CRD) [170]. Other 
members of the collectin family of proteins include: mannose-binding lectin (MBL), 
conglutinin, collectin liver 1 (CL-L1), collectin placenta 1 (CL-P1), collectin kidney 1 
(CL-K1), collectin of 43 kDa (CL-43) and collectin of 46 kDa (CL-46). Apart from CL-L1 
and CL-P1, all collectins are soluble and secreted proteins [171]. C1q is another 
soluble collagenous defence protein structurally homologous to SP-A and MBL and 
although it does have a collagen-like N-terminal triple helix it is not a collectin, as it 
does not have a lectin domain (CRD). Therefore, it has been used as a tool to explore 
the functionality of SP-A’s collagen domain in various studies.  
SP-A primary structure shows four structural domains and SP-A mature 
protein presents supratrimeric oligomerization, consisting of 18 monomers (Fig. 7).  
Each monomer (36 kDa) is composed by the following domains [172]: 
• N-terminal domain 
It is formed by 8-11 aminoacids, depending on species and variation in N-
terminal processing. Two cysteines residues of this region (positions -1 and 6) have 
been shown to participate in intermolecular disulphide bond formation, which stabilizes 
the oligomer [173, 174]. The Cys6 forms an interchain disulphide bond that is 
necessary for the interaction of the protein with surfactant lipids and type II 
pneumocytes [175]. 
• Collagen domain 
The collagen domain or collagen-like region of SP-A consists of 23 Gly-X-Y 
repeats, where X and Y are generally proline or hydroxyproline [170]. These repeats 
are interrupted close to the middle. The interruption introduces a link in the region that 
gives flexibility to the protein, allowing SP-A to fold in a bouquet-like structure. The 
collagen domain of SP-A undergoes N- or O post-translational glycosylations. 
Subsequently, three monomeric collagen helices are coiled to form a stable tensile 
domain that is relatively resistant to proteases [176]. This domain is thought to be 
involved in several functions of SP-A, including protein oligomerization, chemotaxis, 
	
	
43	
receptor-mediated effects, pathogen agglutination, increased phagocytosis, and 
binding to target ligands [17, 172, 177]. 
• Neck domain 
This domain is localized between the collagen-like and globular domains and 
comprises a segment of 34 aminoacids with α-helical structure. It is directly involved in 
the trimerization of monomers, since three neck domains associate to form a triple 
coiled-coil structure, maintained by hydrophobic interactions. These structures have 
been also observed in other proteins of the collectin family such as SP-D or mannose-
binding lectin [170]. In addition, this domain is critical for the selective binding of SP-A 
to various ligands, since it can guide the globular domains of SP-A trimers [176]. 
• Globular domain  
The CRD of SP-A is composed of 123 aminoacids, which make up the C-
terminal segment of the protein. This domain has 4 cysteines that form two intrachain 
disulphide bonds (Cys204-Cys218 and Cys135-Cys266). It also has 18 highly 
conserved residues, which are common among C-type lectins [178]. This domain 
resembles a globe-like structure, which is suitable for the interaction of SP-A with a 
range of ligands and lipid membranes [179]. In this domain there are at least two 
calcium-binding sites [179, 180]. 
 
Figure 7. SP-A oligolimerization and structural domains. SP-A monomers consists of a 
globular domain, neck , collagen-like and N-terminal domains. Three monomers oligomerize to 
form a triple coiled-coil structure, leading to the formation of trimeric subunits. Trimeric subunits 
multimerize subsequently into octadecameric forms.  
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3.2.2.2 SP-A processing  
SP-A is synthesized as a preprotein with a leader sequence of 17-28 amino 
acids, which is cleaved from the nascent peptide as it is translocated into the 
endoplasmic reticulum [181].  
After synthesis, SP-A is extensively modified in the rough endoplasmic 
reticulum and Golgi [182]. Most of the folding and assembly of SP-A occurs before the 
protein exits the endoplasmic reticulum. SP-A is also co-translationally glycosylated 
with mannose-rich, endoglycosidase H sensitive carbohydrates in the endoplasmic 
reticulum. Late post-translational carbohydrate modifications in the Golgi apparatus 
include sialylation [183] and sulfation [184]. The complex folding, assembly and 
processing of SP-A likely contributes to the relatively slow rate at which SP-A traverses 
the secretory pathway [185]. 
SP-A is secreted into the alveolar space by two or more routes; via a regulated 
pathway that includes the lamellar body [186, 187] and a principal constitutive pathway 
that bypasses that compartment [188]. 
SP-A multimerizes in a process that can be conceptualized in two parts: First, 
SP-A trimers are built up by the association of three polypeptide chains. The collagen 
regions intertwine to form a collagen triple helix. Second, octadecamers are formed by 
lateral association of the N-terminal half of six triple-helical stems to yield the complete 
protein, an octadecamer of 650 kDa and 20 nm in length, which has the appearance of 
a bouquet of tulips [189, 190]. Furthermore, mammalian SP-A is not only assembled in 
supratrimeric oligomers but can also form multimers by self-association in the presence 
of Ca2+ [17]. Supratrimeric oligomerization and multimerization of SP-A are required for 
many of its functions, because the binding activity of a single SP-A lectin domain is 
very low [17, 173, 177]. Among carbohydrates, SP-A binds preferentially to mannose 
and fucose, which are sugars commonly found on fungal and microbial surfaces [191]. 
One of the most important properties of SP-A is its ability to bind lipids, preferentially to 
dipalmitoylphosphatidylcholine or sphingomyelin [192-194]. In fact, and SP-A co-
isolates with surfactant lipids and is highly associated with them [194]. SP-A's ability to 
bind to surfactant lipids improves the biophysical activity of surfactant membranes, 
protects them from the inhibitory action of serum proteins, and allows SP-A to position 
and concentrate together with surfactant membranes at the front lines of defence 
against inhaled toxins or pathogens [9].  
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3.2.2.3 SP-A gene and differences between SP-A1 and SP-A2 
In the course of evolution, the genetic complexity of SP-A gene has increased, 
particularly in the regulatory regions (i.e. promoter, untranslated regions). Most species 
have a single SP-A gene however; in humans and primates SP-A is encoded by two 
genes (SFTPA1 and SFTPA2) [195]. Both genes are expressed in type II pneumocytes 
[196], but only SP-A2 gene is expressed in tracheal and bronchial submucosal gland 
cells [197, 198]. It has been proposed hat both gene products may be expressed in a 
2:1 ratio (SP-A1:SP-A2) [199].  
Qualitative differences between in vitro–expressed variants SP-A1 and SP-A2 
include differences in their ability to enhance phagocytosis by alveolar macrophages 
[200, 201] and inhibit surfactant secretion by epithelial type II cells [202]. Differences in 
their aggregation, structural stability, oligomerization properties, sugar-binding 
characteristics, and ability to form phospholipids monolayers have also been observed 
[177, 202-204]. In most of these assays, SP-A2 was shown to be more active than SP-
A1 indicating that some fundamental differences may exist between SP-A1 and SP-A2. 
Moreover, the ability of SP-A2 to bind with higher affinity to a wider variety of sugars 
than SP-A1 indicates that the structural pattern or other attributes of SP-A2 make it 
more favourable for more diverse carbohydrate binding [205]. Similar observations with 
regard to oligomerization patterns have been made with in vivo–expressed SP-A1 and 
SP-A2 variants in humanized transgenic mice [206]. These in vivo experiments also 
showed that both SP-A1 and SP-A2 gene products are necessary for the formation of 
the extracellular structural form of surfactant, the tubular myelin. In summary, the 
available data indicate that in vitro– or in vivo–expressed single gene products are 
functional, although with some qualitative and structural differences between the two 
gene products [195]. 
3.2.2.4 Regulation of SP-A expression 
SP-A is undetectable in human foetal lung tissue during the early part of the 
second trimester (prior to the differentiation of the alveolar epithelium) [207]. 
Differentiated type II cells that contain lamellar bodies are observed in human foetal 
lung by ∼22 weeks of gestation, and active surfactant secretion into amniotic fluid 
occurs after ∼30 weeks of gestation. Immunoreactive SP-A can be detected in amniotic 
fluid at 30 to 32 weeks of gestation [208]. 
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SP-A gene expression is regulated by several growth factors, hormones, and 
regulatory agents [185]. SP-A mRNA and protein levels are increased by treatment with 
cAMP analogs [209], epidermal growth factor [210], IFN-γ [211], prostaglandins [212], 
oxygen [213, 214], endotoxins [215, 216], and β-adrenergic agonists [217]. SP-A 
protein lelves are decreased by insulin [218] and transforming growth factor (TGF-β) 
[210]. Also, TNF-α [219], and 12-O-tetradecanoyl-phorbol-13-acetate [220] decreased 
SP-A mRNA and protein levels. Both inhibitory and stimulatory effects of 
glucocorticoids on SP-A expression have been reported, with the inhibitory effect 
observed at higher hormone concentrations [221, 222].  
Abnormalities in SP-A levels have been detected in several diseases. For 
example, SP-A levels are decreased in the amniotic fluid of diabetic pregnant mothers 
[223, 224]. Pregnancies characterized by low levels of SP-A protein in the amniotic fluid 
are associated with an increased risk of the infant being born with respiratory distress 
syndrome [225].  
SP-A protein levels are increased in BAL of patients with pulmonary alveolar 
proteinosis, sarcoidosis, and hypersensitivity pneumonitis [226-228]. Additionally, an 
increase of SP-A protein levels in BAL of asthmatic patients has been observed, 
however it is unclear whether this SP-A is functional or it is modified by factors secreted 
by eosinophils, since SP-A from asthmatics patients has been found to have 
diminished its anti-inflammatory activity [229].  BAL SP-A levels in patients with both 
cystic fibrosis and lower airway infections are higher than in cystic fibrosis patients 
without infection [230]. This increase may occur in response to infection. Additionally, 
BAL and serum SP-A levels in patients with AIDS-related pneumonia are increased 
when compared to normal healthy subjects [231]. This increase is not pathogen 
specific and is seen in infections with P. carinii and non-P. carinii. Whether the increase 
in SP-A in AIDS-related pneumonia is a cause or an effect of infection is unclear. 
Serum SP-A levels have been also reported in patients diagnosed with idiopathic 
pulmonary fibrosis [229]  and combined pulmonary fibrosis and emphysema [232], 
probably due to extensive damage of lung tissue, leading to transfer of alveolar 
contents to the blood.  
However, a decrease in BAL SP-A protein levels was observed in patients with 
bacterial and viral pneumonia [233, 234]. Decreased BAL SP-A levels have also been 
reported in bronchopulmonary dysplasia with infection in baboons [235], in interstitial 
pneumonia with collagen vascular disease [236], and in smokers versus non-smokers 
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[229]. Decreased SP-A levels are observed in lavage of patients with idiopathic 
pulmonary fibrosis [229, 236, 237].  
3.2.2.5 SP-A beyond the alveolus  
The major site of SP-A synthesis is the lung; however it has been also detected 
in extra-pulmonary mucosal tissues [238]. SP-A mRNA and/or protein have been 
detected in the conducting airways [197, 239, 240], middle ear and paranasal sinuses 
[241, 242], gastrointestinal tract [243, 244], reproductive tract (vagina and prostate) 
[245], spleen [246], thymus [245], mesothelium, synovium (pleura, pericardium, and 
peritoneum) [247], and ocular system [248, 249]. The presence of SP-A in these 
extrapulmonary sites, especially in mucosal tissues, which are largely exposed to 
pathogens and external particles, supports the important role of SP-A in host defence. 
 
3.2.3 - Immunoprotective role of SP-A 
 
SP-A is one of the soluble factors that contribute to host defence and to create 
an anti-inflammatory state in the lungs through various mechanisms. SP-A recognizes 
pathogen-associated molecular patterns on some microorganisms, resulting in 
aggregation, opsonisation, or permeabilization of microorganisms and facilitation of 
microbial clearance [11, 250]. It has been reported that SP-A-deficient mice show 
decreased microbe clearance from the alveolar space and increased tissue markers of 
inflammation [251]. One of the mechanisms through which SP-A protects the lung of 
respiratory pathogens is through synergy with other components of the alveolar fluid, 
such as the antimicrobial peptide SP-BN, which leads to improved clearance of 
Klebsiella pneumonia [250]. Moreover, SP-A is also able to bind to membrane 
receptors present in macrophages, epithelial cells, and lymphocytes, modifying their 
response to different stimuli [11]. These findings make SP-A’s protective role in alveolar 
immune defence evident. 
 
3.2.3.1 Anti-infective roles of SP-A  
There is evidence that SP -A limits infection through its ability to bind 
pathogens. This binding in some cases exerts a direct microbicidal effect and in other 
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cases promotes pathogen agglutination facilitating its removal by phagocytosis [11] 
(Fig. 8).  
• Direct Microbicidal Activity 
SP-A performs this activity mainly because its capability to bind to various 
ligands existing on the surface of microbes, such as rough LPS on Gram-negative 
bacteria, glycoprotein on fungi, lipoarabinomannan on mycobacteria, phospholipids on 
mycoplasma, and glycoproteins on virus surface [11].  
It has been shown that SP-A directly inhibits the growth of some Gram-negative 
bacteria such as E. coli, Bordetella pertussis, Legionella pneumophila and P. 
aeruginosa by increasing bacterial membrane permeability [252-255]. It has been 
suggested that bacterial permeabilization and killing require interaction between SP-A 
and LPS, most likely through the protein binding to the proximal core and/or lipid A 
moieties of LPS [256]. However, SP-A has no direct bactericidal effect against Gram-
negative respiratory pathogens such as Klebsiella pneumonia; but SP-A synergizes 
with the antimicrobial peptide SP-BN found in the alveolar fluid to bind, kill and enhance 
phagocytosis of K. pneumonia [14]. This effect of SP-A acting in synergy with other 
humoral defence alveolar factors is another mechanism that may explain the greater 
susceptibility of SP-A-/- mice to respiratory pathogen infections [11]. 
There are no reports about direct killing of SP-A in Gram-positive bacteria 
however; it has been shown that SP-A is able to inhibit the growth of other bacterial 
groups, as mycoplasma or mycobacteria [257, 258].  
Direct activity of SP-A on virus can be referred to as viral neutralization. It has been 
shown that SP-A binds to influenza A viruses (via its sialic acid residues) and inhibits 
recognition of host cell and entry of the viral genome into the target cell [259]. 
Additionally, SP-A can interact with herpes simplex virus type 1 [260], respiratory 
syncytial virus [261] and human immunodeficiency virus neutralizing their infectivity 
[262].  
It has been also reported that SP-A has a direct killing effect on some species of 
fungi. SP-A has been reported to inhibit the growth of Histoplasma capsulatum by 
altering the cell membrane [263]. The interaction of SP-A with fungi seems to be 
directed by two mechanisms: binding to structural polysaccharides consisting of 
repetitions of the same oligosaccharide elements, and interaction with glycosylated 
proteins expressed by fungi on their surface [170].  
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• Agglutination and Enhancement of Phagocytosis  
SP-A is able to interact through its C-terminal domain with a variety of 
molecules present in bacterial, viral or fungal surfaces (i.e. LPS, and other 
glycoproteins and glycolipids). This feature allows SP-A to agglutinate molecules or 
microorganisms enhancing mucociliary removal of inhaled dangerous particles, 
preventing the attachment of pathogens to cell surfaces, and/or inhibiting microbial 
colonization, invasion and dissemination [170]. 
SP-A is capable to opsonize microorganisms facilitating uptake by phagocytic 
cells without the necessity of SP-A interaction with the cell [264, 265]. However, the 
interaction of SP-A with specific membrane receptors located in alveolar immune cells, 
such as scavenger receptor A or Myo18A, results in the enhancement of pathogen 
phagocytosis [266]. Furthermore, SP-A is able to indirectly stimulate phagocytosis by 
up-regulating the expression of immune cell-surface receptors that are involved in 
microbial recognition, like the macrophages cell receptors scavenger receptor A [267], 
complement receptor 3 [268] or mannose receptor [269].  
 
Figure 8. SP-A functions in lung innate defence against infection. SP-A is able to 
agglutinate and increase phagocytosis of microbes, as well as to act in synergy with the 
antimicrobial peptide SP-BN to bind, kill and increase phagocytosis of pathogens such as K. 
pneumoniae . In addition, SP-A modulates phagocytosis and production of inflammatory 
mediators through interaction with several immune cells receptors. Modified from [11]. 
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3.2.3.2 Immuno-regulatory functions of SP-A and SP-A’s receptors  
Another level on which SP-A participates in the immune regulation relies on its 
capacity to modulate leucocyte function by binding to a vast repertoire of receptors 
present in these immune cells (Fig. 9 and table 2) [11]. Studies involving SP-A null 
mice showed that these mice exhibited an augmented inflammatory response to a 
variety of stimuli, suggesting an anti-inflammatory role of SP-A [256].  
 
Figure 9. Surfactant protein A (SP-A) receptors. SP-A potentially binds several receptors, 
including Myo18A, Toll-like receptor 2 (TLR2), TLR4, signal-inhibitory regulatory protein-α 
(SIRP-α) and CD91-calreticulin. SP-A binds to SIRP-α and inhibits production of inflammatory 
mediators. By contrast, when SP-A is bound to a pathogen or cellular debris, its collagen-like 
region is bound to CD91-calreticulin and induces inflammatory-mediator production. Taken from 
[11].  
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Table 2. Summary of SP-A receptors on immune cells. Taken from [270] 
Receptor SP-A domain Expressed by Functions 
Myo18A Collagen-like tail T-cells, epithelial 
type II cells and 
macrophages 
 
Inhibits T-cell 
proliferation, 
enhances bacterial 
phagocytosis and 
exerts immuno-
regulatory 
functions on 
macrophages 
TLR2 --- Macrophages  Modulates 
inflammatory 
responses against 
zymosan or 
peptidoglycan 
TLR4 and MD-2 CRD region Macrophages Attenuates cell 
surface binding of 
smooth LPS and 
subsequent NF-kB 
activation 
CD14 Neck region Macrophages Inhibits 
smoothLPS/CD14 
interactions 
Calreticulin-CD91 
complex 
Collagen-like tail Macrophages Enhances 
phagocytic uptake 
of apoptotic cells 
C1qRp (CD93) --- Myeloid lineage of 
hematopoietic cells  
Removes 
pathogens and 
immune complexes 
via phagocytosis 
SIRPα Globular domain Macrophages Inhibits pro-
inflammatory 
mediators 
CD11b (CR3) Asparagine-linked 
glycosilation 
moieties and 
collagen-like 
domain 
Alveolar 
macrophages 
Augments 
phagocytosis 
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• Effect of SP-A on macrophages  
Numerous in vitro and in vivo studies in alveolar macrophages have shown that 
SP-A plays an important anti-inflammatory role by suppressing TLR-ligands activity on 
these cells [256, 271-275]. SP-A blocks the binding of TLR ligands to their receptors by 
direct SP-A interaction with TLR4 [273], TLR2 [276], the TLR co-receptor MD2 [276], 
and CD14 [16, 17]. Additionally, SP-A modifies signalling cascades elicited by TLR 
ligands in macrophages. For example, SP-A inhibits LPS-induced stimulation of 
macrophages through increasing the expression of negative regulators of TLR-
signalling, such as IRAK-M [277] and β-arrestin 2 [278]. SP-A has been shown to 
reduce the production of reactive oxygen intermediates by inhibiting NADPH oxidase 
activity in human monocyte-derived macrophages activated by PMA or serum-
opsonized zymosan [279]. Some effects of SP-A inhibiting TLR-ligands-induced 
signalling have been proved to require SP-A endocytosis. For example, SP-A-induced 
PKCζ activation and IκBα stabilization, which results in diminished NFκB activation 
upon LPS stimulation, requires SP-A endocytosis by macrophages [280]. Moreover, 
SP-A inhibition of IκBα, ERK, p38, and Akt phosphorylation in macrophages stimulated 
with TLR2 and TLR4 ligands, required SP-A internalization [281].   
With regard to the effect of SP-A on IFN-γ-induced classical activation of 
macrophages, it has been shown that SP-A modulates alveolar macrophages-immune 
response to IFN-γ however; contradictory results have been reported. One study 
suggested that SP-A enhances production of NO and iNOS in rat alveolar 
macrophages stimulated with IFN-γ or INF-γ plus LPS [282]. In contrast, other studies 
indicate that SP-A suppresses NO production by IFN-γ and IFN-γ plus M. avium-
stimulated murine alveolar macrophages [283] or IFN-γ plus M. tuberculosis-activated 
murine alveolar macrophages [284]. Similarly to these contrasting results about SP-A 
effect on IFN-γ-stimulation of macrophages, few studies suggested an enhancing effect 
of SP-A on LPS-treated THP-1 and Raw264.7 cell lines [285-288]. Although co-purified 
proteins obtained with different methods of SP-A isolation have been suggested to be 
responsible of either attenuating or enhancing response of macrophages to LPS [288], 
the three contrasting studies about the effect of SP-A on IFN-γ-stimulation of 
macrophages have been done with SP-A extracted by the butanol/octylglucoside 
method. Therefore, different modulation of LPS/IFN-γ-induced classical activation of 
macrophages by SP-A may depend on other factors rather than on the SP-A isolation 
method used. 
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Although a host of reports indicate a suppressive role of SP-A during 
macrophage activation, a few studies have shown that SP-A has a role in promoting 
inflammation [266, 289, 290]. Furthermore, Gardai and collaborators [42] showed that, 
in a model of peritoneal inflammation, SP-A, promotes phagocytosis as well as 
inflammation by binding to pathogen-associated molecular patterns or apoptotic cells 
through its globular heads and to calreticulin-CD91 on macrophages with its 
collagenous tails. Alternatively, interaction of the signal-regulatory protein SIRPα 
(which mediates a so-called ‘do not eat me’ signal) on macrophages with the globular 
heads of SP-A suppresses macrophages inflammatory responses and phagocytosis.  
Another receptor of SP-A is Myosin 18A (Myo18A or MyoXVIIIA), also called 
surfactant protein A receptor 210 (SP-R210) [291]. This SP-A receptor has been shown 
to mediate SP-A enhanced phagocytosis of the bacillus Calmette-Guérin and 
Staphylococcus aureus by macrophages [266, 292]. The two isoforms of Myo18A (the 
large, Myo18Aα, and the short isoform, Myo18Aβ) have been found to regulate 
expression and/or internalization of other receptors on macrophages, such as 
scavenger receptor A (SR-A), CD14 or CD36, and the short isoform has been found to 
physically associate with SR-A and CD14 to enhance response to LPS, suggesting 
additional mechanisms through which SP-A may modulate macrophages [288]. These 
contrasting results indicate that, depending on the environmental cues; SP-A can have 
pro- or anti-inflammatory effect on macrophages, which may be determined by the 
interaction of the tail or the head of SP-A with different receptors on the alveolar 
macrophages [42].  
The effect of SP-A on the alternative activation of macrophages is less well 
defined. It has been suggested that SP-A may contribute to the alternative activation of 
macrophages as it has been shown that SP-A induces the expression of CD206, which 
is a commonly used marker of alternative activation [13, 269]. However, until now no 
studies have been made about the effect of SP-A on IL-4/IL-13 stimulation of alveolar 
macrophages.  
• SP-A targets other immune cells  
Besides the effects of SP-A on alveolar macrophages there is evidence that SP-
A targets other cells of the immune system. In vitro and in vivo studies have indicated 
that SP-A attracts neutrophils [293, 294]. It has been suggested that SP-A performs 
neutrophil chemotactic activity by stimulating the release of neutrophil chemotactic 
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factors by alveolar type II pneumocytes [295]. However, SP-A represses the production 
and secretion of IL-8 by isolated eosinophils stimulated with ionomycin [296]. 
Additionally, SP-A expression is up-regulated in patients with allergic rhinitis as 
compared to controls and positively correlated with eosinophil numbers in the 
basement membrane of the epithelium, suggesting a key role in mediating inflammation 
associated with this disease [297]. 
It has been shown that SP-A interacts with antigen-presenting cells (APCs) and 
T cells, thereby linking the innate and adaptive immune systems [297] (Fig. 10). It has 
been shown that SP-A inhibited bone-marrow derived dendritic cells maturation and 
their phagocytic and chemotactic function [11]. SP-A has been reported to inhibit T-cell 
proliferation via two mechanisms: an IL-2-dependent mechanism observed with T cells 
that have been stimulated with plant lectins, CD3-specific antibodies or phorbol esters 
and an IL-2-independent mechanism that potentially involves downregulation of 
calcium signalling [11]. However, it has been shown that SP-A enhances T cell 
proliferation at low strength of signal imparted by exogenous mitogens, specific 
antibodies, APCs or in homeostatic proliferation, whereas SP-A inhibits T lymphocytes 
proliferation at higher strength of signal [298].  Additionally, SP-A has been shown to 
favour T regulatory cells differentiation in a TGF-β-dependent manner [299]. 
These effects of SP-A on adaptive immune cells have been proposed to be one 
of the mechanisms of the protective role of SP-A in allergic airway diseases. It has 
been demonstrated that SP-A reduce allergen-induced lymphocyte proliferation and 
histamine release in peripheral blood mononuclear cells harvested from children with 
asthma [300]. In vivo studies have shown that SP-A null mice are more susceptible to 
allergic bronchopulmonary aspergillosis, an allergic disorder induced by Aspergillus 
fumigatus, and exogenous administration of SP-A reduced A. fumigatus associated, T 
cell-mediated, inflammatory indices [301]. SP-A null mice also have enhanced 
susceptibility to allergic airway disease induced by the single antigen model ovalbumin 
(OVA). It has been shown that SP-A null mice treated with OVA have greater 
eosinophilia, TH2-associated cytokine levels, and IgE levels as well as elevated 
proportions of CD4+ effector memory T cells in their lungs compared to wild-type mice 
treated with OVA [302].  
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Figure 10. Surfactant protein A (SP-A) regulates dendritic-cell and T-cell functions, 
thereby providing a link between innate and adaptive immunity. SP-A has been shown to 
inhibit the maturation of dendritic cells (DCs). Additionally, SP-A inhibits T-cell proliferation. As 
DCs migrate to the lymph nodes and undergo a maturation process, they acquire the ability to 
present antigen and activate T cells in the lymph nodes. Modified from [11]. 
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V. OBJECTIVES 
Lung respiration moves massive amounts of air containing hundreds of 
microorganisms and particles over the respiratory surface. Most, but not all, inhaled 
contaminants are trapped on the mucus layer coating the nasal epithelium and upper 
respiratory tract. Organisms and particles that reach the alveolar compartment are 
deposited on the alveolar lining fluid, a thin aqueous film containing lung surfactant 
[303] that participates in alveolar innate immune defense, especially due to the activity 
of surfactant proteins SP-A and SP-D [11].  
The major effector cells of innate immunity in the alveolar fluid are resident 
alveolar macrophages (aMφs) that constitute a unique class of professional phagocytes 
[3, 4]. Some proteins and peptides present in the alveolar fluid, such as SP-A, 
constitute the humoral arm of innate immunity in the alveoli. Macrophages recognize 
danger signals through receptors capable of inducing specialized activation programs. 
The so-called classical activation of macrophages is induced by TLR-ligands and/or 
IFN-γ, which trigger a harsh pro-inflammatory response that is required to kill 
pathogens [3, 4]. Macrophages also acquire alternative activation by IL-4 and IL-13, 
which trigger a different phenotype that is important for the immune response to 
parasites and tissue repair [3, 4]. Recent studies have demonstrated that a hallmark 
feature of macrophage activation by IL-4 is the induction of macrophage proliferation, 
which may be necessary to generate sufficient numbers of macrophages for pathogen 
control or wound repair [5, 102, 103, 304].  
It is known that SP-A inhibits macrophage activation induced by TLR-ligands 
and some microorganisms [11, 303]. Many studies have demonstrated that SP-A 
inhibits macrophage activation induced by LPS [16, 17], zymosan [305], and 
peptidoglycan [276] by binding to different components of TLR4 and TLR2 receptors. In 
contrast, the action of SP-A on IFN-γ-activated macrophages is less clear [282-284], 
and the effect of SP-A on the alternative activation of macrophages remains unknown. 
As most evidence suggests an anti-inflammatory effect of SP-A on resident alveolar 
macrophages [11, 303], we hypothesized that SP-A may regulate alveolar macrophage 
activation, probably reducing the pro-inflammatory response induced by IFN-γ or IFN-γ 
plus LPS and promoting the alternative phenotype induced by IL-4. 
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The main objective of this thesis was to evaluate the effect of SP-A on 
classical activation, induced by IFN-γ or IFN-γ plus LPS, and on alternative 
activation of alveolar macrophages induced by IL-4.  
This thesis comprises three chapters with the following specific objectives: 
1. To evaluate the effect of SP-A on classical activation of alveolar 
macrophages induced by IFN-γ in the presence or absence of LPS.  
 
Rationale: SP-A has been reported to modulate alveolar macrophage immune 
responses to IFN-γ in the absence or presence of LPS or pathogens; however, there 
are contradictory reports: While it was shown that SP-A enhances production of NO 
and iNOS in rat alveolar macrophages stimulated with IFN-γ or INFγ plus LPS [282], 
other studies indicate that SP-A suppresses NO production by IFN-γ– and IFN-γ plus 
pathogen–stimulated murine alveolar macrophages [283]. Besides, the molecular 
mechanism by which SP-A could modulate alveolar macrophage responses to IFN-γ is 
unknown. To understand the modulatory effects of SP-A on the response of aMφs to 
IFN-γ  and IFN-γ+LPS stimuli, we studied the effect of SP-A on IFN-γ-stimulated human 
and rat alveolar macrophages and human M-CSF-derived macrophages (Mφ(M-CSF)) 
in the absence or presence of LPS. The results of this chapter show that SP-A has an 
anti-inflammatory effect on rat and human aMφs and human Mφ(M-CSF), counteracting 
the stimulation exerted by IFN-γ and/or LPS, and disclose a novel mechanism by which 
SP-A controls IFN-γ-induced inflammation in the alveolus. 
 
2. To discover the role of SP-A during IL-4Rα-mediated alternative 
activation and proliferation of alveolar macrophages and to investigate whether 
SP-A might be a tissue-specific factor that determines the ability of 
macrophages to respond to IL-4. 
Rationale: It has been shown that SP-A enhances the expression of CD206 
[13, 269], a widely used marker of Mφ alternative activation. This observation led us to 
hypothesize that SP-A could favour IL-4-induced alternative activation of alveolar 
macrophages. To address this question and to determine the mechanism by which SP-
A could modulate alternative activation of macrophages, we treated mouse, rat, and 
human alveolar macrophages with IL-4 in the presence and absence of SP-A. In 
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addition, we compared the response of alveolar macrophages from wild type vs. SP-A-
deficient mice to exogenous IL-4 treatment in vivo. We also determined which receptor 
mediates SP-A effects on IL-4-stimulated alveolar macrophages, in vitro and in vivo. 
Finally, the physiological relevance of SP-A’s effect on the alternative activation and 
proliferation of alveolar macrophages was assessed in a model of Nippostrongylus 
brasiliensis infection. The larvae of this parasite migrate transiently through the lung, 
causing tissue disruption and promoting alternative activation of lung macrophages, 
which mediate tissue repair and parasite control [306].  
To determine whether SP-A acts directly and specifically on alveolar 
macrophages, adherence-purified macrophages from the alveolar and peritoneal 
spaces were treated with IL-4, and the ability of SP-A to enhance Mφ proliferation or 
activation was compared with that of C1q, which was chosen as a control because it is 
a protein structurally homologous to SP-A in its supra-trimeric assembly and collagen 
tail. The response of macrophages from wild type vs. C1qa-deficient mice to 
exogenous IL-4 treatment was studied. Finally, to ascertain the physiological relevance 
of C1q-dependent enhancement of type 2 responses, we evaluated the role of C1q in a 
murine model of peritoneal fibrosis. The results of this chapter show that SP-A and C1q 
act in a tissue-specific manner to enhance IL-4Rα-mediated macrophage proliferation 
and activation with consequences for tissue repair, parasite killing, and fibrosis.   
Critically, both the ligands (SP-A in the lung, C1q in the peritoneal cavity) and their 
Myo18A receptor are highly conserved across mammals, and we demonstrated that 
the interaction also takes place in human macrophages.   
 
3. To study the mechanisms by which SP-A enhances IL-4Rα-
mediated macrophage activation and proliferation.  
Rationale: In chapter 2 we identified the unconventional myosin Myo18A as the 
SP-A receptor involved in the enhancement of IL-4Rα-mediated macrophage activation 
and proliferation. Blockade or silencing of Myo18A completely abrogated the effects of 
SP-A on IL-4-treated alveolar macrophages, suggesting that the synergy between SP-
A and IL-4 must occur downstream from their respective receptors. To explore this 
hypothesis, we treated rat alveolar macrophages with IL-4 and SP-A in the presence of 
pharmacological inhibitors of IL-4 and SP-A signaling pathways. The results of this 
chapter show that the pro-proliferative and pro-M2 effects of SP-A require intracellular 
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activation of Akt and PKCζ, respectively, which in turn depend on the SP-A-induced 
upstream activation of PI3K. 
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VI. CHAPTER 1 
 
Surfactant protein A prevents IFN-γ/IFN-γR interaction and 
attenuates classical activation of human alveolar macrophages  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research results presented in this chapter have been published in: 
Minutti C.M., García-Fojeda B, Saenz A., De Las Casas-Engel M., Guillamat-Prats R., De 
Lorenzo A.,Serrano-Mollar A., Corbí A.L., Casals C. Surfactant protein A prevents IFN-gamma/IFN-
gammaR interaction and attenuates classical activation of human alveolar macrophages. Journal of 
Immunology 197(2):590-598, 2016
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Abstract 
 Lung surfactant protein A (SP-A) plays an important function in modulating 
inflammation in the lung. However, the exact role of SP-A and the mechanism by which 
SP-A affects IFN-γ-induced activation of alveolar macrophages remains unknown. To 
address these questions, we studied the effect of human SP-A on rat and human alveolar 
macrophages stimulated with IFN-γ, LPS, and combinations thereof, and measured the 
induction of pro-inflammatory mediators, as well as SP-A´s ability to bind to IFN-γ or IFN-
γR1. We found that SP-A inhibited [IFN-γ+LPS]-induced TNF-α, iNOS, and CXCL10 
production by rat alveolar macrophages. When rat macrophages were stimulated with 
LPS and IFN-γ separately, SP-A inhibited both LPS-induced signaling and IFN-γ-elicited 
STAT1 phosphorylation. SP-A also decreased TNF-α and CXCL10 secretion by ex vivo 
cultured human alveolar macrophages and M-CSF-derived macrophages stimulated by 
either LPS, IFN-γ, or both. Hence, SP-A inhibited up-regulation of IFN-γ-inducible genes 
(CXCL10, RARRES3, and ETV7) as well as STAT1 phosphorylation in human M-CSF-
derived macrophages. In addition, we found that SP-A bound to human IFN-γ (KD =11 ± 
0.5 nM) in a Ca2+-dependent manner and prevented IFN-γ interaction with IFN-γR1 on 
human alveolar macrophages. We conclude that SP-A inhibition of [IFN-γ+LPS]-
stimulation is due to SP-A attenuation of both inflammatory agents and that the binding of 
SP-A to IFN-γ abrogates IFN-γ effects on human macrophages, suppressing their 
classical activation and subsequent inflammatory response.   
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Introduction 
  Pulmonary surfactant is a lipoprotein complex that lines the alveolar surface. Its 
main function is to reduce alveolar surface tension [9]; however, it also functions as a 
modulator of immune responses. The two principal surfactant components involved in 
innate immunity in the alveolus are surfactant proteins A (SP-A) and D (SP-D) [11]. 
 SP-A is an oligomeric extracellular protein that is found mainly in the alveolar 
fluid, associated with surfactant extracellular membranes that line the alveolar epithelium 
and with alveolar cells. SP-A recognizes pathogen-associated molecular patterns on some 
microorganisms, resulting in aggregation, opsonization, or permeabilization of 
microorganisms and facilitation of microbial clearance [11, 250]. Moreover, SP-A is also 
able to bind to membrane receptors present in macrophages, epithelial cells, and 
lymphocytes, modifying their response to different stimuli [11]. It has been reported that 
SP-A-deficient mice show decreased microbe clearance from the alveolar space and 
increased tissue markers of inflammation [251]. These findings make SP-A’s protective 
role in alveolar immune defense evident. 
The major effector cells of innate immunity in the alveolus are the alveolar 
macrophages (aMφs) that constitute a unique class of professional phagocytes [2]. 
Macrophages change their phenotype reversibly in response to stimuli. This process is 
called macrophage activation, which varies from classical activation to alternative 
activation [73]. The term ‘‘classical activation” refers to macrophages stimulated with IFN-
γ (host factor) and pathogen products (e.g., TLR agonists such as LPS) [73]. IFN-γ is the 
main cytokine associated with classical activation of macrophages. It is mainly produced 
by TH1 and natural killer cells and exerts its effects through interactions with its IFN-γ 
receptor complex, composed of the IFNγR1 and IFNγR2 chains, whose cytoplasmic tails 
are associated with JAK1 and JAK2 kinases respectively. IFN-γ binds to IFNγR1 with high 
affinity and activates crosslinking of two molecules of each IFNγR1 and IFNγR2 chain, 
which results in activation of tyrosine kinases JAK1 and JAK2 and phosphorylation of 
STAT1. Activated P-STAT1 translocates to the nucleus, where it mediates the 
transcription of IFN-γ-induced genes such as CXCL10 or IRF transcription factors, among 
others [74, 307]. On the other hand, the transmembrane TLR4 serves as the primary 
mediator of LPS signaling, which leads to activation of NF-κB, MAPK, AP-1, IRFs, and 
early growth response family members, many of which participate in the IFN-γ response 
[308]. LPS-stimulated macrophages produce pro-inflammatory molecules such as TNF-α, 
IL-1β, and CXCL10, among others [73, 308]. IFN-γ can ‘prime’ macrophages to give an 
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enhanced response to TLR ligands, such as LPS [92, 93]. Synergy between IFN-γ and 
LPS occurs at multiple levels, ranging from signal recognition to convergence of signals at 
the promoters of target genes [92]. Thus the presence of both IFN-γ and TLR ligands 
induces resting macrophages to rapidly acquire a set of effector functions (production of 
inflammatory cytokines, chemokines, and reactive oxygen species) that contribute to 
microbial clearance.  
 SP-A has been reported to inhibit LPS-induced signaling (p-IκBα, p-ERK, p-p38, and 
p-Akt) in human monocyte-derived macrophages [281] and to increase expression of the 
negative regulators of LPS-induced signaling in murine [278] and human monocyte-
derived macrophages [277]. SP-A also inhibited the production of pro-inflammatory 
mediators by human [309] and rat [276, 310] aMφs, human monocyte-derived 
macrophages [279], and human macrophage-like U937 cells [16, 17, 273, 276] stimulated 
with LPS and other TLR ligands. Moreover, SP-A has been reported to modulate aMφs 
responses to IFN-γ in the absence or presence of LPS or pathogens, but contradictory 
observations have also been made. For example, Stamme et al. [282] have shown that 
SP-A enhances production of NO and iNOS in rat aMφs stimulated with IFN-γ or IFN-γ 
plus LPS. In contrast, other studies indicate that SP-A suppresses NO production by 
murine aMφs stimulated with IFN-γ– and IFN-γ plus M. avium [283] or IFN-γ plus M. 
tuberculosis [284].  
 To understand the modulatory effects of SP-A on the response of aMφs to IFN-γ 
and IFN-γ+LPS stimuli [Mφ(LPS/IFN-γ)], we studied the effect of SP-A on IFN-γ-stimulated 
human and rat alveolar macrophages and human M-CSF-derived macrophages (Mφ(M-
CSF)) in the absence or presence of LPS. Our data show that SP-A reduces IFN-γ-
triggered inflammation in rat and human aMφs and human Mφ(M-CSF). SP-A inhibition of 
LPS/IFN-γ-induced macrophage stimulation is due to SP-A attenuation of both 
inflammatory agents. Our findings show, for the first time, that SP-A binds to IFN-γ 
preventing IFN-γ interaction with IFN-γR1 on the cell surface. We conclude that this could 
be one of the mechanisms by which SP-A attenuates IFN-γ effects.   
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Materials and Methods 
 
Isolation, purification and characterization of human SP-A 
 Surfactant protein A was isolated from bronchoalveolar lavage of patients with 
alveolar proteinosis using the sequential butanol and octylglucoside extraction [173, 177]. 
Endotoxin content of isolated human SP-A was about 300 pg endotoxin/mg SP-A as 
determined by Limulus amebocyte lysate assay (Lonza, Basel, Switzerland). The purity of 
SP-A was checked by one-dimensional SDS-PAGE in 12 % acrylamide under reducing 
conditions and mass spectrometry.  SP-A consisted of supratrimeric oligomers of at least 
18 subunits (MW, 650 KDa). The oligomerization state of SP-A was assessed by 
electrophoresis under nondenaturing conditions [173, 177], electron microscopy [173], and 
analytical ultracentrifugation as reported elsewhere [177]. Each subunit had an apparent 
molecular weight of 36 kDa. Biotinylated SP-A was prepared using the Mini-biotin-XX 
protein labeling kit (Invitrogen, Carlsbad, CA) as previously described [311]. The structure 
and functional activity of biotinylated SP-A was similar to that of unlabeled SP-A.  
Animal handling and human lung tissue procurement  
 Rat aMφs were obtained from Sprague Dawley male rat lungs. Rats 
(approximately 350 g) were anesthetized with Ketamine (Merial, Duluth, Georgia) (80 
mg/kg) and Xylazine (Bayer, Leverkusen, Germany) (10 mg/kg). The cardiopulmonary 
block was extracted to perform bronchoalveolar lavages with PBS, 0.2 mM EDTA. All 
animals received humane care in accordance with the Guide for the Care and Use of 
Laboratory Animals [312] and Spanish guidelines for experimental animals. 
 As a source of human lung tissue we used multiple organ donors. The review 
board and the ethics committee of the Hospital Clinic of Barcelona, as well as the Spanish 
and Catalan Transplant Organizations, approved this study, which was conducted in 
accordance with the guidelines of the World Medical Association's Declaration of Helsinki. 
Donors with recent history of tobacco smoking, obesity or any radiological pulmonary 
infiltrate were excluded from this study. Immediately after obtaining the lungs, we 
performed a bronchoalveolar lavage at 4°C using 1 liter of 0.9 % NaCl to isolate human 
aMφs.  
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Isolation and culture of primary alveolar macrophages  
 Bronchoalveolar cells were separated from lavage fluid by centrifugation (250 x g, 
7 min). The sedimented cells were washed twice with PBS and the cell pellet resuspended 
in RPMI 1640 medium (10 % heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, supplemented with glutamine 2 mM) (Lonza). Human and rat aMφs were 
purified by adherence for 90 min at 37°C under a 95% air-5 % CO2 atmosphere in 150-
cm2 culture flasks as previously reported [309, 313, 314]. Adherent cells were 94.0 ± 1.1 
% viable (trypan blue exclusion test). To evaluate the purity of the isolated human 
macrophages, cells were cytospun in a CytoSpin 3 Cytocentrifuge (Shandon Scientific Ltd, 
Waltham, Massachusetts) and the cytospin preparations were stained by Diff-Quick kit 
(Diagnostics Grifols S. A., Barcelona, Spain) following the manufacturer’s protocol. Four 
fields of each sample were counted. Adherent cells were found to be composed of 94.8 ± 
0.8 % of aMφs. On the other hand, flow cytometry analysis of rat macrophages 
immunostained with anti-CD11c (AbD Serotec, Kidlington, UK) confirmed the purity of rat 
aMφ preparations. 
Incubation Conditions 
 Adherent cells were gently scraped, plated in 96-well plastic dishes (7.5 x 104 
cells per well) in 0.2 ml of RPMI with 5 % FBS and precultured overnight. Cells were 
incubated for another 24 h in the presence or absence of smooth LPS (Escherichia coli 
055:B5, 1 ng/ml) (Sigma, St. Louis, Missouri), either rat or human recombinant IFN-γ 
(Calbiochem, Darmstadt, Germany) (0.05-10 ng/ml), human SP-A (5, 12.5, 25 and 50 
μg/ml), and combinations thereof. Higher doses of both LPS (10-100 ng/ml) and IFN-γ 
(100 ng/ml) were also assayed. At the SP-A concentrations used the effect of SP-A was 
greater at lower doses of LPS and/or IFN-γ than at higher doses. Cell viability was higher 
than 97 % under assay conditions. Macrophage cultures were plated in triplicate wells, 
and each series of experiments was repeated at least three times. 
Generation of human M-CSF-derived macrophages 
 Human PBMC were isolated from buffy coats from normal donors over a 
lymphoprep gradient (Nycomed Pharma, Oslo, Norway), according to standard 
procedures. Monocytes were purified from PBMC by magnetic cell sorting using CD14 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Monocytes (95 % CD14+ 
cells) were cultured at 0.5 x 106 cells/ml for 7 days in RPMI 1640 supplemented with 10 % 
FBS at 37°C in a humidified atmosphere with 5 % CO2, and containing M-CSF 
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(ImmunoTools, Friesoythe, Germany) (10 ng/ml) to generate M-CSF-derived 
macrophages as previously described [315]. Cytokines were added every 2 days. Cells 
were treated with human recombinant IFN-γ (1 ng/ml), human SP-A (50 μg/ml), and 
combinations thereof on the 8th day. Cultures were plated in triplicate wells, and each 
series of experiments was repeated at least three times. 
Cytokine determinations 
 Secreted cytokines were quantified in supernatants of treated human and rat 
aMφs using specific ELISA kits following the supplier's instructions. Rat and human TNF-α 
and human CXCL10 ELISA kits were purchased from BD Biosciences (San Diego, CA) 
and rat CXCL10 from Peprotech (Rocky Hill, NJ). In brief, antibodies were coated on a 96-
well Nunc-Immuno Plate MaxiSorp Surface (Thermo Scientific, Waltham, Massachusetts) 
in 0.1 M sodium carbonate, pH 9.5, overnight. After blocking with PBS, 10% FBS, and 
extensive washing, samples and standards were incubated for two hours at room 
temperature. Cytokines were detected with biotinylated detection antibodies and 
streptavidin-horseradish peroxidase. The colorimetric reaction was developed with 
tetramethylbenzidine (BD Biosciences) and was stopped with 4 M sulfuric acid (Sigma), 
and the absorbance at 450 nm was read on an ELISA reader (DigiScan; Asys HiTech 
GmbH, Eugendorf, Austria).  
Western blot analysis 
 Cells were lysed with three freezing-thawing cycles in a buffer containing: 
10 mM HEPES, pH 7.9, 15 mM MgCl, 10 mM KCl, 0.5 mM EDTA, 0.2 % Triton X-100, 1 
mM benzamidine, 200 µg/ml aprotinin, 200 µg/ml leupeptin, and 1 mM 
phenylmethylsulfonyl fluoride (Sigma). When phosphorylated proteins were analyzed, 
phosphatase inhibitors were added to the buffer: 20 mM β-glycerophosphate, 10 mM NaF, 
10 mM sodium pyrophosphate, and 2 mM orthovanadate (Sigma). Samples were resolved 
by SDS-PAGE in reducing conditions and transferred to polyvinylidene fluoride 
membranes (Bio-Rad, Hercules, California). After blocking with 2.5 % skim milk, 
membranes were washed in PBS, 0.1% tween, and incubated with anti-iNOS, GAPDH, P-
ERK, total ERK, P-STAT1, and total STAT1 (Cell Signaling, Danvers, Massachusetts). 
Membranes were incubated with horseradish-peroxidase-labeled anti-rabbit IgG (Sigma), 
then washed and exposed to ECL reagents (Merk Millipore, Darmstadt, Germany). 
Immunoreactive bands were densitometered (Quantity One Software, BioRad) and then 
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normalized to GAPDH for iNOS quantification and to the respective total protein for 
quantification of phosphorylated proteins.  
Quantitative real-time RT-PCR  
 Total RNA was extracted using an RNeasy kit from Quiagen (Venlo, 
Netherlands), retrotranscribed and amplified in triplicates with the reverse transcription 
system kit (Applied Biosystems, Waltham, Massachusetts) [316]. Oligonucleotides for 
selected genes were designed according to the Universal Probe Library system (Roche 
Diagnostics, Rotkreuz, Switzerland) for quantitative real-time PCR (qRT-PCR). The 
analyses for selected genes were made by lightcycler 480 (Roche). For quantification of 
selected genes, the next oligonucleotides were used: 5´-aagcagttagcaaggaaaggtc-3´ and 
5´-gacatatactccatgtagggaagtga-3´ for CXCL10, 5´-gacccagggggtctgttc-3´ and 5´-
aaggagcagctgatacacgtaa-3´ for ETV7, 5´-ctcctcttggcttcgagatg-3´ and 5´-
aaggcggaaaatctcaatca-3´ for RARRES3, and 5´-agccacatcgctcagacac-3´ and 5´-
gccaatacgaccaaatcc-3´ for GAPDH. Levels of mRNA were quantitated using ΔΔCt 
method [317] and were then normalized to maximal expression levels obtained in the 
presence of IFN-γ.  
Solid-phase binding assays 
Solid-phase binding assays were performed as previously described [311] with minor 
modifications. Either rat IFN-γ, human IFN-γ, human sIFN-γR1 (R&D, Minneapolis, MN), 
or human serum albumin (HSA) (Sigma) (1 μg per well) was coated on a 96-well maxisorp 
microtiter plate in 0.1 mM sodium bicarbonate buffer, pH 9.5, overnight at 4°C. The wells 
were washed three times with buffer A (5 mM Tris-HCl, pH 7.4, containing 150 mM NaCl) 
with 0.1 mM EDTA. Wells were blocked with buffer A with 0.1 mM EDTA containing 5 % 
skim milk for 2h. After the plate was washed, biotinylated SP-A, in concentrations ranging 
from 0 to 470 nM (0 to 333 µg/ml), was added to the wells in buffer A in the presence or 
absence of 2 mM CaCl2. Incubations were performed for 1 h at RT. After extensive 
washing, streptavidin-horseradish peroxidase (Sigma) was added to the wells. To assay 
the inhibition of the IFN-γ/sIFN-γR1 interaction by SP-A the mixture of IFN-γ (0.1 μg/ml) 
and SP-A (in concentrations ranging from 0 to 160 μg/ml) was added to the sIFN-γR1-
coated wells in buffer A, with or without 2 mM CaCl2, and incubated at RT for 1 h. The 
binding of IFN-γ to sIFN-γR1 was detected using a polyclonal anti-human IFN-γ (Abcam, 
Cambridge, UK) and horseradish peroxidase-conjugated anti-rabbit antibody. The binding 
of either biotin-labeled SP-A or anti-human IFN-γ was detected with tetramethylbenzidine. 
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The colorimetric reaction was stopped with 4 M sulfuric acid, and the absorbance was 
read at 490 nm on an ELISA reader. 
Dynamic light scattering 
 The hydrodynamic diameters of human and rat IFN-γ, human sIFN-γR1, and 
human SP-A, as well as mixtures of these components, were determined at 25°C in a 
Zetasizer Nano S (Malvern Instruments, Malvern, UK) equipped with a 633-nm HeNe 
laser as previously reported [311]. Six scans were performed for each sample, and all of 
the samples were analyzed in triplicate. The interaction of SP-A with IFN-γ in solution was 
measured by the addition of different SP-A concentrations (from 0 to 150 nM; 0-100 µg/ml) 
to 322 nM (7.7 µg/ml) IFN-γ in buffer A in the absence and presence of 175 μM or 2.5 mM 
CaCl2. 
Binding of [125I]-IFN-γ to IFN-γR1 at the cell surface of human alveolar 
macrophages and inhibition by SP-A 
 Recombinant human IFN-γ was labeled with [125I]-Bolton Hunter reagent 
(PerkinElmer, Waltham, Massachusetts) as described previously [318]. In brief, 10 µg of 
human IFN-γ in 10 µl of 0.1 M sodium borate buffer, pH 8.5, was added to 0.7 mCi of 
[125I]-Bolton Hunter reagent, and the reaction mixture was agitated for 15 minutes at RT. 
The reaction was stopped by the addition of 0.5 ml of 0.2 M glycine in 0.1 M borate buffer, 
pH 8.5 for 5 minutes at RT. Free-iodine was separated from the labeled protein using 
disposable PD-10 desalting columns (GE Healthcare, Waukesha, WI) according to 
manufacturer’s instructions. The concentration of the labeled IFN-γ was determined by 
sandwich-type ELISA by using a polyclonal anti-human IFN-γ, a horseradish peroxidase-
conjugated anti-rabbit antibody and tetramethylbenzidine for color detection.  
 Human aMφs were plated in 96-well plates (1 x 105 cells per well) in 0.2 ml of 
RPMI containing 5% FBS and primed overnight with LPS (1 ng/ml) (37°C, under 5 % CO2 
atmosphere). Control wells with no cells were coated with the same medium 
supplemented with 5% HSA.  Subsequently, the cells were washed with PBS. Wells were 
blocked with PBS plus 0.5% HSA for 30 minutes at 4ºC. After the plate was washed with 
PBS, [125I]-IFN-γ (10 ng/ml) and SP-A (in concentrations ranging from 0 to 100 µg/ml) 
were added to the cells in RPMI either with 2.5 mM CaCl2 or with 5 mM EDTA. Incubations 
were performed for 2 h at 4ºC. After extensive washing, the cells were lysed with 10% 
SDS, and radioactivity was counted with a Perkin Elmer Wallac Wizard 1470-020 Gamma 
Counter. To confirm that the detected [125I]-IFN-γ bound specifically to its receptor at the 
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cellular surface, we used a mouse mAb (BD Biosciences) (50 µg/ml), which recognizes 
the region of human IFN-γR1 that binds to IFN-γ, to inhibit IFN-γ interaction with its 
receptor [307]. An irrelevant, isotype-matched mouse IgG1 mAb (AbD Serotec) was used 
as a control for these experiments. 
Statistics  
Data are presented as means ± SEM. Differences in means between groups were 
evaluated by one-way ANOVA followed by the Bonferroni multiple-comparison test. An α 
level ≤ 5% (P≤ 0.05) was considered significant. 
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Results 
 
SP-A inhibits LPS and IFN-γ effects on rat alveolar macrophages  
 
 To determine the effects of SP-A on the classical activation of aMφs, primary 
aMφs isolated form rat lungs were activated with LPS and/or IFN-γ in the absence and 
presence of SP-A. Figures 1A and 1B show that LPS induced significant TNF-α secretion 
and iNOS expression in rat aMφs, and that the induction of both factors was even greater 
when macrophages were simultaneously incubated with LPS plus IFN-γ. This indicates 
that IFN-γ treatment results in efficient priming/amplification of TLR4-induced cellular 
responses. However, IFN-γ alone did not induce TNF-α secretion and iNOS expression in 
rat aMφs, which is contrary to previous results in RAW 264.7 peritoneal macrophages cell 
line [319], where IFN-γ up-regulates TNF-α and iNOS production. 
 When different concentrations of SP-A were tested (5, 12.5, and 25 μg/ml), we 
found that SP-A significantly inhibited, in a dose-dependent manner, TNF-α secretion 
(Figure 1A) and iNOS production (Figure 1B) by rat aMφs stimulated with either LPS alone 
or LPS plus IFN-γ. The effect of SP-A on LPS-stimulated rat aMφs is consistent with 
previous results [16, 17, 276, 309]. In line with previous findings [281], SP-A also 
significantly inhibited LPS-induced phosphorylation of ERK1/2 (T202/Y204) in a dose-
dependent manner (Figure 2A and B), whereas ERK activation was not significantly 
induced in the presence of either SP-A alone or IFN-γ (Figure 2A and B).  
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Figure 1. Inhibitory effect of SP-A on TNF-α and iNOS production by rat alveolar 
macrophages stimulated with IFN-γ and/or LPS. Purified rat aMφs were cultured in the 
presence or absence of IFN-γ (10 ng/ml), LPS (1 ng/ml), SP-A (5, 12.5, 25 μg/ml), and 
combinations thereof. We measured TNF-α secretion by ELISA (A) and iNOS production by 
Western blot (B) after 24 hours of IFN-γ and/or LPS-stimulation. The results are expressed as 
percent of LPS plus IFN-γ-stimulated TNF-α and iNOS production in the absence of SP-A. The 
mean value of LPS plus IFN-γ-induced TNF-α secretion in the absence of SP-A was 6.8 ± 0.5 
ng/ml (100%). The data shown are means ± SEM of three different aMφs cultures. ##P < 0.01, ###P 
< 0.001 when compared with the response elicited by LPS in the absence of SP-A. °°°P < 0.001 
when compared with the response elicited by LPS+ IFN-γ without SP-A. 
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Figure 2. Inhibitory effect of SP-A on LPS induced ERK 
phosphorylation by rat alveolar macrophages. Purified rat 
aMφs were cultured in the presence or absence of LPS (1 
ng/ml), IFN-γ (10 ng/ml), SP-A (5, 12.5, 25 μg/ml), and 
combinations thereof. We measured ERK phosphorylation by 
Western blot after 30 minutes of LPS-stimulation in the 
presence or absence of SP-A or IFN-γ. In A, the results are 
presented as means (± SEM) from three different aMφs 
cultures, and expressed as percentages of LPS-induced ERK 
phosphorylation. ##P < 0.01 when compared with the 
response elicited by LPS in the absence of SP-A. In B, 
representative Western blot images of ERK phosphorylation 
in rat aMφs exposed to either LPS and/or SP‐A (upper panel) 
or LPS and/or IFN‐γ  (lower panel) are shown. 
 
 
 
 
SP-A attenuates IFN-γ effects on rat alveolar macrophages  
 IFN-γ signaling is mediated by the cytosolic factor STAT1 that is activated during 
IFN-γ-dependent JAK-STAT activation [92]. STAT1 is phosphorylated at two sites 
(tyrosine 701 and serine 727) following IFN-γ exposure [92]. To determine whether the 
inhibitory effect of SP-A on aMφs stimulated with LPS plus IFN-γ was also due to SP-A 
attenuation of IFN-γ, we measured the effect of SP-A on IFN-γ-induced STAT1 Y701 
phosphorylation and CXCL10 secretion by rat aMφs (Figure 3). 
 We found that SP-A dose-dependently inhibited IFN-γ-stimulated CXCL10 
secretion (Figure 3A) and STAT1 Y701 phosphorylation (Figure 3B, C) by rat aMφs. LPS 
alone had no effect on STAT1 Y701 phosphorylation after 30 minutes of LPS-stimulation 
(Figure 3B, D). This was expected since S727, but not Y701, is phosphorylated by p38 
MAPK activated by TLR agonists [92]. However, LPS alone induced CXCL10 secretion 
(137 ± 15 pg/ml) by rat aMφs, and simultaneous stimulation with LPS plus IFN-γ induced 
higher CXCL10 secretion than with IFN-γ alone (305 ± 12 pg/ml and 172 ± 12 pg/ml, 
respectively) (Figure 3A). The CXCL10 promoter contains response elements for STAT1, 
NF-kB, and AP-1 [92], which would explain why aMφs produce CXCL10 after stimulation 
with IFN-γ and/or LPS. Secretion of CXCL10 induced by LPS, IFN-γ, or LPS plus IFN-γ 
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was also inhibited by SP-A in a dose-dependent manner (Figure 3A), consistent with the 
results obtained with TNF-α and iNOS described above. Together, these data 
demonstrate that SP-A inhibition of [IFN-γ+LPS]-stimulation is due to SP-A attenuation of 
both inflammatory agents. 
 
 
Figure 3. Inhibitory effect of SP-A on IFN-γ-induced STAT1 Y701 phosphorylation and 
CXCL10 secretion by rat alveolar macrophages. Purified rat aMφs were cultured in the 
presence or absence of IFN-γ (1-10 ng/ml), LPS (1 ng/ml), SP-A (5, 12.5, 25 μg/ml), and 
combinations thereof. (A) CXCL10 secretion was measured after 24 hours IFN-γ (1 ng/ml) and/or 
LPS-stimulation by ELISA. The results are presented as means (± SEM) from three different cell 
cultures and expressed as percentages of LPS plus IFN-γ-induced CXCL10 secretion. The mean 
value of LPS plus IFN-γ-induced CXCL10 secretion by rat aMφs in the absence of SP-A was 305 ± 
12 pg/ml (100 %). (B) STAT1 Y701 phosphorylation was measured after 30 minutes stimulation 
with IFN-γ (10 ng/ml), LPS (1 ng/ml), or both, by Western blot. The data shown are means ± SEM 
of three different aMφs cultures and were expressed as percentages of IFN-γ-induced STAT1 
phosphorylation. (C, D) Representative Western blot images of STAT1 phosphorylation in rat aMφs 
exposed to either IFN‐γ (10 ng/ml) and/or SP‐A (C) or IFN‐γ (10 ng/ml) and/or LPS (1 ng/ml) (D) 
are shown. #P < 0.05 when compared with LPS stimulation without SP‐A. **P < 0.01, ***P < 0.001 
when compared with the response elicited by IFN-γ alone in the absence of SP-A. °P < 0.05, °°P < 
0.01 when compared with the response elicited by LPS+IFN-γ without SP-A. 
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SP-A inhibits LPS and IFN-γ effects on ex vivo cultured human alveolar 
macrophages 
 Given the above set of data on rat aMφs, we sought to extend our findings to the 
case of primary human aMφs. Figure 4A shows that SP-A inhibited TNF-α secretion by 
human aMφs stimulated with LPS alone or LPS plus IFN-γ in a dose-dependent manner. 
Similarly to the observations using rat aMφs presented above, IFN-γ itself was not capable 
of significantly stimulating TNF-α secretion. However, IFN-γ increased the levels of LPS-
induced TNF-α secretion by human aMφs, as previously reported [313], and this further 
increase was significantly impaired by SP-A. Therefore, similar to the case of rat aMφs, 
SP-A is capable of limiting the production of pro-inflammatory cytokines by human aMφs 
exposed to the classical activation stimuli LPS+IFN-γ. 
 Moreover, as shown in Figure 4B, SP-A dose-dependently inhibited IFN-γ-
induced CXCL10 secretion by ex vivo cultured human aMφs. Simultaneous stimulation 
with IFN-γ and LPS induced higher CXCL10 secretion than with IFN-γ alone (367 ± 36 
pg/ml and 268 ± 16 pg/ml, respectively), and SP-A also inhibited [LPS+ IFN-γ]-induced 
CXCL10 secretion (Figure 4B). On the other hand, iNOS protein did not increase in 
response to LPS or LPS plus IFN-γ in human aMφs (Extended Figure 4.1). This was 
expected since little to no iNOS and NO have been detected in human macrophages 
obtained from normal donors [309, 320], mainly due to epigenetic silencing of NOS2 [321].  
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Figure 4. Inhibitory effect of SP-A on IFN-γ and/or LPS-challenged human macrophages. In 
A and B, human aMφ were cultured in the presence or absence of IFN-γ (1 ng/ml), LPS (1 ng/ml), 
SP-A (12.5, 25, 50 μg/ml), and combinations thereof. We measured TNF-α (A) and CXCL10 (B) 
secretion after 24 h IFN-γ and/or LPS-stimulation. In (C) Human Mφ(M-CSF) were cultured in the 
presence or absence of IFN-γ (1 ng/ml), SP-A (50 μg/ml), and combinations thereof. We measured 
CXCL10, RARRES3, and ETV7 induction by RT-qPCR after 24 hours IFN-γ-stimulation. In (D) 
Human Mφ(M-CSF) were cultured in the presence or absence of IFN-γ (0.05 ng/ml), SP-A (50 
μg/ml), and combinations thereof. STAT1 Y701 phosphorylation was evaluated by Western blot 
after 30 minutes of stimulation. In (A) and (B) the results are expressed as percent of LPS plus IFN-
γ-stimulated secretion of TNF-α (A) or CXCL10 (B) in the absence of SP-A. The mean values of 
LPS plus IFN-γ-induced TNF-α and CXCL10 secretion in the absence of SP-A were 875 ± 134 
pg/ml and  367 ± 36 pg/ml, respectively (100 %). In (C) results were expressed as percentages of 
IFN-γ-induced gene in the absence of SP-A. In (D) results were expressed as percentages of IFN-
γ-induced STAT1 phosphorylation. The data shown are means ± SEM of three different Mφ 
cultures. #P < 0.05, ###P < 0.001 when compared with the response elicited by LPS without SP-A. 
*P < 0.05, **P < 0.01, ***P < 0.001 when compared with the response elicited by IFN-γ in the 
absence of SP-A. °°°P < 0.001 when compared with the response elicited by LPS+IFN-γ in the 
absence of SP-A. 
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Extended Figure 4.1. iNOS protein is not induced upon LPS+IFN-γ stimulation in human 
alveolar macrophages. Human and rat aMφ were cultured in the presence or absence of IFN-γ 
(10 ng/ml) and/or LPS (10 ng/ml) for 24 hours. iNOS protein expression was examined by Western 
blot. A representative Western blot image is shown. 
 
SP-A inhibits IFN-γ effects on human monocyte-derived macrophages Mφ(M-
CSF) 
We then used human monocyte M-CSF-derived macrophages [human Mφ(M-CSF)]. 
Alveolar macrophages show phenotypical features of anti-inflammatory macrophages [1] 
and M-CSF prime monocytes to differentiate into anti-inflammatory macrophages [322]. 
As in the case of ex vivo cultured human aMφs, SP-A inhibited TNF-α and CXCL10 
secretion by Mφ(M-CSF) stimulated by LPS, IFN-γ, and LPS+IFN-γ (Extended Figures 4.2 
A and B). Human Mφ(M-CSF) stimulated with IFN-γ and/or LPS led to higher CXCL10 
secretion (21.7 ± 1.5 ng/ml, 17.4 ± 2.9 ng/ml, and 13.1 ± 1.7 ng/ml in response to 
LPS+IFN-γ, IFN-γ, and LPS, respectively) than ex vivo cultured human aMφs (367 ± 36 
pg/ml, 268 ± 16 pg/ml, and 164 ± 7 in response to LPS+IFN-γ, IFN-γ, and LPS, 
respectively).  
 CXCL10 is one of the paradigmatic genes induced by IFN-γ [92]. To find out 
whether SP-A affected other IFN-γ-regulated genes, we evaluated the effect of SP-A on 
the IFN-γ–dependent gene expression in human Mφ(M-CSF). To that end, human Mφ(M-
CSF) were stimulated with IFN-γ in the presence and absence of SP-A, and IFN-γ-
induced genes were analyzed by quantitative real-time RT-PCR. Figure 4C shows that 
IFN-γ up-regulated the expression of CXCL10 (fold change 65 ± 6), RARRES3 (fold 
change 34 ± 13) identified as a retinoic acid responder gene [323], and ETV7 (fold change 
177 ± 43) (also known as the human ETS family gene TEL2/ETV7, which promotes 
proliferation and has a role in oncogenesis [324]). Importantly, SP-A inhibited the IFN-γ-
induced expression of CXCL10, RARRES3, and ETV7 genes by 49 %, 85 %, and 70 %, 
respectively (Figure 4C). Moreover, we found that SP-A inhibited IFN-γ–stimulated STAT1 
Y701 phosphorylation in human Mφ(M-CSF) (Figure 4D). Together, these findings 
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Figure S1. iNOS protein is not induced upon LPS+IFN-γ stimulation in human alveolar 
macrophages. Human and rat aMφ were cultured in the presence or absence of IFN-γ 
(10 ng/ml) and/or LPS (10 ng/ml) for 24 hours. iNOS protein expression was examined 
by Western blot. A representative Western blot image is shown. 
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demonstrate that SP-A also suppressed IFN-γ effects in the absence and presence of 
LPS on human Mφ(M-CSF).  
                 
Extended Figure 4.2. SP-A inhibits TNF-α and CXCL10 secretion by human Mφ(M-CSF) 
stimulated with IFN-γ, LPS, or IFN-γ +LPS. Human Mφ(M-CSF) were cultured in the presence or 
absence of IFN-γ (0.5 ng/ml), LPS (0.5 ng/ml), SP-A (50 μg/ml), and combinations thereof. We 
measured TNF-α (A) and CXCL10 (B) secretion after 24 h of IFN-γ and/or LPS-stimulation. The 
results are expressed as percent of LPS plus IFN-γ-stimulated secretion of TNF-a (A) or CXCL10 
(B) in the absence of SP-A. The data shown are means ± SEM of four different Mφ cultures. The 
mean values of LPS + IFN-γ-induced TNF-α and CXCL10 secretion in the absence of SP-A were 
2.6 ± 0.3 ng/ml and 21.7 ± 1.5 ng/ml, respectively (100 %). #P < 0.05, ###P < 0.001 when 
compared with the response elicited by LPS without SP-A. *P < 0.05, **P < 0.01, ***P < 0.001 when 
compared with the response elicited by IFN-γ in the absence of SP-A. οοο P < 0.001 when 
compared with the response elicited by LPS+IFN-γ in the absence of SP-A. 
 
SP-A binds to IFN-γ and prevents IFN-γ binding to its receptor on human 
alveolar macrophages 
 To determine the mechanism by which SP-A diminishes IFN-γ effects on rat and 
human aMφs as well as human Mφ(M-CSF), we first studied the potential interaction 
between SP-A and IFN-γ in a solid phase binding assay. Figure 5A shows that 
biotinylated SP-A bound to human IFN-γ-coated wells in a dose- and Ca2+-dependent 
manner, with KD =11 ± 0.5 nM. Biotinylated SP-A bound neither to IFN-γ-coated wells in 
the absence of Ca2+, nor to wells coated with human serum albumin, nor to wells 
containing buffer alone, regardless of the presence of Ca2+. Biotinylated SP-A also bound 
to rat IFN-γ in a dose- and Ca2+-dependent manner with KD = 28 ± 4 nM (data not shown). 
Figure 5B shows that the percentage of biotinylated SP-A binding to human IFN-γ-coated 
wells decreased by addition of unmodified SP-A, indicating that binding of biotinylated SP-
A to IFN-γ-coated wells was not due to the biotin moiety. 
2 
 
 
 
Figure S2. SP-A inhibits TNF-α and CXCL10 secretion by human Mφ(M-CSF) 
stimulated with IFN-γ, LPS, or  IFN-γ +LPS. Human Mφ(M-CSF) were cultured in the 
presence or absence of IFN-γ (0.5 ng/ml), LPS (0.5 ng/ml), SP-A (50 μg/ml), and 
combinations thereof. We measured TNF-α (A) and CXCL10 (B) secretion after 24 h of 
IFN-γ and/or LPS-stimulation. The results are expr ssed as percent of LPS plus IFN-γ-
timulated secretion of TNF-D (A) or CXCL10 (B) in the abs nc  of SP-A. The data 
shown are means ± SEM of four different Mφ cultures. The mean values of LPS + IFN-γ-
induced TNF-α and CXCL10 secretion in the absence of SP-A were 2.6 ± 0.3 ng/ml and 
21.7 ± 1.5 ng/ml, respectively (100 %). #P < 0.05, ###P < 0.001 when compared with the 
response elicited by LPS without SP-A. *P < 0.05, **P < 0.01, ***P < 0.001 when 
compared with the response elicited by IFN-γ in the absence of SP-A. οοο P < 0.001 
when compared with the response elicited by LPS+IFN-γ in the absence of SP-A. 
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 In addition, the interaction of SP-A with human and rat IFN-γ was examined in 
solution by dynamic light scattering. Figure 5C (left panel) shows that human IFN-γ alone 
displays a major peak, which corresponds to particles with a hydrodynamic diameter of 
10.5 ± 0.5 nm. The hydrodynamic diameter of human IFN-γ determined in these 
experiments approaches the predicted diameter of 7 ± 1 nm, which does not take into 
account water molecules enclosing the protein in solution [325]. In the case of human SP-
A, two identifiable peaks were recognized for SP-A alone, one corresponding to SP-A 
particles with a hydrodynamic diameter of 38 ± 5 nm and another minor peak 
corresponding to SP-A aggregates with a hydrodynamic diameter of 1000 nm (data not 
shown). Self-aggregation of SP-A occurs in a Ca2+- and NaCl-dependent manner [326]. To 
reduce SP-A self-aggregation, experiments were performed in the presence of 175 μM 
CaCl2.  
 Figure 5C (central panel) shows that the addition of increasing concentrations of 
SP-A (ranging from 0 to 120 nM; 0-80 µg/ml) to an IFN-γ solution (322 nM) containing 
calcium caused an SP-A concentration-dependent decrease of the IFN-γ peak. At an IFN-
γ/SP-A molar ratio of approximately 3:1, only one peak (58 nm) was observed with a 
hydrodynamic diameter higher than those of SP-A and IFN-γ alone. This new peak likely 
consists of SP-A/IFN-γ complexes. This peak did not appear in the absence of Ca2+ 
(Figure 5C, right panel). Similar results were obtained with rat IFN-γ (data not shown). 
Therefore, this set of experiments demonstrates that SP-A and IFN-γ interact in solution in 
a Ca2+-dependent manner. 
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Figure 5. SP-A binds to IFN-γ. (A) Either human IFN-γ or human serum albumin (HSA) (1 µg) 
was coated onto microtiter plate wells. Biotinylated SP-A (0-470 nM; 0-333 µg/ml) was then added 
to the wells in the presence or absence of 2.5 mM Ca2+, and levels of bound SP-A were determined 
with streptavidin-horseradish peroxidase. (B) Competition by unlabeled SP-A of biotinylated 
SP-A binding to human IFN-γ. Unlabeled SP-A was added simultaneously with biotinylated SP-A 
(100 nM; 80 µg/ml) to human IFN-γ-coated wells (1 µg) in presence of 2.5 mM Ca2. In A and B, 
the data shown are means ± SEM of three different experiments. The assays from each SP-A 
concentration were performed with six independent determinations. (C) DLS analysis of the 
hydrodynamic diameter of human IFN-γ (10.5 ± 0.5 nm) and SP-A (38 ± 5 nm). The y axis 
represents the relative intensity of the scattered light; the x axis denotes the hydrodynamic 
diameter of the particles present in the solution. The analysis of the hydrodynamic diameter of 
particles after the addition of increasing concentrations of SP-A (0-120 nM) (0-80 µg/ml) to a 
solution containing a constant concentration of IFN-γ (322 nM) (7.7 µg/ml) is shown in the 
presence or absence of calcium. In C, one representative experiment of three is shown.  
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To clarify whether SP-A has a direct effect on IFN-γ-induced cell response by 
interacting not only with IFN-γ but also with its cellular receptor, the extracellular domain 
of IFN-γR1 (sIFN-γR1) was coated onto microtiter plate wells. Biotinylated SP-A was then 
added to the wells, and the level of bound SP-A was determined with streptavidin-
horseradish peroxidase. No detectable binding of SP-A to sIFN-γR1 was observed (Figure 
6A). In addition, no detectable SP-A/sIFN-γR1 interaction was observed in solution when 
examined by dynamic light scattering (Figure 6B). 
 To determine whether SP-A interferes with the binding of IFN-γ to its receptor, 
IFN-γ binding to coated sIFN-γR1 was determined by ELISA using a polyclonal anti-
human IFN-γ and in the presence and absence of SP-A (Figure 6C). We found that SP-A 
interfered with the binding of IFN-γ to IFN-γR1 in the presence but not the absence of 
Ca2+. The inhibition caused by SP-A was saturable and dose- and Ca2+-dependent, with a 
∼80 % inhibition at concentrations equal to or higher than 20 μg/ml (30 nM). As expected, 
the binding of IFN-γ to its receptor IFN-γR1 was not affected by Ca2+ (data not shown). 
 We next examined whether SP-A could effectively inhibit the binding of IFN-γ to 
IFN-γR1 on the cell surface. To achieve this, we analyzed the binding of [125I]-IFN-γ to 
IFN-γR1 on human aMφs. To confirm that the detected [125I]-IFN-γ bound specifically to its 
receptor at the cellular surface, we used a monoclonal antibody (mouse anti-human 
CD119) that recognizes the region of IFN-γR1 that binds to IFN-γ to block [125I]-IFN-γ 
binding to its receptor. Figure 6D shows that, in the absence of SP-A, [125I]-IFN-γ bound to 
human aMφs and that this binding was specifically abrogated by the blocking antibody. 
Conversely, an isotype-matched mouse IgG1 control did not inhibit [125I]-IFN-γ binding to 
human aMφs (data not shown). However, addition of SP-A clearly inhibited the [125I]-IFN-γ 
binding to IFN-γR1 in a dose-dependent manner in the presence but not absence of 
calcium. Similar results were found on rat aMφs. Therefore, our results indicate that SP-A 
impairs IFN-γ recognition by IFN-γR1 on the cell surface. This could be at least one of the 
mechanisms by which SP-A suppresses IFN-γ effects. 
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Figure 6. SP-A prevents IFN-γ interaction with IFN-γ receptor 1 (IFN-γR1/CD119). (A) sIFN‐
γR1 (1 μg) was coated onto microtiter wells. Coated sIFN‐γR1 was detected using rabbit polyclonal 
anti‐human IFN‐γR1. Either biotinylated (B-SP-A) or unlabeled SP‐A (160 μg/ml) was incubated for 
1 h in the presence of 2.5 mM Ca2+. SP-A binding to coated sIFN‐γR1 was determined with 
streptavidin‐horseradish peroxidase. (B) DLS analysis of the hydrodynamic diameter of particles 
after the addition of increasing concentrations of SP-A (0-80 µg/ml) to a solution containing a 
constant concentration of sIFN‐γR1 (5 µg/ml) (C) sIFN-γR1 (1 μg) was coated onto microtiter wells. 
IFN-γ (100 ng/ml) and different concentrations of SP-A (0-160 μg/ml) in the presence or absence of 
2.5 mM Ca 2+ were incubated for 1 h. The binding of IFN-γ to sIFN-γR1-coated wells was detected 
using a polyclonal anti‐human IFN‐γ and horseradish peroxidase‐conjugated anti‐rabbit antibody. 
**P < 0.01, ***P < 0.001, when compared with IFN-γ binding without SP-A (defined as 100 %.) (D) 
LPS primed human aMφs were blocked and incubated with [125I]-IFN-γ (10 ng/ml) and SP-A (at 
concentrations ranging from 0 to 100 µg/ml) with either 2.5 mM CaCl2 or 2.5 mM EDTA. Incubations 
were performed for 2 h at 4 ºC. Cells were lysed with 10 % SDS and radioactivity was measured. 
Human aMφs incubated with anti-IFN-γR1 antibody were used as a positive control to prevent 
interaction between IFN-γ and its receptor. The gamma counts of IFN-γ binding without SP-A were 
defined as 100 %. The data are means ± SEM of three different experiments (with different human 
aMφ cultures in D). The assays from each macrophage preparation were performed with triplicate 
determinations. **P < 0.01, ***P < 0.001, when compared with IFN-γ binding to its receptor in the 
absence of SP-A.  
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Discussion 
 
Innate immune defense in the alveolar space is characterized by a delicate balance 
between an effective inflammatory response and the maintenance of tissue integrity. 
Alveolar macrophages play a major role in this equilibrium by producing and releasing a 
variety of biologically active products in response to stimuli such as LPS and IFN-γ [1, 2]. 
Macrophage activation and the initiation of inflammation involve a complex balancing act 
between activating and repressing signals. The results of the present study show that SP-
A has an anti-inflammatory effect on rat and human aMφs and human Mφ(M-CSF), 
counteracting the stimulation exerted by IFN-γ or LPS+IFN-γ. 
In this study we have shown that SP-A, used at concentrations within the ranges 
found in healthy individuals (15-105 μg/mL) [327], inhibited the production of pro-
inflammatory molecules such as TNF-α and CXCL10 by rat and human aMφs and human 
Mφ(M-CSF) stimulated with IFN-γ, LPS, and LPS+IFN-γ. SP-A also inhibited iNOS 
production by rat aMφs stimulated with LPS and LPS+IFN-γ. iNOS production by 
stimulated human aMφ was not detected, confirming previous results that indicate that 
human aMφ and blood-monocyte-derived macrophages obtained from normal donors and 
stimulated in vitro generally do not express iNOS [309, 320, 321]. SP-A also inhibited IFN-
γ-induced STAT1 phosphorylation in rat aMφs and human Mφ(M-CSF) and inhibited up-
regulation of IFN-γ-inducible genes (CLCX10, RARRES3, and ETV7) by human Mφ(M-
CSF). In addition, we have shown for the first time that human SP-A bound to IFN-γ with 
high affinity (KD = 11 ± 0.5 nM for human IFN-γ and KD = 28 ± 4nM for rat IFN-γ) and 
prevented IFN-γ interaction with its receptor IFN-γR1 on human aMφs. These data 
disclose a novel mechanism by which SP-A controls inflammation in the alveolus. 
Our observation that SP-A reduces IFN-γ-triggered inflammation in rat and human 
aMφs and human Mφ(M-CSF) is in agreement with the previous studies that showed that 
SP-A suppresses NO production by murine alveolar Mφs stimulated with IFN-γ– and IFN-γ 
plus M. avium [283] or IFN-γ plus M. tuberculosis [284]. However, our results appear to 
contradict the data from Stamme and colleagues [282] using rat aMφs. We do not 
currently have a clear explanation for these contrasting results, although there might be 
some differences in the experimental design. For instance, starting cell number, media 
and supplements, different types of plastic, and other conditions such as whether 
macrophages are rested prior to activation might have substantial effects on activation 
status. In addition, the source and concentration of cytokines is also important.  
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Alveolar macrophages reside in a tissue compartment that is constantly exposed to 
contaminated air. Thus alveolar macrophage activation is tightly controlled through several 
cell-cell and soluble mediator interactions to limit unwanted inflammatory responses [1]. 
SP-A is one of the soluble factors that contribute to create an anti-inflammatory state in 
the lungs through various mechanisms. First, SP-A blocks the binding of TLR ligands to 
their receptors by direct SP-A interaction with TLR4 [273], TLR2 [276], the TLR co-
receptor MD2 [276], and CD14 [16, 17]. Second, SP-A modifies macrophage response to 
TLR ligands by modulating signaling cascades. For example, SP-A increases the 
expression of negative regulators of TLR-signaling, such as IRAK-M [277] and β-arrestin 2 
[278], thereby inhibiting LPS-induced stimulation of macrophages. Moreover, SP-A 
promotes PKCζ activation and IκBα stabilization through mechanisms that require SP-A 
endocytosis by macrophages [280]. Internalized SP-A also inhibits IκBα, ERK, p38, and 
Akt phosphorylation by macrophages stimulated with TLR2 and TLR-4 ligands [281]. 
Third, SP-A reduces the production of reactive oxygen intermediates by inhibiting NADPH 
oxidase activity in human monocyte-derived macrophages activated by PMA or serum-
opsonized zymosan [279]. Here we showed that the binding of SP-A to IFN-γ, which 
suppressed IFN-γ interaction with its receptor IFN-γR at the cell surface, is another 
mechanism by which SP-A limits inflammation and maintains a tolerant lung environment 
in the steady state. However, following an infection, a harsh IFN-γ induction would 
potentially override SP-A capability to block IFN-γ, leading to a desirable inflammatory 
response to fight against infection. The fact that SP-A is induced in response to IFN-γ 
[211] suggests that SP-A may also be implicated in the regulation of detrimental 
inflammation at the resolution phase after infection.  
IFN-γ is essential for anti-mycobacterial immunity, and disorders of IFN-γ production 
confer predisposition to mycobacterial disease in humans [328]. However, high levels of 
secreted IFN-γ may be harmful. It has been shown that IFN-γ and IFN-γ-induced CXCL10 
are directly involved in the exacerbation of different lung inflammatory diseases (acute 
lung injury and bronchiolitis) in murine experimental models and/or humans [329, 330]. 
Moreover, IFN-γ causes emphysema and alterations in pulmonary protease/antiprotease 
balance when expressed in pulmonary tissues [331]. Furthermore, the administration of 
neutralizing antibodies against IFN-γ or CXCL10 has been shown to attenuate lung injury 
and/or improve mice survival rate [332, 333].  
 The alveolar fluid from normal lungs contains high concentrations of SP-A that 
probably minimize the biological effects of low concentrations of endotoxins that enter the 
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alveolus and IFN-γ.  In patients with acute lung injury in which proinflammatory cytokines 
and neutrophils accumulate in the air spaces, the concentration of SP-A significantly 
decreases [334, 335]. The observation that SP-A restores lung tissue integrity in response 
to sterile inflammation [336] supports the hypothesis that SP-A may be important in 
modulating inflammation and epithelial integrity in the lung in response to acute injury.  
In summary, we have shown that human SP-A inhibits IFN-γ, LPS, and LPS+IFN-γ 
effects on rat and human aMφs and human Mφ(M-CSF) and that SP-A binds to IFN-γ with 
high affinity, inhibiting IFN-γ recognition by its receptor on the cell surface. These data 
unravel a previously unknown mechanism by which SP-A/IFN-γ interaction plays a 
significant role in tipping the balance of inflammation to protect the alveolar epithelium. 
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VII. CHAPTER 2 
 
Defense collagens, SP-A and C1q, enhance IL-4Rα-mediated 
macrophage activation and proliferation promoting local repair  
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Abstract  
Macrophages activated by the IL-4Rα are central effectors of type 2 immunity and 
play important roles in helminth infection, asthma, allergy, and fibrosis.  However, tissue-
specific enhancers of IL-4Rα-mediated type 2 responses remain unknown. In this study, 
we found that secreted soluble defense collagens acted as local enhancers of IL-4Rα-
mediated macrophage effector functions. In the lung, surfactant protein A (SP-A) 
enhanced IL-4-dependent proliferation and activation of alveolar macrophages, resulting 
in better parasite clearance and lung injury resolution following infection with the lung-
migrating nematode Nippostrongylus brasiliensis. Beyond the lung, the structurally 
related molecule, C1q amplified type 2 activation of peritoneal macrophages, leading to 
enhanced dialysis-induced peritoneal fibrosis. SP-A and C1q both generated their 
effects on macrophages via the unconventional myosin18A (aka SP-R210) that acts as 
a cell surface receptor. Thus, SP-A and C1q are tissue-specific factors that act through 
myosin18A to amplify local type 2 responses with consequences for lung repair, 
parasite control, and peritoneal fibrosis.  
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Introduction  
 
The type 2 cytokines IL-4 and IL-13 trigger a specialized macrophage phenotype 
(M(IL-4)) that promotes control of helminth infection [337] and localized wound healing 
to rapidly repair damaged tissue [6, 128, 131]. IL-4 and IL-13 also induce macrophage 
proliferation, which may be necessary to generate sufficient numbers of macrophages 
for pathogen control or wound repair [5]. In addition to these beneficial roles, M(IL-4)s 
contribute to pathology associated with allergy, asthma, and tissue fibrosis [131]. 
Despite the importance of IL-4Rα signaling throughout the body, little is known about 
tissue-specific factors that control IL-4/IL-13 mediated effects, with the potential to 
promote both beneficial and detrimental actions of M(IL-4). 
 
Infection with Nippostrongylus brasiliensis is a widely used mouse model for the 
study of helminth-induced type 2 responses in the lung. Migration of the larvae through 
the lung causes significant damage to the epithelium and vasculature and alveolar M(IL-
4) are essential to mediate lung repair [6]. Alveolar macrophages (aMφs) together with 
the respiratory epithelium are covered by pulmonary surfactant, a lipid-protein network 
that contains associated proteins essential for keeping the alveolus open and for host 
defense [9, 11]. One of these proteins, surfactant protein A (SP-A), constitutes the major 
surfactant protein component by weight in the alveolar fluid [11]. SP-A is a versatile 
recognition protein that binds to a great variety of ligands [11] and is a member of a 
group of secreted soluble defense collagens. All defense collagens contain a 
recognition domain contiguous with a collagen-like triple helical domain and play 
important roles in protecting the host from pathogen entry [338]. Defense collagens 
oligomerize as trimers or multiples thereof due to their collagen domains. Members of 
this group include the first component of the complement system (C1q), collectins (e.g., 
SP-A, SP-D, mannan-binding lectin), ficolins, and adiponectin [338].  
 
The majority of studies on SP-A have focused on bacterial clearance [11, 14] and 
its role in the context of type 1 immune responses [11, 336, 339]. Here we chose to 
examine the role of SP-A in the context of helminth-induced type 2 immune responses. 
We found that SP-A enhanced IL-4-dependent activation and proliferation of aMφs and, 
critically, this contributed to resolution of lung injury following N brasiliensis infection. We 
also identified the unconventional myosin, Myo18A (aka SP-R210) as the receptor for 
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SP-A involved in the enhancement of M(IL-4). The identification of Myo18A, which is not 
restricted to the lung, led us to discover that beyond the alveolus other secreted soluble 
collagens acted through Myo18A to promote type 2 immunity. Specifically, we show that 
C1q enhances M(IL-4) proliferation and activation in the peritoneal cavity, promoting 
dialysis-induced peritoneal fibrosis. Thus, we found that SP-A and C1q are local 
amplifiers of type 2 responses suggesting that other secreted soluble defense collagens 
present in distinct tissues might have the same action.   
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Methods 
Proteins. Surfactant protein A was isolated from BAL of patients with alveolar 
proteinosis using a sequential butanol and octylglucoside extraction [14, 173, 177, 339, 
340]. The purity of SP-A was checked by one-dimensional SDS-PAGE in 12 % 
acrylamide under reducing conditions and mass spectrometry. The oligomerization state 
of SP-A was assessed by electrophoresis under non-denaturing conditions [173, 177], 
electron microscopy [173], and analytical ultracentrifugation as reported elsewhere 
[177]. SP-A consisted of supratrimeric oligomers of at least 18 subunits. Each subunit 
had a relative molecular mass (Mr) 36 kDa. Recombinant human SP-A1 (SP-A1hyp) was 
expressed in insect cells and purified from the medium by mannose affinity 
chromatography [177, 340]. The stability of SP-A1hyp collagen domain was assessed by 
circular dichroism [177, 340] and differential scanning calorimetry [177]. The 
oligomerization state of SP-A was evaluated by electrophoresis under non-denaturing 
conditions [177, 340] and analytical ultracentrifugation [177]. SP-A1hyp consists of 
trimers and hexamers. The endotoxin content of native or recombinant human SP-A 
was < 0.1 endotoxin units /mg of SP-A as determined by Limulus amebocyte lysate 
assay (GenScript, Piscataway, New Jersey). The microbicidal activity of native and 
recombinant human SP-A against Escherichia coli J5 was evaluated by bacterial killing 
assays as described previously [14]. Levels of mouse SP-A from BAL, pleural exudate, 
or lung tissue were detected by Western-blot analysis as reported elsewhere [14, 173, 
177, 339, 340]. Native human C1q was obtained from Abcam (Cambridge, UK). C1q 
consists of octadecameres of 18 subunits with a Mr 410 kDa. 
 
Experimental animals  
C57BL6 mice used in this study (SP-A (Sftpa1-/-) [341], C1q (C1qa-/-) [342] (kindly 
provided by Dr. Mohini Gray), and IL-4Rα (Il4ra-/-) [343] deficient mice and WT mice) 
were bred and maintained at the University of Edinburgh in specific-pathogen free 
conditions. Sex-matched mice were 6-8-weeks old at the start of the experiment, and all 
mice were housed in individually ventilated cages. Sftpa1-/- and Sftpa1+/+ littermates were 
genotyped using specific primers (Table 1) and used for experiments of N. brasiliensis 
infections. Mice were not randomized in cages, but each cage was randomly assigned 
to a treatment group. Investigators were not blinded to mouse identity during necropsy; 
however, the analysis of adult worms, eggs in faeces, lung and peritoneal pathology 
were performed in a blinded fashion. Experiments were performed in accordance with 
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the United Kingdom Animals (Scientific Procedures) Act of 1986 and the Spanish 
guidelines for experimental animals. All researchers were accredited for animal handling 
and experimentation by the UK and Spanish government Home Office. Dispensation to 
carry out animal research at The University of Edinburgh was approved by the 
University of Edinburgh Animal Welfare and Ethical Review Body and granted by the UK 
government Home Office; as such all research was carried under the project licenses 
PPL70/8548 and PPL70/8470. Sample size was calculated on the basis of the number 
of animals needed for detection of macrophage proliferation in WT mice, based on 
published experiments [5, 102]. Data was not excluded under any circumstances.  
 
Table 1. Genotyping of the Sftpa1-/- and Sftpa1+/+ littermates 
SP-A-deficient mice genotyping 
Primer Sequence   
Sftpa1 F neo  GTGGGGTGGGATTAGATAAATGC 
Sftpa1 1743-1766  GCATTAGACGACAGAACTCCAGCC 
Sftpa1 R 1981-1957  TACTGAGAGATGTGTGCTTGGTGAG 
 
Sprague Dawley rats (~350 g) were purchased from Harlan (Indianapolis, IN). All 
animal experiments were fully compliant with the regulations set by the local ethical 
committee. Animals were treated according to the Directive 2010/63/EU of The 
European Parliament and the Spanish act RD53/2013 of 8th February 2013 on 
protection of animals used for experimentation and other scientific purposes. 
 
Nippostrongylus brasiliensis infection 
N. brasiliensis was maintained by serial passage through C57BL/6 mice, as 
described previously [344]. Mice were infected subcutaneously with 250 or 400 N. 
brasiliensis third-stage larvae. Analysis of samples was performed at day 6 post-
infection. Egg output was analysed in faeces and adult worm burden was determined by 
removing the small intestine and exposing the lumen by dissection. For macrophage 
proliferation analysis, mice were injected with 100 μl of 10 mg/ml  BrdU in Dulbecco’s 
phosphate buffered saline 3h before experimental end-point. The lungs and pleural 
cavities were washed to obtain the bronchoalveolar lavage (BAL) and pleural exudate. 
Subsequently, the right lung was perfused and fixed for histology. Alternatively, one 
section of the left lung was stored for mRNA quantification; another section was 
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homogenized to obtain single cell suspensions for flow cytometry analysis, and a third 
section was stored for SP-A quantification. In this case, lung tissue was homogenized in 
HBSS containing protease inhibitor cocktail. SP-A was detected in both lung 
homogenates and BAL by Western blot analysis using an anti-mouse SP-A (GeneTex, 
Inc, Irvine, CA). SP-A levels were normalized by BAL volume or GAPDH. Only samples 
on which the same BAL volume was recovered were used for SP-A quantification.  
BAL cells were obtained by washing the lung with Dulbecco’s phosphate buffered 
saline containing 0.5% BSA (m/v). Cells from pleural or peritoneal exudate were 
obtained by washing either pleural or peritoneal cavity with RPMI 1640 containing 2 mM 
L-glutamine, 200 U/ml penicillin, 100 µg/ml streptomycin. Single cell suspensions of 
thoracic lymph node tissue were re-stimulated ex vivo with N. brasiliensis excretory 
secretory antigen [345] (1 μg/ml) or anti-CD3 (1 μg/ml), and cell supernatants were 
analysed by ELISA 72 h later.  
 
Peritoneal fibrosis model  
Peritoneal fibrosis was induced by continuous administration of Dianeal PD-4 
[(Baxter, Deerfield, Illinois), as described previously [346] with slight modifications. Mice 
received a total of 14 injections of 500 μl (~200 ml/kg) of Dianeal PD-4 (i.p.) on alternate 
days. Animals were sacrificed a day after the last delivery. The right section of the 
parietal layer of the peritoneum was collected for histology analysis. The left section of 
the peritoneum was stored in RNAlater for subsequent analysis. Peritoneal 
macrophages were isolated from the peritoneal cavity as described below. 
 
Histology  
The right lung lobes were perfused and fixed with 10 % neutral buffered formalin, 
incubated overnight and transferred to 70 % ethanol. Lungs were paraffin-embedded, 
sectioned and stained with H&E. Linear means intercept (Lmi) method was used to 
quantify emphysema like damage [347]. To calculate Lmi, 20 random non-overlapping 
fields (magnification x200) per H&E stained lung sample were taken. Six horizontal lines 
were drawn across each image (ImageJ 1.44) and the total number of alveolar wall 
intercepts counted per line. The length of each line was then divided by the number of 
intercepts to give the Lmi value. Images that included large bronchi and vessels were 
avoided and analysis was performed in a blinded and randomised fashion. With respect 
to histological analysis of the peritoneum tissue, the right parietal layer of the 
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peritoneum was fixed with 10% neutral buffered formalin, incubated overnight and 
transferred to 70 % ethanol. Subsequently, peritonea were paraffin-embedded, 
sectioned and stained for Masson’s trichrome. The thickness of the submesothelial 
compact zone was measured using ImageJ and this value was used to score the extent 
of peritoneal fibrosis. Five independent (×200) images were taken to examine the 
overall section. For each image, six horizontal lines were randomly drawn across the 
submesothelial compact zone to measure its thickness and the average value of each 
sample was used for analysis.  
 
IL-4 complex delivery and in vivo blocking of Myo18A 
IL-4 was delivered as a 2:1 molar ratio of recombinant mouse IL-4 (Peprotech) and 
anti-IL-4 mAb (clone 11B11; BioXcell,) [5, 102]. For pulmonary macrophage analysis, 
mice were injected i.p. with IL-4 complex (IL-4c) containing 5 µg of IL-4 and 25 µg of 
11B11, or PBS vehicle control on days 0 and 2. Simultaneously, 50 µg of anti-Myo18A 
antibody [348] or Rabbit IgG (R&D Systems) were delivered intra-nasally on days 2 and 
3, and samples were collected on day 4. For studies of peritoneal macrophages, mice 
received a single i.p. injection of 1 µg of IL-4 and 5 µg of 11B11, or PBS vehicle control. 
Anti-Myo18A neutralizing antibody or Rabbit IgG (100 µg) was delivered 2 hours before 
IL-4c injection and samples were collected 24 hours later.  Mice received a pulse of 
BrdU 3 h before experimental end-point. Bronchoalveolar, pleural and peritoneal cavity 
lavages as well as lung tissue collection were performed as described above.  
 
RNA extraction and quantitative real-time PCR 
A section of the left lung or parietal peritoneum was stored in RNAlater (Ambion, 
Carlsbad, CA). Tissue was homogenised in Trizol (Invitrogen) with a TissueLyser 
(Qiagen, Hilden, Germany). Similarly, human alveolar macrophages were collected with 
Trizol, and RNA was prepared according to manufacturer’s instructions. Reverse 
transcription was performed using 2 μg of total RNA, 50 U Tetro reverse transcriptase 
(Bioline, London, UK), 40 mM dNTPs (Promega, Fitchburg, WI), 0.5 μg Oligo dT15 
(Roche, Basel, Switzerland), and RNasin inhibitor (Promega). Transcript levels of genes 
of interest were measured by real-time PCR with the Lightcycler 480 II system (Roche) 
using SYBR Green I Master kit and specific primers (Table 2) as previously described 
[347]. PCR amplification was analysed using 2nd derivative maximum algorithm 
(LightCycler 480 Sw 1.5, Roche) and the expression of the gene of interest was 
	99		
normalised to a housekeeping gene Rn18s, Rpl13a, or GAPDH. In the case of human 
alveolar macrophages, cells from at least 8 humans were used for all groups. 
 
Table 2. Primer sequences used for quantitative RT-PCR of genes of interest.  
Gene Primer Sequence 
Sftpa1 
  
For CTGGAGAACATGGAGACAAGG 
Rev AAGCTCCTCATCCAGGTAAGC 
Col3a1 
  
For AAGGGTGAAGTCGGTGCTC 
Rev TCCAGCTCCACCTCTAGCA 
Col1a1 
  
For TCTGGTCTCCAGGGTCCTC 
Rev GTCTTTGCCAGGAGAACCAG 
Acta2 
  
For CCAACCGGGAGAAAATGAC 
Rev CAGTTGTACGTCCAGAGGCATA 
Vegf 
  
For ACTCGGATGCCGACACGGGA 
Rev CCTGGCCTTGCTTGCTCCCC 
Mmp12 
  
For CAATTGGAATATGACCCCCTGT 
Rev AGCAAGCACCCTTCACTACAT 
Rpl13a 
  
For CATGAGGTCGGGTGGAAGTA 
Rev GCCTGTTTCCGTAACCTCAA 
Rn18s 
  
For GTAACCCGTTGAACCCCATT 
Rev CCATCCAATCGGTAGTAGCG 
MKI67 
  
For TCGACCCTACAGAGTGCTCA 
Rev GTGGGGAGCAGAGGTTCTTC 
MRC1 
  
For CAGATGCCCGGAGTCAGATC 
Rev TTTATCCACAGCCACGTCCC 
GAPDH 
  
For GATCATGAGCAATGCCTCCT 
Rev TGTGGTCATGAGTCGTTCCA 
 
 
Flow Cytometry 
Single cell suspensions from left lung were prepared by digesting with 0.2 U/ml 
liberase TL (Roche) and 80 U/ml DNase (Life Technologies, Carlsbad, California) in 
HBSS at 37°C for 30 minutes. Tissue was homogenized by forcing through a 70 µM cell 
strainer. Cells from lung homogenates, BAL, pleural exudate, and peritoneal cavity 
exudate were treated with red blood cell lysis buffer (Sigma) and counted using an 
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automated cellometer T4 (Peqlab). Cells were incubated with Fc block (CD16/CD32 and 
mouse serum) and stained with fluorescent conjugated antibodies to CD19 (6D5), Siglec 
F (E50-2440), Ly6G (1A8), CD3 (17A2), CD45.2 (104), Ly6C (HK1.4), CD11c (N418), 
CD11b (M1/70), F4/80 (BM8), I-A/I-E (MHCII) (M5/114.15.), TER119 (TER-119) 
(eBioscience, Hatfield, UK; Biolegend, Cambridge, UK; or BD, Franklin Lakes, NJ), and 
unconjugated anti-Myo18A antibody (5 μg/ml) or isotype control followed by secondary 
reagents (Invitrogen). The following surface lineage-markers identified alveolar 
macrophages: (CD19, Ly6G, CD3 and TER119), CD45.2+, CD11c+ and SiglecF+. 
Pleural/peritoneal macrophages were identified as lineage- (CD19, SiglecF, Ly6G and 
CD3), CD11b+ and F4/80+ [5]. ILC2 cells were identified as lineage- (CD3, CD11b, 
CD11c, FcεR1, CD19, and NK1.1) CD90+ ICOS+ CD45+ cells. T helper cells were 
identified as CD45+, CD3+ and CD4+. 
Following surface staining, cells were fixed with 2% paraformaldehyde in 
Dulbecco’s phosphate buffered saline for 20 min at room temperature, permeabilized 
with Perm wash (BD), and then stained with anti-RELMα, biotinylated anti-Ym1, APC-
conjugated anti-Arg-1 (R&D Systems, Minneapolis, MN), or isotype control followed by 
secondary reagents (Invitrogen). For detection of Ki67 and measurement of BrdU 
incorporation, cells were stained for surface markers, then fixed and permeabilized 
using FoxP3 staining buffer set (eBioscience), and subsequently stained with Ki67 set 
(BV56) or anti-BrdU (BU20a) for 30 min at room temperature. Cells were incubated first 
with or without DNase for 30 mins at 37ºC before staining with anti-BrdU antibody. For 
intracellular cytokine staining, lung single cell suspensions were re-stimulated ex vivo in 
complete RPMI1640 media (supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin) containing 1 μg/ml ionomycin, 500 ng/ml PMA, and 
10 μg/ml Brefeldin A for 4 hours at 37°C. Following surface staining and fixing, cells 
were intracellular stained with anti-IL-4 (11B11), IL-13 (eBio13A), IL-5 (TRFK5), and 
relevant isotypes. Expression of RELMα, Ym1, Arg-1, Ki67, IL-4, IL-13, and IL-5 was 
determined relative to isotype control staining. Incorporation of BrdU was determined 
relative to staining of non-DNase treated cells. Live/Dead (Life Technologies) was used 
to exclude dead cells from analysis. Samples were analysed by flow cytometry using 
Becton-Dickinson FACS LSR II and FlowJo software. 
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ELISAs 
Quantification of RELMα (PeproTech, Rocky Hill, NJ) and Ym1 (R&D Systems) 
were performed by ELISA in BAL, pleural and peritoneal exudates, as well as in cell 
supernatants of ex vivo cultures of peritoneal or alveolar macrophages. IL-4, IL-5, IL-13, 
TNF-α, and IFN-γ (BioLegend and eBioscience) were measured in supernatants of ex 
vivo re-stimulated thoracic lymph node cells. C1q quantification was performed by 
ELISA (Source BioScience, Nottingham, UK) in peritoneal cavity exudates. ELISA 
assays were done following manufacturer instructions. 
 
Isolation and culture of primary alveolar and peritoneal macrophages 
Alveolar macrophages were obtained from BAL of mice and rats, and from human 
lung biopsies obtained from patients that were submitted to a lobectomy. An informed 
consent was obtained from all donors. The review board and the ethics committee of the 
Sabadell Hospital approved this study, which was conducted in accordance with the 
guidelines of the World Medical Association’s Declaration of Helsinki. BAL was 
performed with Dulbecco’s phosphate buffered saline with or without 0.2 mM EDTA and 
0.5% BSA (m/v). Macrophages were purified by adherence for at least 90 min at 37°C, 
5% CO2 as previously reported [313]. Adherent cells were 94.0 ± 1.1 % viable (trypan 
blue exclusion test). Flow cytometry analysis determined that 90 ± 1 % of adherent cells 
isolated from BAL were CD11c and SiglecF positive. To estimate the purity of isolated 
human macrophages, cells were cytospun in a CytoSpin 3 Cytocentrifuge (Shandon 
Scientific, Waltham, MA), and the cytospin preparations were stained with either 
immunostained with anti-CD68 or Diff-Quick kit (Diagnostics Grifols, Barcelona, Spain) 
following the manufacturer’s protocol. 95 % ± 1.5 % (n=6) of adherent cells were 
macrophages. 
 
Peritoneal macrophages were obtained from mice by washing the peritoneal cavity 
with RPMI 1640 containing 2 mM L-glutamine, 200U/ml penicillin, 100 µg/ml 
streptomycin. For thioglycollate-induced macrophages, mice were injected with 4% 
Brewer’s thioglycollate (Sigma) for 48–96 h before peritoneal cells were harvested. Cells 
were separated from the lavage fluid by centrifugation (250 x g, 5 min), resuspended in 
RPMI 1640 medium (5% heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, supplemented with glutamine 2 mM), and purified by adherence.  Viability 
of adherent cells was assessed by trypan blue exclusion test. Flow cytometry analysis 
	102		
determined that 90 ± 1 % of adherent cell isolated from the peritoneal exudate were 
F4/80 and CD11b positive.  
 
In vitro stimulation of alveolar and peritoneal macrophages 
Macrophages were pre-cultured for 24 h. Subsequently, cells were treated with IL-4 
(0.5-1 μg/ml) (ImmunoTools, Berlin, Germany) and/or SP-A (25, 50 and 100 μg/ml) or 
native human C1q (10 and 100 μg/ml). The following blocking antibodies were added 2 
hours before stimulation: 10 μg/ml of anti-Myo18A, 10-50 μg/ml anti-SIRPα 
(eBioscience,), and 10-50 μg/ml anti-calreticulin (Thermo Scientific). Under these 
conditions cell viability was higher than 97%. Macrophage cultures were plated in 
triplicate wells and each series of experiments was repeated at least three times. 
 
Cell proliferation assays  
For 5–ethynyl–2′–deoxyuridine (EdU)/BrdU incorporation analysis, cells were 
treated with IL-4, SP-A, C1q and combinations thereof for 24 hours. Then, cells were 
exposed to 10 μM EdU/BrdU for another 24 hours. For confocal microscopy analysis of 
EdU incorporation, cells were fixed with 2% formaldehyde for 15 minutes at room 
temperature and permeabilized with 0.2% saponin in PBS. EdU was detected with 
Alexa Fluor 647-azide using Click-iT EdU assay kit (Life Technologies). Sequential 
double immunostaining was performed with a monoclonal antibody to CD11c (AbD 
Serotec, Kidlington, UK), and immune complexes were visualized with FITC-conjugated 
secondary antibody (Invitrogen). Micrographs were taken with a Leica TCS SP2 
Confocal System. Flow cytometry analysis of BrdU and Ki67 expression was performed 
as described above. 
 
Arginase activity assay  
Arginase activity was measured as previously reported [349]. Briefly, rat alveolar 
macrophages were lysed with 50 μl of 50 mM Tris–HCl pH 7.5, Triton X-100 0.1 %, 1 
mM benzamidine, 200 μg/ml  aprotinin, and 200 μg/ml leupeptin. After 30 min shaking 
at 4ºC, arginase was activated with 50 μl of 10 mM MnCl2 and 50 mM Tris-HCl, pH 7.5, 
for 10 min at 55º C. L-arginine hydrolysis was measured by incubating the cell lysate 
with 25 μl of 0.5 M L-arginine (Sigma) (pH 9.7) at 37ºC for 1 h. The reaction was 
stopped by addition of 200 μl  H2SO4 /H3PO4 /H2O (1:3:7 v/v). The produced urea was 
quantified at 570 nm after addition of 25 μl of α-isonitrosopropiophenone (dissolved in 
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100% ethanol) followed by heating at 99ºC for 45 min. Urea production was normalized 
to cell number for each treatment by quantifying cells with the WST-1 reagent (Roche), 
following manufacturer’ instructions. One unit of arginase activity is defined as the 
amount of enzyme that catalyses the formation of 1 μmol urea per min. 
 
siRNA-mediated gene-silencing effects in vitro 
After isolation, primary alveolar macrophages were resuspended in Amaxa® mouse 
macrophage nucleofector solution (Lonza) and nucleofected with 100 nM siRNA using a 
nucleofector 2b device (Lonza). Experiments were conducted using two Stealth siRNAs 
directed against rat Myo18A (RSS322720 and RSS322721) (Applied Biosystems, 
Carlsbad, California). Medium GC Stealth siRNA was used as control (12935300) 
(Applied Biosystems). Myo18A expression was detected by Western blot analysis with 
an anti-Myo18A antibody. After 48 hours post nucleofection, Myo18A expression was 
reduced 72 ± 4% for RSS322720 and 71 ± 5% for RSS322721 compared to control. At 
this time-point, cells were stimulated. 
 
Statistics  
Normal distribution of data was determined by visual examination of residuals. 
Statistical evaluation of different groups was performed either by analysis of variance 
(ANOVA) followed by the Bonferroni multiple comparison test or by unpaired two-tailed 
Student’s t-test, as indicated. An α level ≤ 5% (p ≤ 0.05) was considered significant. All 
statistical calculations were performed using PRISM, (Graphpad La Jolla, CA). 
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Results  
 
SP-A limits helminth infection and contributes to lung repair 
To examine the role of SP-A during helminth-induced type 2 immune responses in 
the lung, we inoculated WT, IL-4Rα-deficient and SP-A-deficient mice with 250 N 
brasiliensis infective larvae. Larvae enter the lung between days 1 and 2 post 
inoculation, mature in the lung for ∼2 days and migrate to the small intestine by day 3. 
The type 2 response peaks at days 6-7 after inoculation [350]. We observed an up-
regulation of SP-A (mRNA and protein) in lungs of N brasiliensis infected C57BL/6 mice 
at day 6 (Fig. 1a). Analysis of SP-A mRNA and protein in lungs of IL-4Rα-/- mice showed 
that helminth-induced SP-A up-regulation was dependent on IL-4 and/or IL-13 (Fig. 1a). 
  
Consistent with a role for SP-A during type 2 immunity to N brasiliensis infection, 
SP-A-deficient mice had increased adult worm burden (Fig. 1b) and egg output (Fig. 
1c) when infected with either 250 or 400 infective third-stage larvae. In addition, the 
absence of SP-A significantly impaired the lung repair process as indicated by loss of 
alveolar surface area. (Fig.1d,e). Infected SP-A-deficient mice also exhibited increased 
expression of Mmp12 mRNA (Mmp-12) relative to infected WT mice (Fig. 1f). This likely 
reflects increased inflammatory macrophage infiltration, consistent with the known role 
for SP-A in reducing inflammation associated with lung injury [336]. Finally, N 
brasiliensis-infected WT mice, but not SP-A-/- mice, showed increased expression of the 
tissue-repair related gene Col1a1 (Collagen, type I, alpha 1) (Fig. 1g) 
 
Although there were no major differences between WT and SP-A-deficient mice in 
the cellular composition of the bronchoalveolar lavage (BAL), lung homogenates, or 
pleural lavage (data not shown), SP-A-deficient mice exhibited reduced protein 
expression of the M(IL-4) markers RELMα, Ym1, and Arginase (Arg1) in aMφs isolated 
from BAL (Fig. 1h) and lungs (Extended Fig. 1a). Consistent with intracellular flow 
cytometry analysis, secretion of RELMα and Ym1 protein to the alveolar fluid (Fig. 1i) 
and pleural space (Fig. 1j) was enhanced at 6 days post infection in both WT and SP-A-
deficient mice, but reduced in SP-A-/- mice compared to WT mice.  In addition to the 
induction of M(IL-4) markers, IL-4 typically induces macrophage proliferation during 
helminth infection [351]. At day 6 following infection, proliferation of aMφs from BAL 
(Fig. 1k-m) and lung tissue (Extended Fig. 1b) of WT mice was observed, as 
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measured by cell number (Fig. 1k), expression of the nuclear cell-cycle antigen Ki67 
(Fig. 1l and Extended Fig. 1b), and BrdU incorporation (Fig. 1m and Extended Fig. 
1b). In comparison to their WT littermates, SP-A-deficient mice failed to exhibit 
significantly enhanced macrophage proliferation in response to N brasiliensis infection in 
BAL (Fig. 1k-m) and lung (Extended Fig. 1b).  
 
To explore whether SP-A’s effects on worm burden and wound repair might occur 
via promotion of adaptive TH2 responses, we analyzed cytokines secreted by lung-
draining lymph node cells re-stimulated with parasite-antigens.  Samples from SP-A-
deficient mice showed a slight increase of IL-4, IL-5, IL-13, TNF-α, and IFN-γ 
(Extended Fig. 1c), perhaps due to enhanced dendritic cell maturation and therefore T 
cell activation in SP-A-deficient mice [302].  However, we saw no evidence of any 
difference in total numbers of ILC2 and CD4+ lung resident cells or in their ability to 
produce IL-4, IL-13, and IL-5 (Extended Fig. 1d). Similarly, the measurement of Il13, 
Il5, and Tnf mRNA in lung homogenates suggested that both mouse strains induce a 
similar cytokine profile after helminth infection (Extended Fig. 1e).  
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Figure 1. Nippostrongylus brasiliensis infected SP-A-/- mice have higher worm burdens 
and greater nematode-induced lung damage. WT, SP-A-/-, or IL-4Rα-/- mice were left 
uninfected or infected with N. brasiliensis L3’s, and samples were assessed at day 6 after 
infection. (a) SP-A mRNA (normalized by Rn18s) and protein expression in lung tissue of WT 
and IL-4Rα-/- mice. (b) Adult larvae in the small intestine. (c) Egg output in faeces. (d) 
Quantification of lung damage, calculated as ‘linear means intercept’ from (e) microscopy of H&E 
stained lung sections (scale bars, 500 µm). Amplification of (f) Mmp12 and (g) Col1a1-encoding 
mRNA in lung tissue. (h) Expression of RELMα, Ym1, and Arg by alveolar macrophages from 
BAL. Because all aMφ are Ym1 positive, MFI is shown for Ym1 rather than % positive; A 
representative histogram of Ym1 from WT and SP-A-/- infected animals is shown. Levels of 
RELMα and Ym1 in (i) alveolar and (j) pleural spaces. (k) Number of alveolar macrophages 
recovered in BAL. Expression of (l) Ki67 and (m) BrdU incorporation by alveolar macrophages 
from BAL; a representative plot showing BrdU staining in macrophages from WT and SP-A-/- 
infected animals is shown. Numbers by outlined areas indicate percent of BrdU+ macrophages. 
Data are representative from two independent experiments (mean ± SEM; naïve: 3 mice, Nb: 6 
mice). ANOVA followed by the Bonferroni multiple-comparison test or Student’s t-test (b-d) was 
used.  *p < 0.05, **p < 0.01, and ***p < 0.001, when compared with the uninfected group; °p < 
0.05, °°p < 0.01, and °°°p < 0.001 when WT vs. SP-A-/- infected groups are compared. 
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Extended Figure 1. Further characterization of WT vs. SP-A-deficient mice during 
Nippostrongylus brasiliensis infection. WT or SP-A-/- mice were left uninfected or infected 
with 200 N. brasiliensis L3’s, and assessed at day 6 after infection. (a) Expression of the M(IL-4) 
markers RELMα, Ym1, and arginase (Arg), in alveolar macrophages from single-cell 
suspensions of lung tissue. (b) Proliferation of alveolar macrophages from lung tissue, measured 
by BrdU incorporation and Ki67 expression. (c) Levels of IL-4, IL-13, IL-5, TNFα, and IFN-γ in 
supernatants of thoracic lymph node cells from WT and SP-A-/- mice, cultured with N. brasiliensis 
antigen (1 μg/ml ); results are normalized to those obtained for cells cultured with medium alone. 
(d) Expression of IL-4, IL-13 and IL-5 by ILC2 and CD4+ cells from single-cell suspensions of 
lung tissue stimulated ex vivo with PMA and ionomycin. (e) Amplification of Il13, Il5 and Tnf-
encoding mRNA in lung homogenates is also shown. Results are representative from two 
independent experiments (means ± SEM) (naïve: 3 mice, Nb: 6 mice). ANOVA followed by the 
Bonferroni multiple-comparison test (a-c) or Student’s t-test (d) was used. **p < 0.01 and ***p < 
0.001, when compared with the uninfected group; °p < 0.05 and °°°p < 0.001 when WT vs. SP-A-
/- infected groups are compared. 
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SP-A enhances IL-4-induced proliferation and activation of alveolar macrophages 
We chose next to address whether the observed failure of SP-A-deficient mice to 
exhibit full M(IL-4) activation and proliferation was because SP-A enhances IL-4Rα-
mediated effects on aMφs.  We thus injected WT and SP-A-deficient mice i.p. with IL-4 
complex (IL-4c) and assessed macrophage proliferation as described previously [102]. 
Consistent with our previous report [102] Mφs that exhibit high Ki67 expression directly 
correspond to Mφs positive for BrdU following a 3hr BrU pulse (Fig. 2a). Thus 
Ki67high/BrdU+ cells represented the subpopulation of aMφs that were actively dividing 
upon stimulation. Delivery of IL-4c induced proliferation of aMφs isolated from BAL (Fig. 
2a) and lungs (Extended Fig. 2a) of WT mice but not SP-A-deficient mice. Consistent 
with the lack of IL-4c-induced proliferation, SP-A-deficient mice showed reduced IL-4c 
dependent M(IL-4) markers in both BAL (Fig. 2b,c) and lung (Extended Fig. 2b) aMφs, 
as measured by intracellular expression and secretion of RELMα and Ym1 into the 
alveolar fluid (Fig. 2b,c).  
 
Up-regulation of the IL-4Rα could explain SP-A’s ability to enhance IL-4-induced 
effects. However, we observed no differences in IL-4Rα expression between WT and 
SP-A-deficient aMφs following IL-4c treatment (Fig. 2d). Peritoneal delivery of IL-4c was 
sufficient to increase the amount of SP-A protein in BAL and lungs (Fig. 2e), confirming 
that the up-regulation of SP-A observed in the helminth infection model (Fig. 1a) was at 
least in part, due to the type 2 response.  
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Figure 2. Alveolar macrophages from SP-A-/- mice show decreased IL-4-induced 
proliferation and alternative  activation. WT and SP-A-/- mice were treated with 5μg of IL-
4c (i.p.) at days 0 and 2; samples were analyzed at day 4. (a) Expression of Ki67 and BrdU 
incorporation by alveolar macrophages from BAL. A representative plot from WT and SP-A-/- 
mice treated with PBS or IL-4c is shown. Ki67 (green contour) and BrdU+ cells are overlaid as 
blue dots. Numbers below outlined areas indicate percent of BrdU+ and Ki67+ macrophages. 
(b) Expression of RELMα by alveolar macrophages from BAL. (c) Analysis of secreted 
RELMα and Ym1 from BAL. (d) Expression of IL-4Rα by alveolar macrophages from BAL. (e) 
SP-A expression levels in BAL and lung tissue (a representative Western Blot analysis from 
lung homogenates is shown). Data were pooled from three independent experiments (means 
± SEM) (PBS: 9 mice, IL-4c: 11 mice). ANOVA followed by the Bonferroni multiple-
comparison test or unpaired two-tailed Student’s t-test (e) was used. *p < 0.05, **p < 0.01, 
and ***p < 0.001 when compared with the untreated group.  °°p < 0.01 and °°°p < 0.001 when 
WT vs. SP-A-/- groups are compared. 
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Extended Figure 2. Proliferation and activation of alveolar macrophages from lung tissue 
of WT and SP-A-/- mice in response to IL-4c. WT and SP-A-/- mice were treated with 5μg of IL-
4c (i.p.) at days 0 and 2; samples were analyzed at day 4. (a) Proliferation of alveolar 
macrophages from lung tissue in response to IL-4c. (b) Expression of the M(IL-4) markers 
RELMα and Ym1 in alveolar macrophages from lung tissue. Data were pooled from three 
independent experiments (means ± SEM) (PBS: 9 mice, IL-4c: 11 mice). ANOVA followed by the 
Bonferroni multiple-comparison test was used. **p < 0.01 and ***p < 0.001 when compared with 
the untreated group. °p < 0.05 and °°p < 0.01 when WT vs. SP-A-/- groups are compared. 
 
SP-A boosts IL-4 effects on alveolar, but not peritoneal, macrophages  
 
To determine whether SP-A acts directly and specifically on alveolar macrophages, 
adherence purified macrophages from the alveolar and peritoneal spaces were treated 
with 1 μg/ml of IL-4 and the ability of SP-A to enhance proliferation or activation 
assessed. C1q was chosen as a control because it is a defense collagen structurally 
homologous to SP-A [11, 338]. In response to IL-4 alone aMφ, but not resident 
peritoneal (pMφ) or thioglycollate elicited macrophages (Thio-Mφ) proliferated in vitro 
(Fig. 3a). Notably, cultured aMφ did not significantly increase RELMα expression in 
response to IL-4 but were Ym1+ regardless of IL-4 treatment (Fig. 3a). In contrast pMφ 
upregulated both RELMα and Ym1 following in vitro treatment with IL-4. 
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SP-A, but not C1q, significantly boosted IL-4-mediated aMφ but not pMφ 
proliferation and M(IL-4) markers (Fig. 3b). Alveolar macrophages from IL-4Rα-deficient 
mice showed no proliferation or activation when stimulated with IL-4 (1 µg/ml) in the 
absence or presence of SP-A (Fig. 3c). To our surprise C1q, but not SP-A, significantly 
increased IL-4-mediated pMφ but not aMφ proliferation (Fig. 3b). In addition, C1q 
significantly enhanced IL-4 dependent secretion of Ym1, as assessed by ELISA 
analysis of pMφ culture supernatant (Fig. 3b). Thus SP-A acts as a tissue-specific factor 
to directly enhance IL-4-mediated activation and proliferation of alveolar, but not 
peritoneal, macrophages, and C1q appears to have the same function for peritoneal 
cells. 
Having established this in vitro system, we were able to ask whether SP-A’s 
enhancement of IL-4 could be observed in humans. Human aMφs were isolated from 
macroscopically normal tissue biopsies from patients with lung carcinoma. Isolated 
human aMφs were cultured in the presence of recombinant human IL-4 (0.5 µg/mL) with 
or without SP-A for 48 hours. We found that in vitro treatment of human aMφs with IL-4 
was sufficient to increase the mRNA level of MKI67 and MRC1 as markers of 
proliferation and M(IL-4), respectively (Fig. 3d).  Similarly, SP-A significantly enhanced 
proliferation and activation induced by IL-4 in rat aMφs (Fig. 3e).  
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Figure 3. SP-A and C1q enhance IL-4-induced proliferation and activation of alveolar and 
peritoneal macrophages, respectively. Purified alveolar and peritoneal (resident and 
thioglycollate-recruited) from mice (a-c), humans (d), or rats (e) were treated with or without 
IL-4 (0.5-1 μg/ml) in the presence or absence of SP-A or C1q and exposed to BrdU for 
proliferation analysis. (a) Ki67, RELMα, and Ym1 expression by aMφ and pMφ (resident and 
thioglycollate-recruited) in the absence of either SP-A or C1q. (b) BrdU incorporation and 
secretion of Ym1 by resident peritoneal and alveolar macrophages. (c) BrdU incorporation 
and secretion of Ym1 by cultured alveolar macrophages from WT and IL-4Rα-/- mice. (d) 
MKI67 and MRC1 mRNA expression by human alveolar macrophages as measured by qRT-
PCR. (e) EdU incorporation analyzed by flow cytometry and arginase activity of rat alveolar 
macrophages. A representative confocal micrograph of rat alveolar macrophages immuno-
stained with CD11c-FITC and EdU-Alexa Fluor 647 is shown. Numbers below indicate 
percentage ± SEM of EdU+ cells from three independent experiments. The results are 
presented as means (± SEM) from three different cell cultures with at least three biological 
replicates. ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 0.05, 
**p < 0.01, and ***p < 0.001, when compared with untreated macrophages (C); οp < 0.05, °°p 
< 0.01, and °°°p < 0.001, when either SP-A+IL-4- or C1q+IL4-treated macrophages were 
compared with IL-4-treated macrophages. 
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Myo18A mediates the effects of SP-A and C1q on alveolar and peritoneal 
macrophages, respectively 
 
To determine which SP-A receptor is mediating SP-A effects on IL-4-stimulated 
aMφs, we inhibited known receptors for SP-A: signal inhibitory regulatory protein α 
(SIRPα), calreticulin (aka cC1qR), and Myo18A (aka SP-R210) [11]. We observed that 
the blockade of Myo18A, but not of calreticulin or SIRPα receptors abrogated SP-A-
mediated enhancement of IL-4-induced arginase activity in rat aMφs (Extended Fig. 
4a). RNA silencing of Myo18A consistently abolished SP-A-mediated enhancement of 
IL-4-induced proliferation and activation of rat aMφs (Fig. 4a).  Human aMφs also 
showed significant reduction of MKI67 and MRC1 mRNA expression in the presence of 
anti-Myo18A antibody (Fig. 4b), confirming that SP-A must bind to Myo18A receptor to 
enhance proliferation and alternative activation of human aMφs.  
 
Myo18A is an unconventional myosin that does not operate as a traditional 
molecular motor in cells, having both intracellular and cell-surface locations [352]. 
Immune activation results in Myo18A localization on the cell surface, where it binds to 
SP-A with high affinity and thus is also known as SP-R210[291, 338].  The collagen-like 
domain of SP-A is essential for functional interaction with Myo18A [338, 353]. We 
therefore examined the role of the SP-A collagen-like tail for Myo18A receptor signaling 
by comparing the effects of native SP-A and recombinant human SP-A1 expressed in 
insect cells (SP-A1hyp). SP-A1hyp lacks the prolyl hydroxylation in the collagen domain, 
which results in improper folding [340]. We found that SP-A1hyp had no effect on IL-4-
mediated proliferation and activation of rat aMφs (Extended Fig. 4b) but still functioned 
to kill bacteria like native SP-A (Extended Fig. 4c). These results suggest that an intact 
collagen-like domain is required to enhance IL-4-mediated type 2 responses via 
Myo18A receptor. 
 
The role of the collagen-like tail was further supported by our finding that C1q, 
structurally homologous to SP-A in its supra-trimeric assembly and collagen tail [11, 
338], enhanced IL-4 driven activation and proliferation of mouse peritoneal Mφ via 
Myo18A (Fig. 4c). Blockade of Myo18A also abrogated SP-A effects on mouse aMφs 
(Fig. 4d). Notably, we observed that IL-4 promotes Myo18A localization on the cell 
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surface of peritoneal (Fig. 4e) and alveolar (Fig. 4f) Mφs after 24 hour of IL-4 
stimulation. Expression of Myo18A on the cell surface was greater for alveolar than 
peritoneal Mφs nicely matching the greater cellular response to IL-4+SP-A than IL-
4+C1q (Fig. 4c,d). 
 
 
Figure 4. Myo18A mediates the effects of SP-A and C1q on alveolar and peritoneal 
macrophages, respectively. Isolated rat, human, and mouse alveolar macrophages as well as 
purified resident peritoneal macrophages from mice were nucleofected with Myo18A siRNA 
(RSS322720) or control siRNA, pre-treated with 10 μg/ml of anti-Myo18A neutralizing antibody or 
an IgG control for two hours, or untreated. Next, cells were stimulated with or without IL-4 (0.5-1 
μg/ml) in the presence or absence of either SP-A or C1q and exposed to BrdU for proliferation 
analysis. (a) BrdU incorporation and arginase activity in rat alveolar macrophages that were 
nucleofected with Myo18A (RSS322720) or control siRNA. Similar results were found using 
RSS322721 Myo18A siRNA. (b) mRNA expression of MKI67 and MRC1 by human alveolar 
macrophages treated with anti-Myo18A antibody. (c,d) Anti-Myo18A blockade of proliferation 
and activation of mouse macrophages treated with either (c) IL-4+C1q (pMφ) or (d) IL-4+SP-A 
(aMφ). (e,f) Time-dependent expression of Myo18A on the cell surface of peritoneal (e) and 
alveolar (f) macrophages in response to IL-4 treatment. The data shown are means ± SEM of 
three different alveolar or peritoneal macrophage cultures with at least three biological replicates. 
ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 0.05, **p < 0.01, and 
***p < 0.001, when compared with untreated cells (C); °°p < 0.01, and °°°p < 0.001, when either 
SP-A+IL-4- or C1q+IL4-treated macrophages were compared with IL-4-treated macrophages; #p 
< 0.05, ##p < 0.01, and ###p < 0.001, when the effect of either Myo18A siRNA or anti-Myo18A 
antibody is compared in cells treated with SP-A+IL-4 or C1q+IL4. 
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Extended Figure 4. (a) Myo18A, but not calreticulin or SIRPα, mediates SP-A’s effects on 
aMφs stimulated with IL-4. Purified rat alveolar macrophages were treated with either anti-
Myo18A (10 μg/ml), anti-calreticulin (10-50 μg/ml), anti-SIRPα (10-50 μg/ml), or an isotype 
control for two hours. Next, cells were IL-4-stimulated with or without native SP-A. (b) 
Requirement of the collagen-like domain of SP-A for functional interaction with Myo18A. 
Purified rat alveolar macrophages were treated with anti-Myo18A (10 μg/ml) for two hours and 
then cells were IL-4-stimulated with or without either native human SP-A or recombinant human 
SP-A1 expressed in insect cells (SP-A1hyp). Arginase activity and proliferation (BrdU 
incorporation) were measured. SP-A1hyp exhibits an improper collagen domain folding but 
still functions to kill E.coli J5 bacteria (105 CFUs/ml) like native SP-A (c). The survival of 
bacteria in the presence of SP-A is shown as a percentage of the number of colonies of the 
same strain not exposed to SP-A. The data shown are means ± SEM of three different alveolar 
macrophage cultures with at least three biological replicates. ANOVA followed by the Bonferroni 
multiple-comparison test was used. **p < 0.01 and ***p < 0.001, when compared with untreated 
cells; °°p < 0.01 and °°°p < 0.001, when SPA+ IL-4-treated Mφs are compared with IL-4-treated 
Mφs; ###p < 0.001, when either the effect of anti- Myo18A antibody vs. rabbit IgG is compared 
or when the effects of native SP-A vs. SP-A1hyp on arginase activity are compared. 
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Myo18A blockade reduces IL-4-mediated activation and proliferation of 
macrophages in vivo 
We next confirmed the role of Myo18A in vivo.  Delivery of IL-4c i.p. induced the 
expression of Myo18A on the cell surface of both aMφ and pMφ, which was independent 
of the presence or absence of SP-A or C1q, respectively (Fig. 5a,b). Antibody blockade 
of Myo18A phenocopied SP-A deficiency. In both settings, aMφs exhibited little 
proliferation or expression of M(IL-4) markers in response to IL-4 (Fig. 5a). Similarly, the 
secretion of RELMα and Ym1 to the alveolar fluid was highly reduced by the blocking 
antibody (Extended Fig. 5a). Delivery of anti-Myo18A antibody also reduced IL-4c-
induced proliferation and activation of pMφs (Fig. 5b) and secretion of RELMα and Ym1 
to the peritoneal cavity (Extended Fig. 5b). Taken together, these data suggest that 
Myo18A is a common receptor or co-receptor for defense collagens present on alveolar 
and peritoneal Mφs, which helps determine their capacity to respond to IL-4. Given that 
Myo18A lacks a trans-membrane domain [352], transmembrane co-receptors must act 
in concert with Myo18A for signal transduction. Tissue-specificity would then be 
imparted by these coreceptors whose expression would be determined by cell origin or 
local imprinting by the tissue environment. 
 
C1qa-deficient mice show reduced IL-4-mediated type 2 responses 
Similar to SP-A in the lung (Fig. 2e), C1q levels increased in the peritoneal fluid 
after IL-4c delivery (Fig. 5c), consistent with the reported expression of C1q by M(IL-4) 
[354]. We thus evaluated the effect of C1q on IL-4-mediated type 2 responses. In 
contrast to WT mice, pMφs from C1qa-deficient mice had significantly lower levels of 
proliferation and M(IL-4) marker expression following IL-4c delivery (Fig. 5d & 
Extended Fig. 5c). These data show that C1q acts to enhance IL-4 mediated Mφ 
proliferation and activation in the peritoneal cavity.  
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Figure 5. (a, b) Antibodies against Myo18A blocked IL-4-mediated activation and 
proliferation of macrophages in vivo. (a) For aMφ analysis, WT or SP-A-/- mice received 5 μg 
of IL-4c (i.p.) at day 0 and 2. Simultaneously, animals were intra-nasally treated with either anti-
Myo18A or rabbit IgG antibody at day 2 and 3, and samples analyzed at day 4. IL-4-mediated 
proliferation (% BrdU+ and % Ki67+) and activation (% RELMα+ and Ym1) of aMφs is shown. (b) 
For pMφ analysis, WT or C1qa-/- mice received 1 μg of IL-4c (i.p.) at day 0, and samples were 
analyzed at day 1. Some mice were also treated with either anti-Myo18A or rabbit IgG antibody 
(i.p.) 2 hours before IL-4c administration. IL-4-mediated proliferation (% BrdU+ and % Ki67+) and 
activation (% RELMα+ and %Ym1+) of pMφs are shown. (c) C1q protein levels in the 
peritoneal cavity: Following IL-4c delivery, C1q protein was measured by ELISA in WT mice. 
(d) C1qa-deficient mice show reduced IL-4-mediated type 2 responses: IL-4-mediated 
proliferation (% BrdU+ and % Ki67+) and activation (% RELMα+) of pMφs in WT vs C1qa-/- mice; 
RELMα secretion into the peritoneal cavity was measured by ELISA. Data were pooled from 
three independent experiments (means ± SEM) (PBS: 6 mice, other groups: 9 mice). ANOVA 
followed by the Bonferroni multiple-comparison test was used. *p < 0.05, **p < 0.01, and ***p < 
0.001, when compared with PBS-treated mice; °p < 0.05, °°p < 0.01, and °°°p < 0.001 when 
either WT vs. C1qa-/- mice treated with IL-4c are compared or when anti-Myo18A vs rabbit IgG 
treatment is compared in IL-4c-treated mice. 
 
 
	119		
 
Extended Figure 5. Antibodies against Myo18A reduced IL-4-mediated secretion of 
RELMα and Ym1 to the alveolar (a) and peritoneal (b) cavities. (a) For alveolar macrophage 
analysis, WT or SP-A-/- mice received 5 μg of IL-4c (i.p.) at day 0 and 2. Simultaneously, these 
animals were intra-nasally treated with either anti-Myo18A or rabbit IgG antibody at day 2 and 3, 
and samples were analyzed at day 4. (b) For peritoneal macrophage analysis, WT or C1qa-/- 
mice received 1 μg of IL-4c (i.p.) at day 0, and samples were analyzed at day 1. Mice were 
treated with either anti-Myo18A or rabbit IgG antibody (i.p.) 2 hours before IL-4c administration. 
(c) Measurement of Ki67 and Ym1 expression in WT vs C1qa-/- following IL-4c delivery. 
Data were pooled from three independent experiments (means ± SEM) (PBS: 6 mice, other 
groups: 9 mice). ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 
0.05, **p < 0.01, and ***p < 0.001, when compared with PBS-treated mice; °°p < 0.01 and °°°p < 
0.001 when either anti-Myo18A vs rabbit IgG treatment (a,b) or WT vs. C1qa-/- mice (c) are 
compared in IL-4ctreated mice. 
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C1q-dependent enhancement of type 2 responses in a model of peritoneal 
fibrosis  
To ascertain the physiological relevance of C1q-dependent enhancement of type 2 
responses, we evaluated the role of C1q in a murine model of peritoneal fibrosis 
induced by Dianeal-PD4, a lactate dialysate used in the clinic [346]. Peritoneal fibrosis is 
a frequent and serious consequence of peritoneal dialysis [355] and is associated with 
M(IL-4) in both humans and mice [346, 355, 356]. In our model, lactic acid could be 
responsible for the induction of macrophage proliferation and Mφ2 activation [357]. We 
administered Dianeal-PD4 every other day for 28 days to WT and C1qa-deficient mice. 
In WT but not in C1qa-deficient mice, Dianeal-PD4 treatment provoked the induction of 
C1q (Fig. 6a) and morphologic changes in tissue sections of the parietal peritoneum, 
showing significant enlargement of the submesothelial zone caused by collagen 
deposition (Fig. 6b,c). Dianeal-PD4 treatment also induced markers of fibrosis including 
collagen mRNAs (Col1a1 and Col3a1) (Fig. 6d), alpha-smooth muscle actin (Acta2) 
(Fig. 6e), and vascular endothelial growth factor (Vegf) (Fig. 6f). Importantly, significant 
upregulation of these markers was not observed in C1qa-deficient mice (Fig. 6d-f).  
Conversely, Mmp12 mRNA was up-regulated in C1qa-deficient relative to WT mice (Fig. 
6g) consistent with monocyte infiltration [358] (Fig. 6h) and an anti-inflammatory role for 
C1q [359]. Finally, we found that Dianeal-PD4 induced M(IL-4) in WT but not C1qa-
deficient mice, as measured by the intracellular expression of RELMα, Ym1, and Arg 
(Fig. 6i) and protein secretion of RELMα and Ym1 into the peritoneal cavity (Fig. 6j). 
Notably, we found that Dianeal-PD4 also induced a moderate proliferation of pMφs in 
WT but not C1qa-deficient mice (Fig. 6k).  
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Figure 6. C1q-dependent enhancement of type 2 responses in a model of peritoneal 
fibrosis. WT or C1qa-/- mice were either untreated (C) or treated with a total of 14 deliveries of 
500 μl of Dianeal PD-4 (i.p.) on alternate days. Samples were analyzed a day after the last 
delivery. (a) Absolute amount of C1q in the peritoneal washes as determined by ELISA. (b) 
Quantification of the thickness of the submesothelial compact zone from (c) microscopy of 
Masson’s trichrome stained parietal peritoneum slices (scale bars, 0.1 mm). Amplification of (d) 
Col1a1, Col3a1, (e) Acta2, (f) Vegf, and (g) Mmp12-encoding mRNA in peritoneal tissue. (h) 
Percentage of infiltrating monocytes as quantified by FACS. (i) Expression of RELMα, Ym1, and 
Arg by peritoneal macrophages. (j) Analysis of secreted RELMα and Ym1 in the peritoneal 
space. (k) Expression of Ki67 by peritoneal macrophages. Results are representative from two 
independent experiments (means ± SEM) (untreated: 3 mice, PD4: 6 mice). ANOVA followed by 
the Bonferroni multiple-comparison test or Student’s t-test (a) was used.  *p < 0.05, **p < 0.01, 
and ***p < 0.001 when compared with control group;  °p < 0.05,  °°p < 0.01, and °°°p < 0.001 
when WT vs. C1qa-/- mice treated with Dianeal PD-4 are compared. 
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Discussion 
Accumulating evidence suggests that local tissue factors and not necessarily origin 
determine the functional phenotype of macrophages [360]. We show here that ligands 
for the unconventional cell surface myosin18A act in a tissue-specific manner to 
enhance IL-4Rα-mediated macrophage proliferation and activation, with consequences 
for tissue repair, parasite killing, and fibrosis. Myo18A on alveolar macrophages 
recognizes SP-A but not C1q, while Myo18A on peritoneal macrophages recognizes 
C1q but not SP-A.  All three of these factors are also positively regulated by IL-4 
suggesting that in the tissues there is a local response that functions to dramatically 
amplify the type 2 effector response. SP-A and C1q both act via Myo18A but in a tissue-
specific manner suggesting the involvement of local co-receptors that work in concert 
with Myo18A. C1q’s lack of action on alveolar macrophages can be explained by the 
fact that alveolar macrophages do not express some C1q receptors [361]. Among the 
putative C1q receptors on peritoneal macrophages, gC1qR (also known as p33) lacks a 
trans-membrane domain, and signal transduction relies on partnerships with trans-
membrane proteins [362]. Interestingly, gC1qR/P33 forms a signaling complex with DC-
SIGN and integrin β1 [363], which is also a partner of Myo18A [364].  
The need for tissue-specific co-receptors suggests that the origin and/or 
characteristics of the tissue where macrophages reside may condition their capacity to 
respond to IL-4. This is supported by our observation that alveolar but not peritoneal 
macrophages were able to proliferate in response to IL-4 in vitro. Besides having a 
different origin from peritoneal macrophages (fetal monocytes vs. primitive yolk sac 
[54]), alveolar macrophages have a unique phenotype that is determined by the alveolar 
environment, rich in surfactant components and high levels of oxygen [2]. Tissue-
specific macrophage phenotypes are defined by unique transcription factors [365], and 
a recent analysis highlighted that alveolar macrophages of embryonic origin 
preferentially express the transcription factor Wwtr1 [56]. Notably, Wwtr1 is not 
expressed in peritoneal macrophages [366]. 
The observation that C1q can act locally to promote type 2 responses is consistent 
with described roles for C1q independent of the classical complement pathway [359, 
367-370]. For example, C1q is produced by dermal microvascular endothelial cells in 
injured but not intact skin, and promotes repair [368]. Similarly, C1q produced by 
endothelial cells in the tumor microenvironment stimulates division of melanoma cells 
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[369]; in addition, C1q produced by decidual endothelial cells during pregnancy directs 
local cell migration and tissue remodeling [370]. The relevance of C1q as a tissue-
specific factor is further supported by the fact that unlike most other complement 
components, which are produced in the liver, the majority of C1q is produced by myeloid 
cells in the peripheral tissues [371]. We show here that by enhancing M(IL-4) activation 
C1q plays a critical role in a clinically relevant model of dialysis-induced peritoneal 
fibrosis. This is consistent with human studies in which C1q is strongly associated with 
increased fibrosis of skeletal muscle [372].  
The finding that SP-A promotes IL-4Rα-mediated activation and proliferation of 
alveolar macrophages defines an entirely new role for SP-A in the lung. In the context of 
a lung migrating helminth infection, SP-A acted as an important mediator of the host 
protective type 2 response to both control parasite numbers and repair lung damage. 
Enhancement of M(IL-4) may underlie the previously reported contribution of SP-A to 
tissue integrity in other models of acute lung injury [336, 373]. The pro-type 2 effects we 
report here contrast with reports that associate SP-A with protection in asthma [297]. 
However, in addition to promoting M(IL-4) and proliferation of macrophages, the already 
reported anti-inflammatory properties of SP-A [11, 336, 338, 339, 373] may suppress 
the strong inflammatory responses that are responsible for more severe asthma. Our 
data are supported by a recent study demonstrating that the closely related but far less 
abundant SP-D has IL-4 promoting effects similar to those of SP-A [374]. Because SP-D 
is critical for the turnover of surfactant [375, 376] there is a near absence of SP-A in SP-
D-deficient mice [376]. The marked reduction of SP-A levels together with the 
accumulation of surfactant lipids [376] could contribute to observed effects in SP-D-
deficient mice. In contrast, lung morphology, SP-D levels, and alveolar phospholipid 
pool sizes are unaltered in SP-A-deficient mice [377]. 
In conclusion, we have found that SP-A and C1q are tissue-specific factors that act 
through Myo18A to amplify local IL-4Rα-mediated macrophage activation. It is likely that 
other secreted soluble defense collagens present in distinct tissues are Myo18A ligands 
and will play similar roles. The common structural characteristic of these host defense 
proteins is their collagen domain, which mediated the IL-4Rα enhancing features of SP-
A. SP-A, C1q, and Myo18 are highly conserved across mammalian species, and we 
have demonstrated the ability of SP-A and Myo18A to enhance human M(IL-4).  
Consequently, our findings have the potential to provide entirely new directions for 
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tissue-specific targeting of M(IL-4)-driven pathologies such as pathological fibrosis 
[131], a leading killer worldwide. Indeed manipulation of alveolar macrophages has 
been proposed as an attractive strategy for the treatment of pulmonary fibrosis [8].  The 
identification of the tissue-specific Myo18A co-receptors in the lung and other tissues 
will be the critical next step in developing strategies to regulate local macrophage 
activation and proliferation.   
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VIII. CHAPTER 3 
 
Surfactant protein A enhances IL-4-mediated signaling via 
PKCζ and Akt in alveolar macrophages  
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Abstract  
 
Interleukin (IL)-4 induced alternative activation and proliferation of macrophages 
involves intracellular activation of STAT6 and PI3K-Akt signaling. Surfactant Protein 
(SP)-A is a lung factor that enhances both IL-4-dependent activation as well as 
proliferation of alveolar macrophages via the unconventional Myosin18A. The 
mechanism by which SP-A and IL-4 synergistically enhance activation and proliferation 
of alveolar macrophages remains elusive.  Here we show that SP-A, through 
engagement of the cell surface Myo18A receptor, enhanced PI3K activation in isolated 
rat alveolar macrophages. Furthermore, downstream of PI3K, PKCζ activation by SP-A 
selectively promoted the alternative activation of alveolar macrophages while Akt 
activation by SP-A selectively promoted IL-4-induced proliferation. These data show that 
SP-A is a lung-specific factor that enhances the amplitude of IL-4-induced signal in 
alveolar macrophages by activating PI3K-Akt and a complementary PKCζ-mediated 
signaling that feeds into STAT6 pathway.   
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Introduction  
 
During type-2 immune responses, IL-4 and IL-13 signaling through the IL-4Rα 
triggers proliferation [5] and a specialized activation program of macrophages that 
has evolved as a specific immune response to expulse parasites [4]. Engagement of 
IL-4Rα ligands induces dimerization of this receptor with the common gamma chain 
Υc subunit forming a signaling complex. The IL-4R complex itself lacks intrinsic 
kinase activity, but the cytoplasmic tails of its subunits are each associated with the 
member of the JAK family JAK-1 [378]. IL-4R complex activates JAK-1, resulting in 
its auto and trans-phosphorylation as well as phosphorylation of target tyrosine 
residues in the cytoplasmic domains of both receptor chains. Phosphorylated 
tyrosine residues of the IL-4R complex act as docking sites for downstream adaptor 
and signaling molecules such as IRS-2, STAT6 and SHP-1 [100]. Of those signaling 
molecules, activated STAT6 is the master regulator of alternative macrophage 
activation [365]. However, it has also been shown that IL-4-induced proliferation of 
peritoneal macrophages is STAT6-dependent [304]. Alternatively, IRS-2 has been 
shown to serve as initiator of PI3K/Akt signaling pathway, which induces the 
proliferation and cell survival of macrophages [379]. Additionally, Ruckerl et al 
identified Akt as an important downstream target of PI3K signaling during IL-4-
induced alternative activation [379]. 
 
Although type-2 immunity is a protective response to parasites, TH2 responses 
are exacerbated during important non-communicable diseases of contemporary 
society. Consequently, alternatively activated macrophages are central effectors of 
type-2 immunity and play important roles in allergy, asthma, and lung fibrosis [131]. 
In the lung, IL-4Rα-activated macrophages express arginase, insulin-like growth 
factor 1 (IGF-1) and IL-10, all of which contribute to rapid resolution of tissue damage 
induced by the lung-migrating parasite Nippostrongylus brasiliensis [6]. Other studies 
have confirmed the role of alternatively activated alveolar macrophages during lung 
repair. For instance, it has been shown that alternatively activated lung macrophages 
control severe respiratory syncytial virus-induced lung injury [380]. Finally, it has 
been observed that alveolar macrophages are critical promoters of both the local 
induction and maintenance of type 2-dependent lung fibrosis [131]. 
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Alveolar macrophages together with the respiratory epithelium are covered by 
pulmonary surfactant, a lipid-protein network that contains associated proteins 
essential for keeping the alveolus open and for host defense [9, 11]. The two 
principal surfactant components involved in innate immunity in the alveolus are 
surfactant proteins A (SP-A) and D (SP-D) [11]. SP-A is an oligomeric extracellular 
protein that is found mainly in the alveolar fluid, associated with surfactant 
extracellular membranes that line the alveolar epithelium and with alveolar cells. SP-
A recognizes pathogen-associated molecular patterns on some microorganisms, 
resulting in aggregation, opsonization, or permeabilization of microorganisms and 
facilitation of microbial clearance [11, 250]. Moreover, SP-A is also able to bind to 
membrane receptors present in macrophages, epithelial cells, and lymphocytes, 
modifying their response to different stimuli [11]. SP-A blocks the binding of TLR 
ligands to their receptors by direct SP-A interaction with TLR4 [273], TLR2 [276], the 
TLR co-receptor MD2 [276], and CD14 [16, 17]. Furthermore, SP-A modifies 
macrophage response to TLR ligands by modulating signaling cascades. For 
example, SP-A increases the expression of negative regulators of TLR-signaling, 
such as IRAK-M (14) and β-arrestin 2 (13), thereby inhibiting LPS-induced 
stimulation of macrophages. Moreover, SP-A promotes PKCζ activation and IκBα 
stabilization through mechanisms that require SP-A endocytosis by macrophages 
[280]. Internalized SP-A also inhibits IκBα, ERK, p38, and Akt phosphorylation by 
macrophages stimulated with TLR2 and TLR-4 ligands [281]. Although the role of SP-
A and SP-D during type 2 immunity remains less explored, a recent publication 
showed that SP-D induction is essential for immunity to helminth infection, an 
observation that correlated with elevated expression of markers of alternative 
activation by alveolar macrophages in response to SP-D [374]. Similarly, we have 
shown that SP-A is a lung factor that acts through Myo18A to enhance IL-4Rα-
mediated macrophage activation and proliferation with consequences for lung repair 
and parasite control during Nippostrongylus brasiliensis infection [381]. However, 
how SP-A promotes IL-4-induced activation and proliferation of alveolar 
macrophages remains unknown. 
   
Here we show that SP-A, via the unconventional myosin Myo18A, enhanced 
PI3K activation and the phosphorylation of its down-stream targets PKCζ and Akt.  
Accordingly, the activation of Akt by SP-A enhanced IL-4-induced proliferation, while 
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the activation of PKCζ by SP-A increased IL-4 induced alternative activation of 
alveolar macrophages. Thus, our data suggest that SP-A activates a signaling 
pathway that feeds into the signaling initiated by IL-4 enhancing the amplitude of its 
signal. 
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Materials and Methods 
 
Materials 
Cell culture media and reagents were acquired from Lonza (Basel, 
Switzerland). Western blotting materials were obtained from Bio-Rad (Hercules, 
California). All other reagents were of analytical grade, purchased from Sigma (St. 
Louis, Missouri) unless otherwise specified.  
 
Isolation, purification and characterization of native SP-A  
         Surfactant protein A was isolated from BAL of patients with alveolar proteinosis 
using a sequential butanol and octylglucoside extraction [14, 173, 177, 339, 340]. 
The purity of SP-A was checked by one-dimensional SDS-PAGE in 12 % acrylamide 
under reducing conditions and mass spectrometry. The oligomerization state of SP-A 
was assessed by electrophoresis under non-denaturing conditions [173, 177], 
electron microscopy [173], and analytical ultracentrifugation as reported elsewhere 
[177]. SP-A consisted of supratrimeric oligomers of at least 18 subunits. Each subunit 
had a relative molecular mass (Mr) 36 kDa. The endotoxin content of native or 
recombinant human SP-A was < 0.1 endotoxin units /mg of SP-A as determined by 
Limulus amebocyte lysate assay (GenScript, Piscataway, New Jersey).  
 
Animal handling  
Rat alveolar macrophages were obtained from Sprague–Dawley male rats. 
Rats (∼350 g) were anesthetized with ketamine (80 mg/kg; Merial, Duluth, GA) and 
xylazine (10 mg/kg; Bayer, Leverkusen, Germany) and the cardiopulmonary block 
was extracted to perform bronchoalveolar lavages with PBS (0.2 mM EDTA). All 
animals received humane care in accordance with the Guide for the Care and Use of 
Laboratory Animals [312] and Spanish guidelines for experimental animals. 
 
Isolation and culture of primary aMφ´s 
Bronchoalveolar cells were separated from lavage fluid by centrifugation (250 
g, 7 min). The sedimented cells were washed twice with PBS, and the cell pellet was 
resuspended in RPMI 1640 medium (10% heat-inactivated FBS, 100 U/ml penicillin, 
and 100 mg/ml streptomycin, supplemented with 2 mM glutamine) (Lonza). Alveolar 
macrophages were purified by adherence for 90 min at 37°C under a 95% air-5% 
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CO2 atmosphere in 150-cm2 culture flasks as reported previously [313]. Adherent 
cells were 94.0 6 1.1% viable (trypan blue exclusion test). To evaluate the purity of 
the isolated macrophages, rat alveolar macrophages immune-stained with anti-
CD11c (Serotec, Kidlington, U.K.) were analyzed by flow cytometry. Adherent cells 
were found to be composed of 90 ± 1 % alveolar macrophages. 
 
Incubation conditions  
Adherent cells were gently scraped, plated in 96-well plastic dishes (7.5 x 104 
cells/well) in 0.2 ml RPMI 1640 medium with 5% FBS, and pre-cultured overnight. 
Cells were cultured in the presence or absence of IL-4 (1 μg/mL) (ImmunoTools, 
Berlin, Germany) and/or SP-A (25, 50 and 100 μg / mL). Lower doses of IL-4 (0.1-1 
μg/mL) were also assayed; however, alternative activation and proliferation of 
alveolar macrophages was significantly induced only with concentrations of IL-4 
above 1 μg/mL. Different concentrations of inhibitors were titrated to minimize 
innocuous effects and toxicity.  After titration the following concentrations were used: 
50 nM LY294002 (PI3K inhibitor) (Cell Signaling, Danvers, Massachusetts), 25 nM 
Akt Inhibitor VIII (Isozyme-Selective, Akti-1/2), 30 μM PKCζ Pseudosubstrate 
Inhibitor, Myristoylated (Calbiochem, Darmstadt, Germany). Cell viability was 97% 
under assay conditions. Macrophage cultures were plated in triplicate wells, and 
each series of experiments was repeated at least three times. 
 
Arginase activity assay  
Arginase activity was measured as previously reported [349]. Briefly, rat 
alveolar macrophages were lysed with 50 μl of 50 mM Tris–HCl pH 7.5, Triton X-100 
0.1 %, 1 mM benzamidine, 200 μg/mL  aprotinin, and 200 μg/ml leupeptin. After 30 
min shaking at 4ºC, arginase was activated with 50 μL of 10 mM MnCl2 and 50 mM 
Tris-HCl, pH 7.5, for 10 min at 55º C. L-arginine hydrolysis was measured by 
incubating the cell lysate with 25 μL of 0.5 M L-arginine (Sigma) (pH 9.7) at 37ºC for 
1 h. The reaction was stopped by addition of 200 μL H2SO4 /H3PO4 /H2O (1:3:7 v/v). 
The produced urea was quantified at 570 nm after addition of 25 μL of α-
isonitrosopropiophenone (dissolved in 100% ethanol) followed by heating at 99ºC for 
45 min. Urea production was normalized to cell number for each treatment by 
quantifying cells with the WST-1 reagent (Roche), following manufacturer’ 
instructions. One unit of arginase activity is defined as the amount of enzyme that 
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catalyses the formation of 1 μmol urea per min. 
 
Immunoprecipitation of PKCζ 
Alveolar macrophages were stimulated with SP-A, IL-4 or combinations 
thereof for 8 minutes. After culture, cells were lysed at 4ºC for 30 min in 500 μL of 
lysis buffer: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 mM EDTA, IGEPAL 0.5%, 1 
mM benzamidine, 200 µg/mL aprotinin, 200 µg/mL leupeptin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 20 mM β-glycerophosphate, 10 mM NaF, 10 
mM sodium pyrophosphate and 2 mM orthovanadate. The lysates were centrifuged 
at 10 000 × g for 10 min, and the supernatants were precleared by adding protein A-
agarose (50 μL) and incubated at 4°C for 45 min, followed by centrifugation at 10 000 
× g for 10 min. The precleared supernatant was incubated with anti-PKCζ antibody  
(Cell Signaling, Danvers, Massachusetts) or control IgG at 4°C overnight, after which 
50 μL of protein A-agarose (Santa Cruz Biotechnology, Dallas, Texas) was added for 
3 h at 4°C with gentle rotation. The immune complexes were collected by 
centrifugation at 10 000 × g for 5 min at 4°C, washed three times with cold lysis 
buffer, and released by boiling with 5× Laemmli loading buffer. Phosphorylation of 
PKCζ was subsequently analyzed by Western blot using an anti-Phospho-PKCζ/λ 
(Thr410/403) and anti-PKCζ (Cell Signaling) as described below. 
 
Western blot analysis 
Alveolar macrophages were stimulated with SP-A, IL-4 or combinations 
thereof for 90 minutes to determine STAT6 phosphorylation and 30 minutes for Akt 
phosphorylation. Cells were lysed by shaking 30 min at 4ºC with a buffer containing: 
10 mM HEPES, pH 7.9, 15 mM MgCl, 10 mM KCl, 0.5 mM EDTA, Triton X-100 0.2%, 
1 mM benzamidine, 200 µg/mL aprotinin, 200 µg/mL leupeptin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 20 mM β-glycerophosphate, 10 mM NaF, 10 
mM sodium pyrophosphate and 2 mM orthovanadate. Samples were resolved by 
10% (m/v) SDS-PAGE in reducing conditions and transferred to polyvinylidene 
fluoride membranes (PVDF). After blocking with 2.5% (m/v) skim milk, membranes 
were washed and incubated with anti- phospho STAT6 (Tyr641) (Pierce Antibodies), 
phospho Akt (Ser473), STAT6, Akt and α-Tubulin (Cell Signaling) overnight at 4°C. 
The membranes were washed and incubated with horseradish-peroxidase-labeled 
anti-rabbit/mouse IgG for 30 minutes at room temperature (RT), and exposed to ECL 
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reagents. Immuno-reactive bands density was measured with the software Quantity 
One.  
 
Cell proliferation assays  
Detection of BrdU incorporation was performed by ELISA according to the 
manufacturer’s instructions (Cell Signaling). The retention of the cells at the bottom of 
the well after the removal of the supernatant was checked by the wst-1 assay 
(Roche).  Cell number in all treatments was similar before and after supernatant 
removal.  
 
siRNA-targeted silencing of Myo18A  
After isolation, primary alveolar macrophages were resuspended in Amaxa® 
mouse macrophage nucleofector solution (Lonza) and nucleofected with 100 nM 
siRNA using a nucleofector 2b device (Lonza). Experiments were conducted using 
two Stealth siRNAs directed against rat Myo18A (RSS322720 and RSS322721) 
(Applied Biosystems, Carlsbad, California). Medium GC Stealth siRNA was used as 
control (12935300) (Applied Biosystems). Myo18A expression was detected by 
Western blot analysis with an anti-Myo18A antibody as reported previously [381]. 
After 48 hours post nucleofection, Myo18A expression was reduced 72 ± 4% for 
RSS322720 and 71 ± 5% for RSS322721 compared to control. At this time-point, 
cells were stimulated. 
 
Statistics  
Statistical evaluation of different groups was performed by analysis of 
variance (ANOVA) followed by the Bonferroni multiple comparison test. An α level ≤ 
5% (p ≤ 0.05) was considered significant. All statistical calculations were performed 
using PRISM, (Graphpad La Jolla, CA). 
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Results  
 
SP-A enhances IL-4-mediated activation and proliferation of alveolar 
macrophages 
 
We have previously shown that SP-A enhances IL-4Rα-mediated activation 
and proliferation of alveolar macrophages in mice, rats and humans [381]. IL-4Rα-
dependent activation of STAT6 regulates arginase (Arg1) and Mannose receptor 
(CD206) expression by macrophages [365]. Furthermore, it has also been shown 
that IL-4Rα signalling promotes proliferation of macrophages [5]. To confirm the 
effect of SP-A on IL-4Rα-activated alveolar macrophages we measured arginase 
activity, CD206 expression and proliferation of rat alveolar macrophages cultured in 
the presence of IL-4, SP-A and combinations thereof.  
 
As expected, IL-4 induced arginase activity, CD206 expression and the 
proliferation of alveolar macrophages (Fig. 1a). Furthermore, we confirmed that SP-A 
dose-dependently enhanced IL-4-mediated effects on alveolar macrophages as 
measured by the induction of arginase cativity, CD206 expression and BrdU 
incorporation to the newly synthetized DNA of proliferating macrophages (Fig. 1a).  In 
our previous report we identified the unconventional myosin, Myo18A (aka SP-R210) 
as the receptor for SP-A involved in the enhancement of IL-4 effects in alveolar 
macrophages [381]. To corroborate these observations, we silenced Myo18A gene 
using Myo18A-targeted siRNA and measured proliferation and arginase activity of IL-
4 and/or SP-A treated alveolar macrophages. Figure 1b shows that silencing of 
Myo18A completely abrogated SP-A effects of IL-4-treated alveolar macrophages 
confirming our previous observations.    
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Figure 1. SP-A enhances IL-4-dependent activation and proliferation of alveolar 
macrophages. Purified rat aMφ were left untreated or nucleofected with Myo18A or siRNA 
control. Subsequently, aMφ were stimulated with or without IL-4 (1 μg/mL) in the presence or 
absence of SP-A (25, 50 and 100 μg/mL) and exposed to 10 μM BrdU for proliferation 
analysis. We measured (a) arginase activity, CD206 expression and BrdU incorporation to the 
newly synthesised DNA of alveolar macrophages that were not nucleofected. Alternatively, 
we measured (b) arginase activity and BrdU incorporation to the newly synthesised DNA of 
alveolar macrophages that were nucleofected with Myo18A or siRNA control. The results are 
presented as means (± SEM) from three different cell cultures with at least three biological 
replicates. ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 0.05, 
**p < 0.01, and ***p < 0.001, when compared with untreated macrophages; οοp < 0.01, and 
οοοp < 0.001, when SP-A+IL-4-treated macrophages were compared with IL-4-treated 
macrophages; ###p < 0.001, when the effect of Myo18A siRNA is compared with siRNA 
control.  
 
SP-A enhances IL-4 signalling through Myo18A receptor 
 
Mechanistically, SP-A could act extracellularly enhancing IL-4 effects in 
macrophages by binding to IL-4 or IL-4Rα. However, silencing of Myo18A completely 
abrogated the effects of SP-A on IL-4-treated alveolar macrophages, suggesting that 
the synergy between SP-A and IL-4 must occur downstream from their respective 
receptors. Besides the well-established role of STAT6 during IL-4Rα signalling, it has 
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been shown that PI3K-Akt activation is essential for IL-4-driven murine macrophage 
activation and proliferation [379]. Therefore, to determine whether SP-A-Myo18A 
could induce a similar signalling to IL-4, we analysed STAT6 and Akt phosphorylation 
by macrophages cultured in the presence and absence of IL-4, SP-A and 
combinations thereof. As expected, IL-4 induced the phosphorylation of STAT6 and 
Akt by alveolar macrophages (Fig. 2a). Moreover, SP-A dose-dependently enhanced 
IL-4-induced STAT6 and Akt phosphorylation mediated by alveolar macrophages 
(Fig. 2a). Of note, SP-A and IL-4 together induced an additive phosphorylation of Akt; 
however SP-A alone was capable to induced Akt phosphorylation (Fig. 2a) 
supporting the idea that the effect of SP-A on IL-4-treated macrophages occurs at the 
signalling level. To show that Myo18A mediates SP-A signaling on alveolar 
macrophages, we silenced Myo18A and repeated STAT6 and Akt phosphorylation 
determinations in IL-4 and SP-A treated macrophages. We found that silencing of 
Myo18A abrogated the effects of SP-A on IL-4-induced STAT6 and Akt 
phosphorylation by alveolar macrophages (Fig. 2b). Notably, we observed that the 
silencing of Myo18A on alveolar macrophages also impaired the capability of SP-A to 
induce Akt phosphorylation by its own (Fig. 2b) 
 
Myo18A is an unconventional myosin that does not operate as a traditional 
molecular motor in cells, having both intracellular and cell-surface locations [352]. 
Immune activation results in Myo18A localization on the cell surface, where it binds 
to SP-A with high affinity and thus is also known as SP-R210 [291, 338]. We have 
previously shown that blockade or silencing of Myo18A has similar effects on the SP-
A enhancement of IL-4Rα-mediated macrophage activation and proliferation [381]. 
Similarly, blockade of Myo18A abolished the SP-A-mediated activation of Akt (Data 
not shown).  
 
Therefore, these data suggests that SP-A-Myo18A signaling directly activates 
PI3K-Akt signaling by alveolar macrophages and synergises with IL-4 signalling to 
increase the activation and proliferation of alveolar macrophages.  
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Figure 2. SP-A amplifies IL-4 signaling through Myo18A on alveolar macrophages. 
Purified rat aMφ were left untreated or nucleofected with Myo18A or siRNA control. 
Subsequently, aMφ were stimulated with or without IL-4 (1 μg/mL) in the presence or 
absence of SP-A (25, 50 and 100 μg/mL) and exposed to 10 μM BrdU for proliferation 
analysis.  We measured (a) STAT6 and Akt phosphorylation by IL-4 and/or SP-A-treated 
alveolar macrophages that were not nucleofected. Alternatively, we measured (b) STAT6 and 
Akt phosphorylation by IL-4 and/or SP-A-treated alveolar macrophages that were 
nucleofected with Myo18A or siRNA control. A representative WB for p-STAT6 and p-Akt is 
shown in figures a and b. The results are presented as means (± SEM) from three different 
cell cultures with at least three biological replicates. ANOVA followed by the Bonferroni 
multiple-comparison test was used. *p < 0.05, **p < 0.01, and ***p < 0.001, when compared 
with untreated macrophages; οp < 0.05, οοp < 0.01, οοοp < 0.001, when SP-A+IL-4-treated 
macrophages were compared with IL-4-treated macrophages; ###p < 0.001, when the effect of 
Myo18A siRNA is compared with siRNA control.  
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PI3K inhibitor blocks SP-A effects on IL-4 signaling 
 
As mentioned before, a previous report showed that signaling via PI3K-Akt is 
essential for full IL-4-driven activation and proliferation of macrophages [379]. 
Alternatively, PKCζ another target of PI3K signaling [382], is critical for the IL-4-
induced nuclear translocation and tyrosine phosphorylation of STAT6 and Jak1 
activation allowing for Th2 differentiation [383-385]. Regarding SP-A signaling, it has 
been reported that SP-A activates a PI3K signal transduction pathway that up-
regulates mannose receptor (CD206) by human macrophages [13]. Furthermore, 
previous publications have shown that SP-A induces PKCζ activation dampening the 
inflammatory macrophage activation triggered by LPS [310, 386, 387]. Therefore, we 
rationalized that the induction of PI3K signaling by SP-A could explain the 
enhancement of IL-4Rα-mediated macrophage proliferation and activation. To 
address this hypothesis, we inhibited PI3K activation (50nM LY294002) in IL-4 and 
SP-A-treated macrophages and analyzed the phosphorylation of its downstream 
targets Akt and PKCζ. Additionally, we assed the effect of PI3K inhibition on STAT6 
phosphorylation, arginase activity and BrdU incorporation by alveolar macrophages 
cultured in the presence of IL-4, SP-A and combinations thereof. We observed that 
the addition of 50nM of the PI3K inhibitor LY294002 successfully inhibited PI3K 
activity as the presence of the inhibitor abolished the capability of SP-A and IL-4 to 
induce the phosphorylation of Akt and PKCζ in alveolar macrophages (Fig 3a-b). 
Moreover, the inhibition of PI3K abrogated SP-A enhancement of IL-4-induced 
STAT6 phosphorylation and arginase activity by alveolar macrophages (Fig. 3c-d). 
Critically, our results suggested that IL-4 does not depend on PI3K to induce STAT6 
phosphorylation and the alternative activation of alveolar macrophages (Fig. 3c). In 
contrast, we observed that in the presence of PI3K inhibitor the proliferation of 
alveolar macrophages was completely impaired in all the treatments (Fig. 3e).  
 
These results show that PI3K signaling directly instructs macrophage 
proliferation and suggest that there is a crosstalk between STAT6 and PI3K that 
combine IL-4 and SP-A signaling to enhance alternative activation of alveolar 
macrophages potentially mediated by Akt or PKCζ.  
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Figure 3. PI3K inhibitor abrogates SP-A effects on IL-4 signaling by alveolar 
macrophages. Purified rat aMφ were pre-treated with 50 nM LY294002 (PI3K inhibitor) or 
vehicle (DMSO) for two hours. Subsequently, cells were stimulated with or without IL-4 (1 
μg/mL) in the presence or absence of SP-A (100 μg/mL) and exposed to 10 μM BrdU for 
proliferation analysis. We measured (a) Akt, (b) PKCζ and (c) STAT6 phosphorylation; (d) 
arginase activity and (e) BrdU incorporation to the newly synthesised DNA of IL-4 and/or SP-
A-treated alveolar macrophages that were cultured with or without PI3K inhibitor. A 
representative WB for p-Akt, p- PKCζ and p-STAT6 is shown. The results are presented as 
means (± SEM) from three different cell cultures with at least three biological replicates. 
ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 0.05, **p < 0.01, 
and ***p < 0.001, when compared with untreated macrophages; οοp < 0.01, and οοοp < 0.001, 
when SP-A+IL-4-treated macrophages were compared with IL-4-treated macrophages; #p < 
0.05, ##p < 0.01, and ###p < 0.001, when the effect of LY294002 is compared with vehicle.  
 
Akt activation controls SP-A and IL-4-mediated macrophage proliferation 
 
One of the best-characterized targets of activated PI3K is the AKT/mTOR 
signaling pathway [388]. To test whether Akt mediates the crosstalk between STAT6 
and PI3K signaling during IL-4 and SP-A stimulation of alveolar macrophages, we 
inhibited Akt activation with the Akt Inhibitor VIII (25 nM). We observed that the 
inhibition of Akt did not affect STAT6 phosphorylation and arginase activity by 
alveolar macrophages in any of the treatments (Fig. 4a). In contrast, Akt Inhibitor VIII 
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dramatically impaired proliferation of alveolar macrophages induced by IL-4 alone or 
in combination with SP-A (Fig. 4b) confirming previous observations [379].  
 
These results demonstrate that whereas Akt activation is essential for 
macrophage proliferation, activated Akt is not directly involved in the signaling 
pathway that promotes alternative activation of alveolar macrophages. 
 
 
Figure 4. Akt activation controls SP-A and IL-4-
mediated macrophage proliferation. Purified rat aMφ 
were pre-treated with 25 nM Akt Inhibitor VIII or vehicle for 
two hours. Subsequently, cells were stimulated with or 
without IL-4 (1 μg/mL) in the presence or absence of SP-A 
(100 μg/mL) and exposed to 10 μM BrdU for proliferation 
analysis. We measured (a) arginase activity, STAT6 
phosphorylation and b) BrdU incorporation to the newly 
synthesised DNA of IL-4 and/or SP-A-treated alveolar 
macrophages that were cultured with or without Akt 
inhibitor. A representative WB for p-STAT6 is shown. The 
results are presented as means (± SEM) from three 
different cell cultures with at least three biological 
replicates. ANOVA followed by the Bonferroni multiple-
comparison test was used. *p < 0.05 and ***p < 0.001, 
when compared with untreated macrophages; οp < 0.05 
and οοοp < 0.001, when SP-A+IL-4-treated macrophages 
were compared with IL-4-treated macrophages; ###p < 
0.001, when the effect of Akt Inhibitor VIII is compared 
with vehicle.  
 
 
 
 
 
 
PKCζ activation mediates SP-A enhancement of IL-4-induced activation of 
alveolar macrophages 
  
As mentioned previously, another target of the PI3K signaling pathway 
activated either by IL-4 or SP-A is PKCζ [310, 383, 384, 386, 387]. To determine 
whether the effect of SP-A on the IL-4-induced alternative activation of alveolar 
macrophages is mediated by PKCζ, we inhibited PKCζ with a PKCζ 
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Pseudosubstrate. We observed that in the presence of PKCζ inhibitor (30 μM), SP-A 
was unable to enhance IL-4-induced arginase activity by alveolar macrophages (Fig. 
5a). Accordingly, PKCζ inhibition prevented SP-A’s enhancement of IL-4-induced 
STAT6 phosphorylation by alveolar macrophages (Fig. 5a). Of note, the effect of IL-4 
on STAT6 phosphorylation and arginase activity by alveolar macrophages was not 
affected by the presence of PKCζ inhibitor (Fig. 5a). Similarly, the same 
concentration of PKCζ inhibitor did not affect alveolar macrophages proliferation in 
any treatment (Fig. 5b).  
 
These results demonstrate that SP-A enhances IL-4-induced alternative 
activation of alveolar macrophages by sustaining the PI3K-PKCζ-STAT6 signaling 
loop initiated by IL-4. Furthermore, our data establishes that PKCζ signaling 
intersects with activated STAT6 to achieve an effective activation without directly 
affecting proliferation of alveolar macrophages.  
 
 
 
Figure 5. SP-A enhancement of IL-4-mediated activation 
of alveolar macrophages requires PKCζ activation. 
Purified rat aMφ were pre-treated with 30 µM of PKCζ 
Pseudosubstrate Inhibitor or vehicle for two hours. 
Subsequently, cells were stimulated with or without IL-4 (1 
μg/mL) in the presence or absence of SP-A (100 μg/mL) 
and exposed to 10 μM BrdU for proliferation analysis. We 
measured (a) arginase activity, STAT6 phosphorylation and 
(b) BrdU incorporation to the newly synthesised DNA of IL-4 
and/or SP-A-treated alveolar macrophages that were 
cultured with or without PKCζ Pseudosubstrate. A 
representative WB for p-STAT6 is shown. The results are 
presented as means (± SEM) from three different cell 
cultures with at least three biological replicates. ANOVA 
followed by the Bonferroni multiple-comparison test was 
used. *p < 0.05, **p < 0.01, and ***p < 0.001, when 
compared with untreated macrophages; οοp < 0.01, and οοοp 
< 0.001, when SP-A+IL-4-treated macrophages were 
compared with IL-4-treated macrophages; ##p < 0.01, and 
###p < 0.001, when the effect of PKCζ Pseudosubstrate is 
compared with vehicle.  
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Discussion  
 
Accumulating evidences suggest that local factors in the lung largely determine 
the phenotype of alveolar macrophages [57, 58], which help to maintain tissue 
homeostasis and act as sentinels of injury. Following injury, IL-4-activated 
macrophages make a substantial contribution to wound healing [127]. In this context, 
we had shown [381] that SP-A is a local factor that acts to enhance IL-4-dependent 
proliferation and activation of alveolar macrophages, resulting in better lung injury 
resolution following infection with the lung-migrating nematode Nippostrongylus 
brasiliensis. IL-4-induced alternative activation and proliferation of macrophages 
requires intracellular activation of STAT6 and PI3K-Akt signaling. Here we show that 
binding of SP-A to the cell surface receptor Myo18A induced the activation of PI3K, 
which in turn activated its downstream targets Akt and PKCζ. SP-A-mediated Akt and 
PKCz activation induced differential effects on IL-4-activated alveolar macrophages: 
whereas SP-A induction of the PI3K-Akt signaling axis increased IL-4-induced 
proliferation, SP-A-induced PI3K-PKCζ signaling axis increased IL-4-induced 
alternative activation by amplifying STAT6 signaling in alveolar macrophages.  
 
It has been shown that SP-A-mediated PI3K activation enhances the 
expression of CD206, a widely used marker of alternative activation of macrophages 
[13]. Furthermore, our previous report [381] identified the unconventional myosin, 
Myo18A (aka SP-R210) as the receptor for SP-A involved in the enhancement of IL-
4Rα-mediated macrophage activation and proliferation. The present study confirms 
these observations by showing that the silencing of Myo18A impairs SP-A-mediated 
PI3K activity and as consequence SP-A-mediated enhancement of IL-4-induced 
activation and proliferation of alveolar macrophages.  Although it has been reported 
that immune activation results in Myo18A localization on the cell surface of 
macrophages [291, 338, 381], the mechanism by which this receptor, that lacks a 
trans-membrane domain, transduces extracellular signals to the cytosol is not known. 
A recent study provided insights of the potential mechanism by which Myo18A could 
mediate SP-A-induced PI3K activation. This study showed that Myosin 18A co-
immunoprecipitates with SHP-2 [389], a tyrosine phosphatase that is required for 
mediating PI3K-Akt activation [390], which is also one of the molecules that is 
recruited upon activation of the IL-4R complex [100]. Furthermore, Myo18A has been 
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shown to partner with integrin β1 [364] an integrin that activates PI3K signalling [391] 
and which cross-linking induces the assembly of a SHP-2/Gab2 complex in 
hematopoietic cells [392]. Therefore, Myo18A signalling could potentially rely on 
partnership with the trans-membrane protein integrin β1 to recognise and transduce 
the signal upon SP-A ligation.  
 
By using Triciribine, a nucleoside that selectively inhibits the cellular 
phosphorylation/activation of Akt1, Akt2 and Akt3 [393], a previous in vivo study 
showed that the IL-4-driven macrophage proliferation is PI3K-Akt dependent [379]. In 
contrast to Triciribine, Akt Inhibitor VIII at the concentrations used in the present 
study, is a selective inhibitor of Akt1 [394]. Therefore, our data shows that selective 
inhibition of Akt1 is enough to prevent IL-4-induced macrophage proliferation, 
suggesting a critical role of Akt1 during this process.  Furthermore, our study shows 
that SP-A and IL-4 induce the activation of PI3K-Akt in a synergistic manner resulting 
in an increased proliferation of alveolar macrophages. Critically, SP-A-mediated 
enhancement of the IL-4-induced proliferation of macrophahes was also abrogated 
by selective inhibition of Akt1, suggesting that the activation of PI3K-Akt by SP-A and 
IL-4 is convergent. The studies of Ruckerl et al [379] also showed that Triciribine 
impairs IL-4-mediated alternative activation of macrophages. Our results showed that 
low concentrations of Akt inhibitor VIII do not impair IL-4 and SP-A-induced 
alternative activation of alveolar macrophages, suggesting that Akt1 is dispensable 
for this process. However, higher concentrations of Akt Inhibitor VIII, which are 
supposed to inhibit Akt1 but also Akt2 and Akt3 [394], impaired IL-4 and SP-A-
induced proliferation and alternative activation of alveolar macrophages (data not 
shown) confirming Ruckerl et al [379] observations.  
 
All together these observations sugest that there is a crosstalk between PI3K 
and STAT6 signaling that regulates alternative activation of macrophages. Our study 
also suggested that SP-A is capable to amplify this crosstalk resulting in an 
enhanced alternative activation of alveolar macrophages. By activating a PI3K-PKCζ 
signaling axis SP-A enhanced IL-4-induced STAT6 signaling by alveolar 
macrophages. Previous publications have shown that PKCζ is required for the 
nuclear translocation and tyrosine phosphorylation of STAT6 and Jak1 activation 
during CD4+ T cell differentiation in response to IL-4 [384, 385]. Whereas IL-4-
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induced CD4+ T cell differentiation into TH2 cells apeared to be absolutey dependent 
on PKCζ [384, 385], our study shows that in alveolar macrophages IL-4-induced 
alternative activation of macrophages occurs independently of PKCζ signaling. 
However, PKCζ signaling is activated by SP-A to enhance IL-4-induced STAT6 
activation. Previous publications have shown that SP-A promotes PKCζ activation 
and IκBα stabilization inducing dampening of the inflammatory macrophage 
activation triggered by LPS [310, 386, 387]. Here we define a novel function of SP-A-
activated PKCζ during the IL-4-induced alternative activation of macrophages. 
Further studies are required to reveal more details of the mechanism by which SP-A 
mediates PKCζ activation; a better understanding of this process might be important 
to understand why the inhibition of the PI3K-PKCζ signaling axis in alveolar 
macrophages abrogates the effects of SP-A without affecting the effect of IL-4.  
 
This study reveals a so far neglected layer of a tissue-specific pathway in the 
regulation of macrophage function in the context of type 2 immunity. Although it is 
known that IL-4 reduces the expression of IL-4Rα on the cell surface of alveolar 
macrophages [381], we have shown before that IL-4 positively regulates the 
expression of SP-A and its receptor Myo18A [381]. This data suggest that the type-2 
effector function of macrophages will depend on the additive effects of different 
factors present in the local response. In summary, we show that SP-A enhances IL-
4-mediated macrophage activation and proliferation by inducing a signaling pathway 
that converges into IL-4 signaling amplifying and sustaining IL-4 signals.  By 
activating PI3K-Akt signaling, SP-A synergizes with IL-4 to expand the population of 
alveolar macrophages. Furthermore, we show that besides the induction of STAT6 
phosphorylation by IL-4 there are other complementary pathways that can be 
triggered by SP-A to amplify the alternative activation of macrophages. In particular, 
we have shown that by activating PKCζ, SP-A establishes a crosstalk between PIK3 
and STAT6 signaling that increased IL-4-dependent STAT6 activity and therefore the 
alternative activation of macrophages.  
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IX. CONCLUSIONS 
The research presented in this doctoral dissertation provides new evidences 
about the immune properties of surfactant protein A (SP-A) and reveals further details 
about the molecular mechanisms by which SP-A modulates classical and alternative 
activation of alveolar macrophages. Taking all the results into consideration, we 
conclude that: 
• SP-A limits classical activation of macrophages induced by either IFN-γ plus LPS 
or both factors separately. The action of SP-A on [IFN-γ+LPS]-activated 
macrophages is based on its capability to attenuate both inflammatory agents. 
Whereas the mechanism by which SP-A limits LPS-induced activation of 
macrophages was previously described, our study unravels a previously unknown 
mechanism by which SP-A/IFN-γ interaction controls inflammation in the alveolus. 
We demonstrate that SP-A binds to IFN-γ with high affinity, inhibiting IFN-γ 
recognition by its receptor on the cell surface of human alveolar macrophages. 
This mechanism allows SP-A to limit inflammation and maintain a tolerant lung 
environment in the steady state. 
 
• SP-A enhances IL-4-dependent alternative activation and proliferation of alveolar 
macrophages, and this contributes to resolution of lung injury following N 
brasiliensis infection. SP-A acts via myosin18A receptor (Myo18A, aka SP-R210), 
whose expression in the macrophage cell surface was increased following IL-4 
activation. In addition, we found that beyond the alveolus other secreted soluble 
defense collagens, such as C1q, also act through Myo18A receptor to promote 
type-2 immunity. C1q enhances IL-4-mediated macrophage alternative activation 
and proliferation in the peritoneal cavity promoting fibrosis in a model of peritoneal 
dialysis. We conclude that SP-A in the lung and C1q in the peritoneal cavity are 
tissue-specific factors needed to amplify the alternative activation and proliferation 
of IL-4-activated macrophages, with profound consequences for immunity to 
infection, tissue repair, and fibrosis.  
 
• SP-A, through binding to Myo18A receptor, activates PI3K, and blockade of PI3K 
activity abrogated SP-A´s effects on IL-4 signalling. SP-A-dependent activation of 
PI3K and subsequent phosphorylation of its downstream effectors Akt and PKCζ 
amplifies IL-4-mediated macrophage proliferation and alternative activation. On 
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one side, SP-A sustained the PI3K-Akt signaling pathway triggered by IL-4, which 
is involved in macrophage proliferation. On the other hand, the SP-
A/Myo18A/PI3K/PKCζ axis was involved in enhancing IL-4-dependent STAT6 
activation, required for an alternative macrophage phenotype. 
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